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This dissertation describes a novel one-pot preparation of bicyclic heterocycles and 
improved synthetic procedures for the production of compounds possessing established biological 
activity. A five-component condensation reaction was discovered that follows a mechanistic 
sequence starting with a Biginelli reaction and ending in a Diels-Alder reaction to form a new class 
of bicyclic heterocycles. New protocols were developed to synthesize the bioactive compounds 
Gefitinib and analogs of JP4-039. The FDA approved EGFR inhibitor Gefitinib was synthesized 
on a pilot-plant scale using a more efficient synthetic sequence and fewer hazardous reagents. A 
shorter synthetic sequence to ferroptosis inhibitors, JP4-039 and related analogs, was developed 
with a key vinylogous Mannich reaction utilizing an oxazolidinone auxiliary. The biological 
activity of new ferroptosis inhibitors was used to generate a structure-activity relationship (SAR) 
hypothesis.   
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1.0 Five-Component Biginelli-Diels-Alder Cascade Reaction 
1.1 Introduction 
1.1.1 The Biginelli Reaction 
The Biginelli reaction was discovered by Pietro Biginelli in 1891.1 It is a one-pot multi-
component reaction (MCR) that generates dihydropyrimidinones (DHPMs) from an acid catalyzed 
reaction of a -keto ester, aldehyde, and urea in a protic solvent. Biginelli’s earliest example was 
with ethyl acetoacetate, benzaldehyde, and urea (Scheme 1-1).  
 
 
Scheme 1-1 Pietro Biginelli’s initial multi-component reaction1 
 
With three components in the reaction, there are three possible mechanisms. All three 
mechanisms involve protonated intermediates that lead to the formation of the DHPM (Figure 1-
1). The iminium route (Figure 1-1 A) begins with condensation between the aldehyde and urea. 
Following the loss of water, the iminium intermediate acts as an electrophile for the enol tautomer 
of the -keto ester. The ketone carbonyl of the resulting intermediate undergoes an intramolecular 
condensation with the NH2 of the urea to generate the cyclized DHPM product (Scheme 1-2).
2 The 
enamine route (Figure 1-1 B) was hypothesized to begin with a condensation between the urea and 
-keto ester to form an enamine intermediate which subsequently reacts with the aldehyde.3 The 
Knoevenagel route (Figure 1-1 C) was based on the initial reaction between the aldehyde and -
keto ester to form a carbenium intermediate that then reacts with the urea.4 C. Oliver Kappe first 
elucidated that the iminium route (Figure 1-1 A) was the most probable mechanistic route through 
2 
a combination of 1H and 13C NMR spectroscopy and trapping reactions.5 Puripat et al. provided 
the most conclusive evidence of the iminium intermediate pathway through the use of artificial 
force induced reaction (AFIR) method and DFT calculations.6 They calculated the energy barrier 
for the rate determining step in each pathway and determined that C-N bond formation during the 
cyclization step in the iminium route (Figure 1-1 A) had the lowest overall energy barrier, 21.5 
kcal/mol, compared to 31.2 kcal/mol for the cyclization step in the enamine route (Figure 1-1 B) 
and 28.0 kcal/mol for the rate limiting condensation step between the aldehyde and -keto ester in 




Figure 1-1 Biginelli reaction possible mechanistic routes 
3 
 
Scheme 1-2 Acid catalayzed Biginelli reaction2 
 
The synthetic utility of the Biginelli reaction did not garner much interest for almost 100 
years. However, beginning in the 1980s, the MCR became more prominent as it provided easy 
access to biologically active heterocycles and even marine natural products.7-8 DHPMs have been 
shown to have neuroprotective, antiparasitic, antiviral, antitumor, anti-inflammatory, and 
anticancer activities.9 Specifically, they have been shown to be potent A2B receptor antagonists
10 
and antihypertensive agents.11 One of the most studied DHPMs is Monastrol which was found to 
disrupt mitosis in 1999.12-13 Several potent analogs with increased anticancer potency have been 
synthesized since.14 Nifedipine is a drug approved by the Food and Drug Administration (FDA) to 
treat severe high blood pressure in pregnancy that is structurally related to a Biginelli DHPM. 
New, more potent, analogs of Nifedipine with superior half-lives have been synthesized through 
Biginelli reactions. These compounds have been useful tools in the further development of 
structure activity relationships (SAR).15-16 
The synthesis of a structurally diverse library of pharmacologically active compounds is 
an attractive possibility with this three-component reaction. There are many readily available 
aldehydes, (thio)ureas, and -keto esters that can be purchased or synthesized in one step. With 
three aldehydes, three ureas, and three esters, 27 unique compounds can be synthesized. If the 
4 
number of each component increases to five, then 125 unique compounds can be made. Following 
this strategy, we have developed a library of over 100 compounds that act as biologically active 
antagonists and agonists against heat shock protein70 (HSP70) such as MAL3-101, MAL1-271, 
and BBQU015254 (Figure 1-2).17-18 
 
 
Figure 1-2 DHPMs targeting HSP70 synthesized through Biginelli reactions 
 
As more complex molecules were targeted, new synthetic methods were required. The 
standard strong acid conditions limited functional group compatibility on the various components 
and also resulted in lower yields. In place of the typical strong Brønsted acid catalyst, hydrochloric 








 have been used successfully. The Lewis acid catalysts are believed to coordinate to the 
urea oxygen or nitrogen in the iminium route (A) and stabilize the N-acyliminium ions. Lewis 
acids are also hypothesized to interact with the -keto ester (Figure 1-3).21, 25 A number of ionic 
liquids have also been used as catalysts to both increase the rate of reaction and provide a “green 
chemistry” alternative.26 Another catalyst variation includes the use of organocatalysts to impart 
enantioselectivity in the DHPM synthesis.27 More recently, new techniques have been employed 
to enhance the scope of the reaction and also improve isolation and purification. In our group, we 
have utilized highly fluorinated substrates that can easily be isolated from organic solvents through 
liquid-liquid extractions, thus streamlining the synthesis of a large library of diverse DHPMs.28 
We have also employed a resin-linked GABA urea in a solid phase protocol that is readily cleaved 
with trifuloroacetic acid to streamline purification.17 
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Figure 1-3 Lewis acid coordination in N-acylimines and -keto ester 
 
While Biginelli reaction conditions typically furnish 3,4-dihydropyrimidinones, there are 
several examples of conditions that lead to alternative products (Figure 1-4). Overman utilized a 
tethered aldehyde and urea to synthesize hedahydropyrrolo[1,2-c]pyrimidines.29 Kappe and 
coworkers demonstrated the use of precondensed enones, derived from a Knoevenagel 
condensation of the aldehyde and carbonyl, with thioureas to form a library of 1,3-thiazines, an 
isomer of thio-Biginelli compounds.30   
 
 
Figure 1-4 Overman29 and Kappe30 preparation of atypical Biginelli reaction products 
1.1.2 The Diels-Alder Reaction 
The Diels-Alder reaction was first described by Otto Diels and Kurt Alder in 1928; an 
accomplishment for which they would be awarded the Nobel Prize in Chemistry in 1950.31 It is a 
[4+2] cycloaddition between a conjugated diene and an alkene (dienophile) (Scheme 1-3). The 
6 
Diels-Alder reaction is a particularly useful reaction as it provides control over regio- and 
stereochemical properties through a six-member transition state. It can occur inter- or 
intramolecularly and through various hetero π-systems to form functionalized heterocycles. 
 
 
Scheme 1-3 Diels-Alder reaction mechanism and product 
 
Many rules have been established for determining the reactivity, regio-, and stereochemical 
selectivity in the reaction: 1. cycloaddition is most facile when the s-cis conformation is favored 
in the diene; 2. in normal-electron-demand Diels-Alder reactions, reactivity increases when the 
diene is electron rich and the dienophile is electron poor; 3. in inverse-electron-demand Diels-
Alder reactions, electron withdrawing groups on the diene promote reactivity; 4. the 
stereochemistry of the diene and dienophile is retained in the product; 5. the ortho-para directive 
rule for regioselectivity is controlled by frontier molecular orbital (FMO) theory;32-34 and 6. the 
Alder endo rule governs stereoselectivity.35  
Based on the amount of control intrinsic to the reaction, it has been utilized as a key step 
in multiple natural product total syntheses, including cortisone and cholesterol by R.B. 
Woodward36, prostaglandins F2α and E2 by E.J. Corey37, and racemic reserpine by Stephen F. 
Martin.38 
The Biginelli DHPM can function as a tetrasubstituted dienophile in the Diels-Alder 
reaction albeit with low expected reactivity. Accordingly, publications on this topic are rare. 
Sharma and coworkers demonstrated the reaction of the Biginelli heterocycle with N-arylidine-N’-
methylformamidines and N-arylidine guanidine in a hetero Diels-Alder reaction but few other 




Scheme 1-4 Sharma et al. Diels-Adler reaction with Biginelli dienophile39 
1.1.3 Multi-Component Reactions 
MCRs are convergent reactions in which three or more starting materials react to form a 
product and most, if not all, atoms are incorporated into the product structure. In addition to the 
Biginelli reaction, there are many examples of named three-component MCRs including: Mannich 
reaction,40 Hantzsch Dihydropyridine (Pyridine) synthesis,41 Bucherer-Bergs reaction,42 Strecker 
amino-acid synthesis,43 Gewald reaction,44 Passerini reaction,45 Grieco condensation reaction,46 
and  Petasis reaction.47 There have been fewer four-component MCRs reported, the most well-
known of which is the Ugi reaction.48 Other four-component condensation reactions involve slight 
variations in the Ugi protocol, such as replacing the carboxylic acid with Meldrum’s acid.49 
Ghashang et. al recently reported a new four-component condensation synthesis of -amido 
ketones with an aldehyde, enolizable ketone, acetyl chloride, and acetonitrile or benzonitrile in the 
presence of ferric hydrogensulfate as a catalyst.50 
Even less has been published on five-component condensation reactions. Whitwood et al. 
disclosed an economic synthesis of highly functionalized piperidines from methyl acetoacetate, 
two equivalents of an aniline and two equivalents of an aromatic aldehyde (Scheme 1-5). The 
reaction is hypothesized to proceed through a Knoevenagel-like condensation between the imine 





Scheme 1-5 Whitwood et al. five-component condensation formation of piperidines51 
 
Mirkhani et. al described a five-component synthesis of phenylacetamides catalyzed by 
magnesium chloride.52 The reaction components include an aromatic diamine, ethyl malonyl 
chloride, an aromatic aldehyde, isocyanide, and water (Scheme 1-6). The reaction was tolerant of 
limited substitutions on the aldehyde and isocyanide components.   
 
 
Scheme 1-6 Mirkhani et al. five-component condensation to form phenylacetamides52 
 
Hasaninejad et al. described a pseudo five-component synthesis of pyrazoline-containing 
Schiff bases, from 1,1-bis(mehylthio)-2-nitroethylene (BMTNE), two equivalents of hydrazine, 
and two equivalents of aldehyde at room temperature (Scheme 1-7).53 The group further 
demonstrated a pseudo seven-component synthesis to form highly functionalized diazepines 
through the addition of two equivalents of malonitrile (Scheme 1-8).54 
 
 
Scheme 1-7 Hasaninejad et al. five-component condensation to form pyrazoline-containing Schiff bases53 
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Scheme 1-8 Hasaninejad et al. seven-component condensation to form diasepines54 
 
In 1993, Ugi disclosed a seven-component condensation reaction that occurred through a 




Scheme 1-9 Ugi seven-component condensation reaction and proposed route55 
1.2 Results and Discussion57 
While working to advance the scope of our DHPM library, we noted the use of 10% 
indium(III) bromide (InBr3) as a catalyst at reflux in ethanol for 7 h to produce a variety of 
DHPMs.24, 58 Particularly attractive was that these conditions gave good yields even with 
formaldehyde as a reaction component. Many other protocols catalyzed by Brønsted acids were 
not suitable with the unsubstituted aldehyde. Singh et al. demonstrated that 1,3-oxazinane could 
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be used as a formaldehyde substitute,59 but few methods actually utilized the highly reactive 
unsubstituted aldehyde. Initially, we hoped to be able to introduce substituents at the 4-position of 
the DHPM ring through an oxidative photochemical reaction related to the previously reported 
Friedel-Crafts amidoalkylation with the visible light catalyst, Ru(bpy)3Cl2.
60 However, we found 
that InBr3 conditions promoted a new five-component condensation with formaldehyde, and 
decided to first investigate the scope of this process (Figure 1-5). 
 
 
Figure 1-5 Literature precedence and synthetic plans 
 
The originally reported InBr3 reaction conditions utilized an excess of urea and equal 
equivalents of -keto ester and aldehyde. For our initial test reactions, we chose N,N’-dimethylurea 
as the limiting reagent. The reaction of N,N’-dimethylurea, 1.8 equiv of ethyl acetoacetate as the 
-keto ester, and 3 equiv of formaldehyde in 95% ethanol at reflux for 7 h yielded not only the 
expected DHPM product 1-1A but also a higher molecular weight product that we did not 
anticipate (Scheme 1-10). Through NMR and NOE analyses, we were able to assign its fused 
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bicyclic structure as 1-1B. We hypothesized that this secondary product occurred through a five-
component condensation reaction, and an in situ formal hetero Diels-Alder reaction of the expected 
DHPM Biginelli intermediate, which was in agreement with the product structure. 
 
 
Scheme 1-10 Five-component condensation reaction. For conditions see Table 1-1 
 
We subsequently explored a range of reaction conditions in an attempt to improve overall 
yield and selectivity. For these optimizations, we used our original reaction components N,N’-
dimethylurea, ethyl acetoacetate, and formaldehyde (Table 1-1). The traditional Brønsted acid 
catalyst, HCl, gave no conversion with formaldehyde (entry 2). We experimented with other Lewis 
acids (entries 3-6) to catalyze the reaction but saw no conversion with FeCl3 or ZnCl2. Conversion 
was modest with both InCl3 and AlCl3. Increasing the proportions of the -keto ester and the 
aldehyde to 2.5 and 5 equiv, respectively, improved the yield of both products 1-1A and 1-1B 
(entry 7). However, increasing or decreasing the reactant concentration (entries 8 and 9) did not 
improve the overall yield. Doubling the reaction time to 14.5 h also did not increase the conversion 
to product 1-1B (entry 10 vs entry 7). After a shortened reaction time of 2.0 h, only product 1-1A 
was isolated in 28% yield (entry 11). Accordingly, entry 7 represented our optimized conditions: 
1 equiv of urea, 2.5 equiv of -keto ester, 5.0 equiv of aldehyde, and 0.1 equiv of InBr3 at reflux 




Table 1-1 Investigation of reaction time, concentration, equivalents, and catalyst with formaldehyde, N,N-
dimethylurea, and ethyl acetoacetate 
 
We then used these optimized conditions to further explore the scope of the reaction (Table 
1-2). Formaldehyde was used as the aldehyde component in all reactions since preliminary trials 
with other aldehydes and ketones were not successful in producing any fused bicycles B. We also 
used symmetrical ureas exclusively to avoid possible regioisomers (exploratory reactions 
confirmed a lack of regioselectivity with unsymmetrical ureas; for example, while 1-methylurea 
and 1-(4-methoxyphenyl)-3-methylurea provided both the Biginelli DHPM and the Diels-Alder 
products, we were unable to separate the regioisomers formed in approximately 1:1 ratio). 
Curiously, the reaction with the N,N’-dimethylthiourea stopped at the Biginelli product 1-2A, 
which was isolated in 61% yield (entry 2). Methyl acetoacetate with thiourea (entry 3) also gave 
similar results, but product 1-3A was formed in lower yield, likely due to trans-esterification with 
ethanol. Utilizing benzyl acetoacetate, we were able to isolate both Biginelli (1-4A, 1-5A) and 
five-component condensation products (1-4B, 1-5B) in good overall yields with the urea and 
thiourea derivatives (entries 4 and 5). However, the yield of the five-component condensation 
Diels-Alder product 1-4B was considerably higher with the urea derivative than the 
pyranopyrimidinethione 1-5B resulting from the thiourea. With allyl acetoacetate and N,N’-
dimethylurea, we were able to isolate the five-component condensation product 1-6B, but not the 
 
 
























 (0.1) 7 0.2 10 26 
2 1 1.8 3 HCl (1.0) 7 0.5 0 0 
3 1 1.8 3 InCl3 (0.1) 7 0.3 23 25 
4 1 1.8 3 AlCl3 (0.1) 7 0.3 3 14 
5 1 1.8 3 FeCl3 (0.2) 7 0.2 0 0 
6 1 1.8 3 ZnCl2 (0.2) 7 0.3 0 0 
7 1 2.5 
 
5 InBr3
 (0.1)  7 0.2 45 48 
8 1 2.5 5 InBr3
 (0.1) 7 1.0 55 37 
9 1 2.5 5 InBr3
 (0.1) 7 0.05 38 27 
10 1 2.5 5 InBr3
 (0.1) 14.5 0.2 41 36 
11 1 2.5 5 InBr3
 (0.1) 2 0.2 28 0 
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corresponding Biginelli intermediate, as it proved unstable. We also attempted to replace the 
traditional -keto ester with 5,5-dimethyl-1,3-cyclohexanedione (dimedone) to probe the 
feasibility of adding an additional ring in the hetero Diels-Alder reaction (Figure 1-6). 
Unfortunately, with both N,N’-dimethylurea and its thiourea equivalent, we were only able to 
isolate Biginelli products 1-7A and 1-8A, in significantly lower yields than for the -keto ester 
conversions. 
 
Table 1-2 Reaction scope with formaldehyde, N,N’-dimethyl(thio)urea (X=O,S), and alkyl (R1) acetoacetatesa 
 
 
Figure 1-6 Attempted five-component condensation with a cyclic 1,3-diketone  
 
To confirm our hypothesis that the five-component condensation product formed through 
a hetero Diels-Alder reaction with the DHPM (Biginelli) intermediate, we reacted Biginelli 
product 1-1A with ethyl 2-methylene-3-oxobutanoate (Figure Scheme 1-11). After stirring in 












aConditions:  formaldehyde (5 equiv), N,N’-dimethyl(thio)urea (1.0 equiv), alkyl (R1) acetoacetate (2.5 
equiv), InBr3(0.1 equiv), EtOH (0.2 M), reflux.                          
bIsolated yield 
 
No. R1 X A [% Yield]b B [% Yield]b 
1-1 Ethyl O 45 48 
1-2 Ethyl S 61 0 
1-3 Methyl S 31 0 
1-4 Benzyl O 12 73 
1-5 Benzyl S 61 32 
1-6 Allyl O 0 21 
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Product, 1-1B, in 11% yield. We were also able to repeat this conversion with the Biginelli 
intermediate 1-5A to form the hetero Diels-Alder product 1-9B. 
 
 
Scheme 1-11 Stepwise conversions of intermediate DHPM (Biginelli) products in a hetero Diels-Alder reaction 
 
Interestingly, when the five-component condensation product 1-1B was subjected to 
Krapcho dealkylation conditions with LiCl in DMSO, we isolated the DHPM product, 1-1A, in 
87% yield, presumably through a retro Diels-Alder reaction (Scheme 1-12) 61. 
 
 




Scheme 1-13 Proposed mechanism of five-component condensation 
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Scheme 1-13 illustrates our proposed mechanism for the five-component condensation 
reaction. In the presence of a Lewis acid, condensation of the urea with the aldehyde and 
subsequent loss of water generates a sufficiently reactive electrophile for attack by the -keto ester, 
which then undergoes cyclization to give 1-1A. The excess -keto ester and formaldehyde react to 
form a methylene group at the α-position, and this electrophile then undergoes a hetero Diels-
Alder reaction with the intermediate DHPM 1-1A to provide the fused heterocyclic 1-1B a single 
stereoisomer. It should be noted that the hetero Diels-Alder reaction may occur via a step-wise 
addition reaction as many inverse-electron-demand Diels-Alder reactions occur via a step-wise 
mechanism opposed to a concerted mechanism.32 The condensation product resulting from the -
keto ester and formaldehyde is able to adopt the s-cis conformation as the diene. We determined 
the configuration of the methyl group to be cis to the ester at the two quaternary ring fusion atoms 
by converting the ester to the primary alcohol 1-10 with LiBH4, and then using a NOE analysis to 
confirm that the methyl group protons showed a >10% percent double resonance enhancement 
with the newly formed CH2 protons. 
1.3 Conclusions 
We have discovered and optimized experimental conditions for a novel one pot, five-
component condensation reaction with a -keto ester, urea, and formaldehyde. The reaction 
appears to proceed through an intermediate DHPM (Biginelli) product. The DHPM then reacts 
with the condensation product of the -keto ester and formaldehyde through a formal hetero Diels-
Alder reaction. While the scope of this new process is still limited to formaldehyde and 
symmetrical N,N’-dialkylated ureas, it provides easy access to bicyclic ring systems that were 
previously inaccessible through a single transformation. Going forward, nucleophilic additions at 
the 4-position of the Biginelli product can be investigated. Functionalities not compatible with the 
traditional Biginelli reaction can be introduced this way to expand a DHPM library. Additionally, 
the five-component condensation products should be tested for activity in HSP70 and other heat 
shock protein models. The bicyclic heterocycle represents a unique functionality that has not yet 
been tested. 
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1.4 Experimental Procedures 
General. All reagents were obtained commercially unless otherwise noted. All glassware was 
dried in an oven at 140 C for 2 h prior to use. Reactions were monitored by TLC analysis (EMD 
Millipore pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and visualization was 
accomplished with a 254 nm UV light or staining with a PMA solution (5 g of phosphomolybdic 
acid in 100 mL of 95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, 
and 3.5 mL of conc. H2SO4 in 100 mL of 95% EtOH), or a KMnO4 solution (1.5 g of KMnO4 and 
1.5 g of K2CO3 in 100 mL of a 0.1% NaOH solution). Some purification by chromatography was 
performed using a SiO2 Büchi flash chromatography system. 
1H/13C NMR spectra were recorded 
on either a Bruker Avance 300/75 MHz, Bruker Avance 400/100 MHz, Bruker Avance 500/135 
MHz, or Bruker Avance 600/150 MHz instruments. Chemical shifts were reported in parts per 
million with the residual solvent peak used as the internal standard (1H/13C: CDCl3, 7.26, 77.0 
ppm; CD3OD, 3.31, 49.3 ppm; DMSO, 2.50, 39.5 ppm). Chemical shifts were tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quarter, dd = doublet of doublet, 
dt = doublet of triplet, dq = doublet of quartet, m = multiplet, brd = broad, app = apparent), coupling 
constants, and integration. All 1D NMR spectra were processed using Bruker Topspin NMR. IR 
spectra were obtained on an Identity IR-ATR spectrometer. Melting points (uncorrected) were 
determined using a Mel-Temp instrument. HRMS data were obtained on a Thermo Scientific 
Exactive HRMS coupled to a Thermo Scientific Accela HPLC system using a 2.1 x 50 mm 3.5 
µm Waters XTerra C18 column eluting with MeCN/H2O containing 0.1% formic acid.   
 
General five-component condensation reaction procedure. Representative procedure for ethyl 
1,3,6-trimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-1A) and diethyl 
(4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a-tetrahydro-2H-pyrano[2,3-d]pyrimidine-
4a,6(5H)-dicarboxylate (1-1B). A solution of ethyl acetoacetate (1.21 mL, 9.43 mmol, 2.5 equiv), 
paraformaldehyde (0.478 g, 15.3 mmol, 5 equiv), and N,N’-dimethylurea (0.456 g, 5.07 mmol, 1 
equiv) in 95% ethanol (25 mL) was stirred at room temperature for 10 min. Indium(III) bromide 
(0.180 g, 0.507 mmol, 0.1 equiv) was added and the reaction mixture was heated under reflux for 
7 h, cooled to room temperature, filtered through basic Al2O3 (EtOAc) and concentrated under 
reduced pressure. The residue was purified by chromatography on SiO2 (3:1 to 1:3, 
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hexanes:EtOAc) to afford 1-1A (0.481 g, 2.26 mmol, 45%) as a light-yellow wax and 1-1B (0.855 
g, 2.41 mmol, 48%) as a yellow oil. This procedure was followed for all products in Table 1-2 and 
Figure 1-6, and spectral properties are presented below. 
 
Ethyl 1,3,6-trimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-
1A). IR (ATR, neat) 2981, 2908, 1673, 1623, 1414, 1262, 1204, 1077, 1027, 749 cm-1; 1H NMR 
(400 MHz, CD3OD) δ 4.16 (q, J = 7.1 Hz, 2H), 4.01 (d, J = 1.1 Hz, 2H), 3.17 (s, 3H), 2.92 (s, 3H), 
2.46 (t, J = 1.3 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 165.9, 154.8, 
150.8, 98.3, 59.8, 48.5, 34.2, 29.8, 14.8, 13.2; HRMS (HESI) m/z calcd for C10H17N2O3 [M+H]
+ 
213.1234, found 213.1234. 
 
Diethyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a-tetrahydro-
2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-1B). IR (ATR, neat) 2988, 2932, 1705, 
1629, 1498, 1443, 1344, 1234, 1087, 1042, 984, 870, 844, 753 cm-1; 1H NMR (400 MHz, CD3OD) 
δ 4.22-4.14 (m, 4 H), 3.53 (d, J = 12.7 Hz, 1H), 3.30 (d, J = 12.7 Hz, 1H), 2.95 (s, 3H), 2.92 (s, 
3H), 2.69 (dq, J = 17.8, 1.7 Hz, 1H), 2.45 (dq, J = 17.8, 1.6 Hz, 1H), 2.24 (t, J = 1.6 Hz, 3H), 1.61 
(s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 170.6, 
167.2, 160.2, 154.9, 99.8, 87.8, 61.4, 59.9, 49.3, 44.0, 34.9, 27.6, 27.5, 19.5, 18.5, 13.5, 13.1; 
HRMS (HESI) m/z calcd for C17H27N6O2 [M+H]
+ 355.1864, found 355.1862. 
19 
Ethyl 1,3,6-trimethyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(1-2A). IR (ATR, neat) 2978, 1670, 1636, 1525, 1443, 1357, 1267, 1208, 1169, 1141, 1088, 1016 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz, 2H), 4.06 (q, J = 1.0 Hz, 2H), 3.55 (s, 
3H), 3.42 (s, 3H), 2.45 (t, J = 1.0 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 180.8, 165.3, 149.2, 101.3, 60.5, 47.9, 42.9, 37.9, 16.2, 14.3; HRMS (HESI) m/z calcd for 
C10H17N2O2S [M+H]
+ 229.1005, found 229.1004. 
 
Methyl 1,3,6-trimethyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-3A). IR (ATR, neat) 2930, 2829, 1698, 1619, 1516, 1460, 1426, 1366, 1317, 1261, 
1169, 1091, 991, 803, 765 cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.09 (s, 2H), 3.77 (s, 3H), 3.58 (s, 
3H), 3.45 (s, 3H), 2.48 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 180.8, 165.7, 149.6, 101.0, 51.6, 
47.9, 42.9, 37.9, 16.3; HRMS (HESI) m/z calcd for C9H15N2O2S [M+H]




(1-4A). IR (ATR) 2933, 1663, 1554, 1486, 1450, 1193, 1128, 1077, 1027, 692 cm-1; 1H-NMR (300 
MHz, CD3OD) δ 7.37-7.34 (m, 5H), 5.17 (s, 2H), 4.04 (bd, J = 1.2 Hz, 2H), 3.17 (s, 3H), 2.91 (s, 
3H), 2.47 (t, J = 1.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.8, 165.0, 149.9, 136.0, 128.6, 
128.3, 128.1, 101.8, 66.3, 47.9, 42.9, 37.9, 16.4; HRMS (HESI) m/z calcd for C15H19N2O3 [M+H]
+ 
275.1390, found 275.1388. 
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Dibenzyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-4B). IR (ATR, neat) 2937, 
2882, 1713, 1629, 1506, 1448, 1379, 1348, 1232, 1077, 982, 884, 757 cm-1; 1H NMR (300 MHz, 
CD3OD) δ 7.35-7.32 (m, 10H), 5.17 (d, J = 16.4 Hz, 2H), 5.15 (s, 2H), 3.54 (d, J = 12.9 Hz, 1H), 
3.27 (d, J = 12.9 Hz, 1H), 2.90 (s, 3H), 2.84 (s, 3H), 2.73 (dq, J = 17.8, 1.6 Hz, 1H), 2.48 (dq, J = 
17.8, 1.6 Hz, 1H), 2.20 (t, J = 1.6 Hz, 3H), 1.54 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 
167.0, 161.2, 154.1, 136.2, 135.0, 128.6, 128.5 (2C), 128.1 (2C), 128.0, 99.6, 87.6, 67.3, 66.0, 
49.7, 44.1, 35.7, 28.1, 27.8, 20.7, 19.7; HRMS (HESI) m/z calcd for C27H31N2O6  [M+H]
+ 
479.2177, found 479.2176. 
 
Benzyl 1,3,6-trimethyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-5A). IR (ATR, neat) 2934, 1713, 1629, 1450, 1359, 1254, 1215, 1163, 1094, 1066, 
1029, 734 cm-1; 1H-NMR (600 MHz, CDCl3) δ 7.39-7.32 (m, 5H), 5.19 (s, 2H), 4.08 (d, J = 1.0 
Hz, 2H), 3.55 (s, 3H), 3.41 (s, 3H), 2.47 (d, J = 1.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 180.8, 
165.0, 149.9, 136.0, 128.6, 128.30, 128.17, 100.9, 66.3, 47.9, 43.0, 38.0, 16.4; HRMS (HESI) m/z 
calcd for C15H19N2O2S [M+H]
+ 291.1162, found 291.1160. 
 
Dibenzyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-thioxo-1,3,4,8a-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-5B). IR (ATR, neat) 2934, 
1713, 1629, 1450, 1340, 1232, 1215, 1077, 1003, 995, 734, 695 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 7.35-7.32 (m, 10H), 5.19-5.08 (m,4 H), 3.79 (d, J = 13.6 Hz, 1H), 3.39 (s, 3H), 3.34 (s, 3H), 3.31 
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(d, J = 13.5 Hz, 1H), 2.63 (dd, J = 17.8, 1.5 Hz, 1H), 2.36 (dd, J = 17.8, 1.5 Hz, 1H), 2.23 (t, J = 
1.5 Hz, 3H), 1.51 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 178.3, 169.0, 166.8, 160.1, 136.4, 
135.4, 128.3, 128.2 (2C), 128.1 (2C), 128.0, 127.9 (2C), 127.8, 101.1, 86.5, 68.0, 67.1, 65.7, 51.5, 
43.1, 42.7, 34.1, 26.0, 20.2, 18.1, 13.9; HRMS (HESI) m/z calcd for C27H31N2O5S [M+H]
+ 
495.1948, found 495.1945. 
  
Diallyl(4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a- 
tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)- dicarboxylate (1-6B). IR (ATR, neat) 
2934, 1728, 1709, 1646, 1500, 1445, 1410, 1345, 1234, 1214, 1102, 1082, 1040, 987, 882, 754 
cm-1; 1H NMR (400 MHz, DMSO- d6) δ 6.00–5.84 (m, 2H), 5.32–5.21 (m, 4H), 4.61 (dd, J = 16.0, 
4.0 Hz, 4H), 3.51 (d, J = 12.4 Hz, 1H), 3.22 (d, J = 12.4 Hz, 1H), 2.80 (s, 3H), 2.68 (s, 3H), 2.66 
(d, J = 17.6 Hz, 1H), 2.40 (d, J = 17.6 Hz, 1H), 2.20 (s, 3H), 1.52 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6) δ 170.5, 166.6, 160.6, 153.8, 133.5, 132.5, 118.1, 118.0, 99.9, 88.1, 65.8, 64.7, 49.3, 
44.2, 35.7, 28.3, 27.7, 20.7, 19.7; HRMS (HESI) m/z calcd for C19H27N2O6 [M+H]
+ 379.1864, 
found 379.1862.  
 
1,3,7,7-Tetramethyl-4,6,7,8-tetrahydroquinazoline-2,5(1H,3H)-dione (1-
7A). IR (ATR, neat) 2960, 2890, 1722, 1620, 1574, 1438, 1381, 1268, 1224, 1127, 1080, 1007 cm-
1; 1H NMR (400 MHz, CDCl3) δ 4.04 (s, 2H), 3.20 (s, 3H), 2.98 (s, 3H), 2.39 (s, 2H), 2.24 (s, 2H), 
1.11 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 194.3, 153.5, 153.2, 105.6, 49.2, 45.6, 40.2, 35.8, 
32.8, 30.4, 28.6; HRMS (HESI) m/z calcd for C12H19N2O2 [M+H]
+ 223.1441, found 223.1440. 
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1,3,7,7-Tetramethyl-2-thioxo-2,3,4,6,7,8-hexahydroquinazolin-5(1H)-one 
(1-8A). IR (ATR, neat) 2950, 2922, 2869, 1724, 1629, 1450, 1262, 1215, 1128, 1064, 982 cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.12 (s, 2H), 3.60 (s, 3H), 3.44 (s, 3H), 2.43 (s, 2H), 2.26 (s, 2H), 
1.11 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 194.6, 180.1, 151.0, 107.4, 49.3, 45.8, 43.8, 40.6, 
37.4, 33.1, 28.6; HRMS (HESI) m/z calcd for C12H19N2OS [M+H]
+ 239.1213, found 239.1211. 
 
Diels-Alder reaction of DHPM intermediate to form five-component condensation product. 
 
Diethyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a-tetrahydro-
2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-1B). Ethyl 1,3,6-trimethyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-1A, 0.096 g, 0.45 mmol) was added to ethyl 2-
methylene-3-oxobutanoate containing residual sulfolane (0.244 g, 1.72 mmol). The reaction 
mixture was stirred at room temperature for 18 h and then concentrated under reduced pressure. 
The residue was purified by chromatography on SiO2 with gradient elution (4:1 to 1:1, 
hexanes:EtOAc) to afford 1-1B (0.0682 g, 0.192 mmol, 11%) as a yellow oil that was 







tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-9B). Benzyl 1,3,6-
trimethyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1-5A, 0.043 g, 0.15 mmol) was 
added to ethyl 2-methylene-3-oxobutanoate containing residual sulfolane (0.021 g, 0.15 mmol). 
The mixture was stirred at room temperature for 18 h. Another 5 equiv of ethyl 2-methylene-3-
oxobutanoate containing residual sulfolane (0.105 g, 0.738 mmol) was added and the reaction 
mixture was stirred at room temperature for an additional 48 h. The mixture was concentrated 
under reduced pressure and the resulting residue was purified by chromatography on SiO2 (4:1 to 
2:1, hexanes:EtOAc) to afford 1-9B (0.0113 g, 0.0261 mmol, 18%) as a yellow oil: IR (ATR, neat) 
2975, 2934, 1705, 1644, 1525, 1450, 1340, 1232, 1077, 734, 701 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.34-7.25 (m, 5H), 5.13 (d, J = 12.0 Hz, 2H), 4.19-4.08 (m, 2H), 3.78 (d, J = 13.6 Hz, 
1H), 3.38 (s, 3H), 3.32-3.28 (m, 4H), 2.60-2.55 (m, 1H), 2.35-2.29 (m, 1H), 2.20 (t, J = 1.6 Hz, 
3H), 1.48 (s, 3H), 1.27-1.23 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 178.5, 170.0, 166.9, 159.6, 
134.9, 128.7, 128.6, 128.1, 101.3, 86.1, 67.6, 61.7, 60.3, 52.2, 43.9, 43.1, 34.9, 21.5, 19.2, 14.3, 
14.0; HRMS (HESI) m/z calcd for C22H29N2O5S [M+H]
+ 433.1792, found 433.1788. 
 
Conversion of five-component condensation product to DHPM under Krapcho conditions. 
 
Ethyl 1,3,6-trimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (1-1A). A mixture of diethyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-1,3,4,8a-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-1B, 0.050 g, 0.14 mmol), LiCl 
(0.016 g, 0.37 mmol), DMSO (2 mL), and water (4 drops) was heated at 160 C and the reaction 
was monitored by TLC analysis (2:1, hexanes:EtOAc). After 4 h, the reaction mixture was cooled 
to room temperature and extracted with EtOAc. The organic layer was dried (MgSO4), filtered, 
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and concentrated to yield ethyl 1,3,6-trimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(1-1A, 0.026 g, 0.12 mmol, 87%) as a light-yellow oil that was spectroscopically identical to 1-1A 
previously obtained in the one-pot Biginelli-Diels-Alder reaction. 
 
Structural confirmation by conversion to alcohol. 
 
Ethyl (4aRS,8aRS)-4a-(hydroxymethyl)-1,3,7,8a-tetramethyl-2-oxo-
1,3,4,4a,5,8a-hexahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylate (1-10). A mixture of 4 M 
LiBH4 in THF (0.16 mL, 0.63 mmol) and diethyl (4aSR,8aRS)-1,3,7,8a-tetramethyl-2-oxo-
1,3,4,8a-tetrahydro-2H-pyrano[2,3-d]pyrimidine-4a,6(5H)-dicarboxylate (1-1B, 150 mg, 0.42 
mmol) in Et2O (2.1 mL) was heated at 35 C for 3 h. The reaction was monitored by TLC analysis 
(1:2, hexanes:EtOAc). After 3 h, the reaction mixture was quenched with 1 M HCl with ice-
cooling. The solution was diluted with water and extracted with CH2Cl2 (3x5mL). The organic 
layer was dried (MgSO4), filtered, and concentrated under reduced pressure to yield 1-10 (0.0794 
g, 0.254 mmol, 60%) as white solid: Mp 114.8 - 116.9 °C; IR (ATR, neat) 3367, 2924, 1702, 1622, 
1507, 1445, 1407, 1378, 1347, 1291, 1250, 1159, 1110, 985, 885, 839, 754 cm-1; 1H NMR (400 
MHz, DMSO) δ 5.01 (t, J = 5.4 Hz, 1H), 4.08 (q, J = 7.2 Hz, 2H), 3.42 (dd, J = 10.8, 5.2 Hz, 1H), 
3.27 (dd, J = 10.8, 5.2 Hz, 1H), 3.12 (d, J = 12.0 Hz, 1H), 2.94 (d, J = 12.0 Hz, 1H), 2.81 (s, 3H), 
2.80 (s, 3H), 2.32 (brd d, J = 16.4 Hz, 1H), 2.15 (s, 3H), 2.13 (brd d, J = 16.4 Hz, 1H), 1.37 (s, 
3H), 1.21 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO) δ 167.6, 159.9, 154.3, 100.0, 89.9, 
62.1, 59.9, 48.7, 37.6, 35.9, 28.1, 27.1, 19.8, 19.7, 14.8; HRMS (HESI) m/z calcd for C15H25N2O5 




2.0 A Pilot-Plant Synthesis of Gefitinib 
2.1 Introduction 
2.1.1 Background and Early Syntheses 
Gefitinib (Iressa®) is a small molecule tyrosine kinase inhibitor (TKI) of the epidermal 
growth factor receptor (EGFR) originally developed by AstraZeneca.62 The drug was approved in 
2015 by the Food and Drug Administration (FDA) as a first-line treatment for metastatic non-small 
cell lung cancer (NSCLC) with EGFR mutations, specifically exon 19 deletion or exon 21 
substitution mutation.63 Gefitinib was actually the first EGFR-TKI approved by the FDA for 
NSCLC in 2003 but, at the time, the specific target patient population was not known so the 
compound was recommended as a third-line treatment only after chemotherapy failure. It is taken 
orally, once-daily, as a 250 mg tablet.64 In 2017 the market share was estimated at $136 million in 
the European Union (EU). Gefitnib came off patent in the EU in 2019 and Sandoz, a division of 
Novartis, and Lotus Chemicals, a division of Alvogen, both received approval for their generic 
versions in 13 EU countries. Currently, no “therapeutically equivalent” version of Gefitinib is 
available in the United States. 
Worldwide, lung cancer is the most prevalent fatal cancer for both men and women. In 
NSCLC, mutation of the EGFR tyrosine kinase domain destabilizes the kinase conformation and 
affects downstream signaling pathways.65 These disruptions stimulate cancer cell proliferation and 
inhibit apoptosis. Gefitinib reversibly binds to the ATP-site of the EGFR kinase domain to inhibit 
autophosphorylation and signal transduction thus stopping the growth and spread of tumors.66 
Four molecules have been approved for treatment of NSCLC with EGFR mutations (Figure 
2-1). A quinazoline makes up the core structure of Geftinib, Erlotinib, and Afatinib. Osimertinib, 
possessing a pyrimidine and 1-methylindole, was also produced by AstraZeneca specifically to 




Figure 2-1 Drugs approved to treat NSCLC with EGFR mutations 
 
Several syntheses of Gefitinib have been described in the literature. AstraZeneca’s original 
synthesis began with the demethylation of 6,7-dimethyoxyquinazoline-4-one with L-methionine 
and methanesulfonic acid, followed by acetylation, halogenation, aniline SNAr, deacetylation, and 
O-alkylation (Scheme 2-1).68 This six-step synthesis (10% overall yield) required chromatographic 
purifications and utilized hazardous reagents, such as thionyl chloride, which reacts violently with 
water to produce toxic sulfur dioxide and also contaminates the air very quickly upon evaporation 




Scheme 2-1 AstraZeneca synthesis of Gefitinib68 
 
In 2007, Reddy et al. reported a synthesis of Gefitinib from isovanillin (Scheme 2-2).69 The 
nitro group in the isovanillin-derived intermediate was reduced with sodium dithionite, followed 
by treatment with dimethylformamide-dimethylacetal (DMF-DMA) and amination with 3-chloro-
4-fluoroaniline to yield the API. No chromatography was required, but high reaction temperatures 
were needed and DMF was used in large quantities in the seven-step synthesis.  
 
 
Scheme 2-2 Reddy et al. synthesis of Gefitinib69 
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More recently, Suh et al. disclosed a variant of the AstraZeneca synthesis utilizing a 
transient protective group strategy (Scheme 2-3).70 An acetylated quinazoline core was subjected 
to a chlorination with POCl3, substitution with 3-chloro-4-fluoroaniline, and deprotection with 
LiOH, which set the stage for alkylation with 4-(3-chloropropyl)morpholine utilizing TMSI to 
transiently protect the aniline nitrogen. While high yielding, this synthetic route required 
hazardous TMSI and a more elaborate starting material. It also utilized phosphoryl chloride, which 
reacts violently with water to produce toxic gases and is highly corrosive. 
 
 
Scheme 2-3 Suh et al. synthesis of Gefitinib70 
 
At this time we were contacted by a pharmaceutical company interested in a novel 
synthesis of Gefitinib that could eventually be translated to a process-plant. For the synthesis we 
envisioned a new route to Gefitinib with fewer than five steps from inexpensive starting materials 
that would avoid hazardous reagents and chromatographic separations and keep reaction 
temperatures in the 0-60 C range. Such a process would be commercially relevant and potentially 
attractive for pharmaceutical manufacturing. 
2.1.2 Synthesis of Gefitinib from 2,4-Dichloroquinazoline71-72 
We chose the commercially available 2,4-dichloro-6,7-dimethoxyquinazoline (2-1) as the 
starting material (Scheme 2-4). To the best of our knowledge, a synthesis of Gefitinib or related 
analogs that utilizes a 2,4-dichloroquinazoline as a starting material or advanced intermediate is 
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unprecedented. Dichloroquinazoline 2-1 was reacted with 3-chloro-4-fluoroaniline in 20.4 equiv 
of acetic acid at 55 C for 2 h to yield the coupling product 2-2 after extraction and filtration with 
EtOAc. Under these conditions, we were able to exclusively isolate the desired 4-position aminated 
product 2-2 in 65% yield on a 5 g scale. Based on the large volumes of EtOAc and 2 M NaOH 
required for extraction, we were not able to run a single batch of this reaction on a scale larger than 
5 g. Efficient stirring was also a concern with the standard glassware that was readily available. 
The ensuing selective demethylation of 2-2 proved challenging and a variety of conditions 
were attempted to try and improve the ratio of demethylated isomers while not compromising the 
overall yield. It was important that, no matter the crude ratio, we would be able to obtain phenol 
2-3 in high selectivity through crystallization. Eventually we came across a protocol for the 
cleavage of methyl esters through ionic liquid (IL) reagents.73-74 Our IL was synthesized in situ 
from aluminum trichloride and trimethylammonium hydrochloride in dichloromethane and was 
directly used for the demethylation step in a one-pot protocol. With intermediate 2-2, we found 
that treatment with [TMAH][Al2Cl7] at 50 C for 2 h provided a 1.1-1.3 to 1 ratio of mono-
demethylated regioisomers, but that a favorable ratio of >95:5 of the desired product could readily 
be obtained in 30-35% yield without chromatography after crystallization of the concentrated 
reaction mixture from hot methanol. While not required for the next step, a second crystallization 
increased the regioisomeric purity to >99%. Once again, we were limited to a 5 g scale with this 
reaction due to stirring problems with the glassware at hand and also the large volumes of 2 M 
HCl required during the workup.  
For the alkylation of 2-3 we found that 4-(3-chloropropyl)morpholine in the presence of 
cesium carbonate in DMSO at 40 °C for 2.5 h provided ether 2-4 in 80% yield after filtration and 
crystallization in hot methanol. While this was a more concentrated reaction requiring less solvent, 
we were limited to a 1 g scale on this reaction based on the preceding steps scale limitations and 
overall yields.  
The final dehalogenation step also took considerable optimization but we eventually found 
that 15 equiv of zinc dust, 10 equiv of N,N,N’N’-tetramethylethylenediamine (TMEDA) in a 
mixture of MeOH and AcOH provided exclusively the desired dehalogenation of 2-4. After stirring 
the reaction mixture at 40 °C for 24 h, 15 equiv of 2-mercaptonicotinic acid was added to assist in 
the removal of excess zinc and zinc salts.75 Ultimately, we were able to crystallize the product with 
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hot MeOH to provide Gefitinib (2-5) as colorless crystals in 82% yield with >99% purity by LCMS 
analysis on a 1 g scale (Scheme 2-4).  
 
 
Scheme 2-4 A 2,4-dichloroquinazoline as a new starting material for Gefitinib preparation71-72 
2.2 Results and Discussion 
With the route established, we wanted to explore the feasibility of performing the sequence 
on a scale that would be more applicable to an industrial setting. The concept of a pilot-plant was 
described by Frank Vilbrant in Industrial & Engineering Chemistry in 1945.76 A pilot-plant serves 
to translate a concept into a commercially feasible, practical working plan. Chemists devising a 
future process route may readily avoid hazardous reagents and solvents but they fail to consider 
numerous important variables including: 1. just how endothermic or exothermic a reaction will be 
on scale and how to control the temperature; 2. how an amorphous reaction mixture is best mixed; 
and 3. if an extraction is really feasible based on the amount and identity of solvent required. A 
pilot-plant is intermediary between the benchtop and a process-plant. One of the key aspects of a 
pilot-plant is that it is flexible and that chemists operating in the pilot-plant can quickly make 
changes based on real time observations and challenges. This is what we set out to do with our 
benchtop Gefitinib synthesis; to not only run the reaction sequence on a larger scale but to think 
critically and problem solve during each individual step.  
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For our pilot-plant scale synthesis we first considered our choice of reaction vessel. Most 
steps in the reaction sequence are performed at a relatively high concentration, particularly step 1 
at 1.8 M and step 3 at 0.6 M. However, the large volumes of solvents required for work-up and 
extraction made the sequence difficult to execute in most standard glassware. With conventional 
glassware we were successful with the SNAr reaction and demethylation reaction on only a 5 g 
scale and the alkylation and final dehalogenation on 1 g scale. When a larger scale was attempted, 
particularly in step 1, we experienced a dramatic reduction in yields and in most cases were unable 
to isolate clean product. We hypothesized that two reasons for this were the inability to consistently 
and efficiently heat and cool reaction mixtures and also limitations with stirring. We addressed 
both of these concerns by purchasing a jacketed 2-L reactor (Figure 2-2). The reactor was 
compatible with a dual recirculating heater/chiller with a temperature range of -20 °C to 100 °C. 
The recirculating heater/chiller allowed better maintenance of temperature on larger scales both 
during the actual reaction and during the often exothermic work-up protocols. Additionally, with 
the jacketed reactor an overhead stirrer capable of reaching 1000 rpm could be utilized. With high 
speeds and the proper blade, efficient stirring was possible on >10 g scales. The reactor also had 




Figure 2-2 2-L Jacketed reactor design 
 
First, we turned our attention to the SNAr reaction. We had repeated success carrying out 
this reaction on a 5 g scale; however, when we attempted to scale up the reaction to 10 g we 
experienced many problems. The profile of this reaction is unique. If quinazoline 2-1 is too soluble 
in the volume of acetic acid, there are many side products. If quinazoline 2-1 is not soluble enough, 
mixing is insufficient and there is no reaction. Through screening, we determined that the reaction 
worked best at a 1.8 M concentration in acetic acid. At this concentration the reaction mixture is 
very viscous and stirs for ~30 min before solidifying. During the remaining 1.5 h of reaction time, 
pockets of unreacted starting material are seemingly consumed. Initially, when scaling this 
reaction from 5 g to 10 g, sufficient mixing was never achieved; the presence of starting material 
and side products made purification difficult.  
We believed that the 2-L jacketed reactor with specialized overhead stirrer capable of 
reaching 1000 rpm would allow us to scale this reaction beyond 5 g. We decided to perform the 









Reflux Condenser and/or N2
Addition Funnel
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mechanical stirring. Gratifyingly, at 315 rpm we observed homogenous mixing for the first 30 
min. After 30 min, there was partial solidification but some mixing (30 rpm) was maintained. The 
paddle shape of the stirring rod was important for this; it pulled the mixture in instead of pushing 
the reaction mixture out towards the edges of the reactor, something that was not possible when 
performing the reaction in standard glassware. After 2 h, the reaction appeared much more uniform 
compared to previous trials. 
With the goal of demonstrating that this reaction could be performed on a process scale, 
we made modifications to the work up procedure that would reduce solvent volumes and thus 
required process reactor sizes. Previously, the product was extracted in a separatory funnel with 
EtOAc (0.5 L) and 2 M NaOH (275 mL). If this procedure was applied to a 75 g reaction, 7.5 L of 
EtOAc and 4.1 L of 2 M NaOH would be required. These volumes coupled with the use of a 
separatory funnel were not practical on this scale. Accordingly, we decided to carry out the 
extraction in the reactor and switch to dichloromethane and 6 M NaOH for the extraction solvents. 
After cooling to 0 °C, CH2Cl2 (300 mL) and 6 M NaOH (800 mL) were added and the resulting 
mixture was stirred vigorously (400 rpm). Based on density, the top (aqueous) layer was siphoned 
off and the process was repeated with additional 2 M NaOH (200 mL). After the extraction was 
complete, the organic layer was transferred to a fritted funnel, the filter cake collected, and the 
solids recrystallized from methanol (500 mL). With this protocol, 2-2 was successfully obtained 
in 87% yield (91 g, 247 mmol) as a ca. 90% pure colorless solid with a similar purity profile to the 
5 g scale reactions.  
Throughout the reaction sequence, the first step was a major obstacle. We had a difficult 
time generating sufficient material to optimize the subsequent steps. The scale limitations of the 
first step decreased the attractiveness of the route for manufacturing companies. With the 2-L 
jacketed reactor and protocol modifications, we were able to increase the yield to 87% while 
reducing overall solvent use to: CH2Cl2 (500 mL), 6 M NaOH (800 mL), 2 M NaOH (200 mL), 







Table 2-1 Pilot-plant optimizations of step 1 – SNAr reaction 
 5-g Reaction 75-g Reaction 
Reaction Vessel Round bottom flask 2-L jacketed reactor 
Stirring Method Magnetic stirring Overhead stirring (315 rpm) 
Heating Mechanism Ceramic heating block Recirculating heater/chiller 
Cooling Mechanism Ice bath Recirculating heater/chiller 
Extraction Vessel Separatory funnel 2-L jacketed reactor 
Extraction Solvent EtOAc and 2 M NaOH CH2Cl2 and 6 M NaOH 
 
With the success obtained with the 2-L jacketed reactor in the first step, we decided to also 
try the second, demethylation step in the reactor. Like the first step, the demethylation step was 
previously limited to a 5 g scale. The most important aspect of this reaction is the work up. The 
demethylation is catalyzed by the ionic liquid [TMAH][Al2Cl7]. The work up procedure functions 
to break up the aluminum complexes. If the particle size is too large, crystallization of the desired 
phenol regioisomer in high selectivity is difficult. On a 5 g scale, 2 M HCl (200 mL) was added at 
a controlled rate to break up the complexes. However, this addition was very exothermic and in 
standard glassware it was difficult to sufficiently cool the resulting suspension and ensure that the 
internal temperature did not rise above 20 °C.  
We initially targeted an 18 g reaction in the reactor. The ionic liquid [TMAH][Al2Cl7] was 
synthesized directly in the 2-L jacketed reactor. The dual recirculating heater/chiller allowed for 
the addition of aluminum chloride and trimethylammonium chloride at 0 °C and then warming to 
rt once addition was complete. After 2 h, intermediate 3-2 was added through one of the three 
addition ports at the top of the reactor. These addition ports allowed for the reaction to be kept 
under N2, use of a reflux condenser as needed, and also use of an addition funnel when required. 
Once the reaction was complete, the dual recirculating heater/chiller enabled efficient cooling of 
the reactor from 50 °C to 0 °C. An internal thermometer indicated that the recirculating chiller was 
effective in maintaining the desired temperature. The 18 g reaction required 900 mL of 2 M HCl. 
Vigorous stirring (410 rpm) was maintained and 2 M HCl was added through an addition funnel, 
initially dropwise. The recirculating chiller maintained complete control of the exothermic 
addition; the temperature did not rise above 10 °C during the addition. Once the pH was <1, the 
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mixture was transferred to a fritted funnel and the filter cake was collected, concentrated by rotary 
evaporation, and crystallized from methanol two times to provide the desired isomer 2-3 in 43% 
yield (7.65 g, 20.5 mmol) with ~95% purity (Table 2-2). 
The demethylation, step 2 of the reaction, proved to be the lowest yielding step of the 
sequence. In our experience, it was important to carry on intermediate 2-3 with high purity (<10% 
undesired phenol isomer) in order to have success in the alkylation and dechlorination steps. With 
the 2-L jacketed reactor, we were able to efficiently heat/cool the reaction mixture while more than 
tripling our scale and increase the yield to ~40% while maintaining the overall purity of 
intermediate 2-3. 
 
Table 2-2 Pilot-plant optimizations of step 2 – Demethylation reaction 
 5-g Reaction 18.4-g Reaction 
Reaction Vessel Round bottom flask 2-L jacketed reactor 
Stirring Method Mechanical stirring Overhead stirring (310 rpm) 
Heating Mechanism Ceramic heating block Recirculating heater/chiller 
Cooling Mechanism Ice bath Recirculating heater/chiller 
Extraction Vessel Separatory funnel 2-L jacketed reactor 
 
With the material obtained from step 2 in the 2-L jacketed reactor, we attempted the 
alkylation step on larger scale. Our major limitations in this step had been a lack of material, thus 
the largest successful scale this reaction was performed was a 1 g scale. Step 3 is relatively 
concentrated (0.6 M), so on a 4.4 g scale, the 2-L reactor was not required. Intermediate 2-3 (4.38 
g), cesium carbonate (8.14 g), and 4-(3-chloropropyl)morpholine (2.12 mL) were dissolved in 
DMSO (35 mL) in a 250 mL round bottom flask. Minimum changes were made from the 1 g scale 
work-up protocol as the volume of the extraction solvents was <650 mL; a 1-L separatory funnel 
could be used. After extraction, concentration, and crystallization in MeOH, intermediate 2-4 was 
obtained in 37% yield (2.18 g, 4.53 mmol) (Table 2-3). 
This yield was significantly lower than the 80% yield obtained on a 1 g scale. There was 
still room for optimization on this step. We hypothesized that there was oxidation of phenol 2-3 
which, when stirred in MeOH, resulted in the loss of the quinazoline Cl and subsequent attack by 
methanol to form the methyl isourea at the 2-postion (Figure 2-3). This could be avoided by 
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running the reaction under an N2 atmosphere. Accordingly, we repeated the reaction on a 1.8 g 
theoretical yield scale and kept the mixture under an N2 atmosphere until work-up/extraction. We 
also used degassed solvents during the extraction. With these modifications, 2-4 was obtained in 
70% yield.  It was evident that the N2 atmosphere was critical as the reaction remained a light 
brown color and did not turn black like the previous trial. 
 
 
Figure 2-3 Proposed oxdiation side product 
 
Table 2-3 Pilot-plant optimizations of step 3 – Alkylation reaction 
 1-g Reaction 4.3-g Reaction 
Reaction Vessel Round bottom flask Round bottom flask 
Stirring Method Conventional stirring Conventional stirring 
Heating Mechanism Ceramic heating block Ceramic heating block 
Extraction Vessel Separatory funnel (500 mL) Separatory funnel (1 L) 
 
Finally, we attempted to double our scale for the final, dechlorination step of the sequence. 
The dechlorination step was the step we had the least experience with, so we were interested to 
see how scalable it was. In scaling from 1 g to 2 g, we altered the ratios of zinc dust and 2-
mercaptonicotinic acid used. We did not believe the full 15 equiv of zinc dust and 2-
mercaptonicotinic acid were required for the reaction and that using less of these reagents, 
particularly zinc dust, would make this step more amenable to a process scale. Accordingly, to 
intermediate 2-4, zinc dust (10 equiv), TMEDA (10 equiv), and acetic acid (20 equiv) were added 
and after stirring for 24 h at 40 °C, 2-mercaptonicotinic acid (5 equiv) was added to help complex 
and remove the zinc. After extraction, concentration, and crystallization from methanol, 2-5 
(Gefitinib) was obtained in 75% yield (1.51 g, 3.38 mmol) (Table 2-4). 
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On a 2 g scale, we successfully reduced the amount of zinc dust and 2-mercaptonicotinic 
acid used while maintaining the >70% yield and high purity of the final API 2-5.  
 
Table 2-4 Pilot-plant optimizations of step 4 – Dechlorination reaction 
 1-g Reaction 2.2-g Reaction 
Reaction Vessel Round bottom flask Round bottom flask 
Stirring Method Conventional stirring Conventional stirring 
Heating Mechanism Ceramic heating block Ceramic heating block 





We have successfully demonstrated that our Gefitinib synthesis route can be carried out on 
a pilot-plant scale. With the use of a 2-L jacketed reactor, recirculating heater/chiller, overhead 
mechanical stirrer capable of spin speeds up to 1000 rpm, and modifications to extraction solvents 
and volumes and reagent equivalents, we were able to conduct all reaction steps on a larger scale: 
SNAr reaction - 75 g, demethylation reaction – 18 g, alkylation reaction – 4.3 g, dechlorination 
reaction – 2.2 g. In the future, the alkylation step should be carried out on a >4 g scale, under an 
inert N2 atmosphere, to confirm our hypothesis for the formation of oxidation side products. Once 





2.4 Experimental Procedures 
General. All reagents and solvents were used as received unless otherwise specified. CH2Cl2 was 
distilled over CaH2. Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254 
plates, 250 µm layer thickness) and visualization was accomplished with a 254/280 nm UV light 
and/or by staining with KMnO4 solution (1.5 g KMnO4 and 1.5 g K2CO3 in 100 mL of a 0.1% 
NaOH solution), a ninhydrin solution (2 g ninhydrin in 100 mL EtOH), a PMA solution (5 g 
phosphomolybdic acid in 100 mL EtOH), or a p-anisaldehyde solution (2.5 mL p-anisaldehyde, 2 
mL AcOH and 3.5 mL conc. H2SO4 in 100 mL EtOH). Melting points were determined on a Mel-
Temp II capillary melting point apparatus fitted with a Fluke 51 II digital thermometer. Infrared 
spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer. NMR spectra were 
recorded on a Bruker Avance 400 MHz instrument. Chemical shifts were reported in parts per 
million (ppm) and referenced to residual solvent. 1H NMR spectra are tabulated as follows: 
chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, brd s = broad singlet, dd = doublet of doublets, app t = apparent triplet), coupling 
constant(s), number of protons. 13C NMR spectra were obtained using a proton-decoupled pulse 
sequence and are tabulated by observed peak. 19F NMR spectra were obtained using a proton-
decoupled pulse sequence. HRMS data were obtained on a Thermo Scientific Exactive Orbitrap 
LC-MS (ESI positive ion mode) coupled to a Thermo Scientific Accela HPLC system using a 2.5 
μM Waters XBridge C18 column (2.1 x 50 mm; 10 min gradient elution with MeCN/H2O/ MeOH 
containing 0.1% formic acid at a flow rate of 500 μL/min from 3:92:5 at 0-0.5 min to 93:2:5 at 4.0 
min, back to 3:92:5 from 6.0 to 7.5 min). Where applicable, both an internal and external 





amine (2-2). In a jacketed 2-L reactor, a vigorously mechanically stirred (315 rpm), pale pink, 
homogeneous solution of 3-chloro-4-fluoroaniline (46.4 g, 312 mmol, 1.1 equiv) in acetic acid 
(332 mL, 5787 mmol, 20.4 equiv) was treated at 45 °C with neat 2,4-dichloro-6,7-
dimethoxyquinazoline (75.0 g, 283 mmol) in three portions. The temperature was monitored with 
an internal digital thermometer probe. After the addition was complete (1 min), the resulting 
mixture was warmed to 55 °C for a total of 2 h. The pink solution turned golden yellow and viscous 
and solids precipitated after about 15 min. After 30 min, the stirring speed was decreased (30 rpm). 
TLC analysis (5% MeOH:CH2Cl2; product Rf=0.2) after 2 h showed that the aniline and 
quinazoline starting materials were consumed and the product had formed. The heterogeneous 
pinkish brown reaction slurry was cooled to 0 °C, diluted with CH2Cl2 (300 mL), and 6 M NaOH 
(800 mL) was added over 1 h (5 mL/min for the first 150 mL and 15 mL/min afterwards) under 
vigorous stirring (215-400 rpm). The aqueous layer (top, pH 14) was siphoned off, additional 2 M 
NaOH (200 mL) was added to the organic layer (pH 7 before addition of 2 M NaOH). The biphasic 
mixture was stirred vigorously (400 rpm) to generate a slurry with small particle size. The aqueous 
layer (top) was siphoned off again, and the organic layer was transferred onto the top of a fritted 
funnel. Liquids were filtered off under aspirator vacuum. The filter cake was washed with CH2Cl2 
(200 mL) and dried under reduced pressure to yield a first batch of product (133 g) that was mostly 
brown but retained some pink clumps. 19F NMR indicated >85% product (ratio of product to side 
products, 10:1:1.5). 
The combined aqueous layers can be back-extracted with CH2Cl2 (2 x 200 mL). The 
resulting organic layers were combined, dried (Na2SO4), filtered, and concentrated to yield a light 
brown residue (25.2 g). This residue was dissolved in MeOH (45 mL) and allowed to precipitate 
at rt for 3 h. The precipitate was filtered, washed with MeOH (30 mL), and concentrated under 
reduced pressure to provide additional product (6.6 g). 
The combined solids (139 g) were dissolved in MeOH (500 mL) and vigorously 
magnetically stirred at reflux for 30 min. The suspension was allowed to cool at rt for 3 h and 
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transferred to a fritted funnel. The filter cake was washed with cold (0 °C) MeOH (3 x 30 mL), 
and dried under reduced pressure to provide 2-2 (91 g, 247 mmol, 87%) as a ca. 90% pure colorless 
solid (19F NMR indicated a product to side products ratio of 20:1:2) that was used for step 2 without 
further purification: TLC 5% MeOH/CH2Cl2 Rf=0.2; Mp 271.5-273.9 C; IR (ATR, neat) 3392, 
1664, 1624, 1608, 1572, 1497, 1430, 1137, 1207, 1144, 997, 963, 845, 795, 695; 1H NMR (DMSO-
d6, 400 MHz) δ 9.92 (s, 1H), 8.01 (dd, J = 6.8, 2.4 Hz, 1 H), 7.83 (s, 1 H), 7.77-7.73 (m, 1 H), 
7.50 (app t, J = 8.8, Hz, 1 H), 71.9 (s, 1 H), 3.95 (s, 3 H), 3.93 (s, 3 H); 13C NMR (DMSO-d6, 400 
MHz) δ 158.2, 155.6, 154.4, 149.6, 148.7, 136.3, 124.7, 123.5, 123.4, 117.3, 117.1, 107.6, 107.2, 
102.5, 56.8, 56.5; 19F NMR (376 MHz, DMSO-d6) δ -121.9; HRMS (LCMS ESI+) m/z calcd for 
C16H13Cl2FN3O2 [M+H] 368.0363, found 368.0364.  
 
 [TMAH][Al2Cl7]. A suspension of aluminum chloride (51.6 g, 383 mmol) 
in CH2Cl2 (500 mL) was cooled to 0 C for 10 min in a 2-L reactor and then treated with 
trimethylammonium chloride (18.7 g, 192 mmol) under N2 atmosphere. Upon addition of 
trimethylammonium chloride, the reaction mixture changed from a yellow to a golden-brown 
color. After addition was complete, the reaction mixture was warmed to 23 C and allowed to stir 
via mechanical stirring at 72 rpm for 2 h. This mixture (69.4 g in 500 mL CH2Cl2) was used in the 
subsequent reaction without further purification or concentration. 
 
2-Chloro-4-((3-chloro-4-fluorophenyl)amino)-7-
methoxyquinazolin-6-ol (2-3). In a jacketed 2-L reactor, a suspension of 2-chloro-N-(3-chloro-4-
fluorophenyl)-6,7-dimethoxyquinazolin-4-amine (18.4 g, 50.0 mmol) in CH2Cl2 (100 mL) was 
added in 6 portions to a freshly prepared solution of the ionic liquid [TMAH][Al2Cl7] (69.4 g, 191 












as a wash. The golden yellow-brown reaction mixture was mechanically stirred (250 rpm) and 
heated for 2.5 h at 50 C. After 2.5 h, the suspension was cooled to 0 °C (over 0.5 h), and 2M HCl 
(~900 mL) was added through an addition funnel at the top of the reactor, drop-wise for the first 
125 mL, and subsequently at a rate of 20.0 mL/min over 40 min while the rapidly forming 
suspension was stirred vigorously (410 rpm). The internal temperature of the solution was 
maintained below 10 °C. After complete addition of 2M HCl, the resulting mixture was transferred 
to a fritted funnel (5 L) with filter paper and the solid/filter cake was collected. 
The collected filter cake was washed with water (200 mL) and briefly dried by vacuum filtration 
to give ~350 g of a viscous residue which was transferred into a round bottom flask and 
concentrated by rotary evaporation until a slurry of 90 g was obtained. This residue was then 
suspended in hot MeOH (450 mL), heated to reflux for 30 min, and allowed to cool and precipitate 
for 12 h; 4 h while stirring was maintained and 8 h once stirring was stopped. The sticky solid was 
collected by filtration, washed with MeOH (250 mL), and suspended in hot methanol (500 mL), 
and allowed to precipitate for 20 h. The solid was collected by filtration, washed with MeOH (60 
mL), and dried in vacuo (0.5 Torr, 20 °C) to provide a first batch of product (5.85 g).  
The filtrate was concentrated, suspended in hot MeOH (150 mL), heated to reflux for 30 
min, and allowed to cool and precipitate for 5 h while stirring was maintained. The solid was 
collected by filtration, washed with MeOH (40 mL), and dried in vacuo (0.5 Torr, 20 °C) to provide 
a second batch of product (1.8 g).  
Total, 2-3 (7.65 g, 20.5 mmol, 43%) was obtained as a >95% pure off-white solid: TLC 
(5% MeOH:CH2Cl2) Rf= 0.4; Mp 348.2-349.6 C; IR (ATR, neat) 2941, 1631, 1541, 1499, 1458, 
1337, 1303, 1262, 1226, 1080, 1062, 1009, 864, 826, 743, 694; 1H NMR (400 MHz, DMSO-d6) δ 
9.86 (s, 1 H), 8.09 (dd, J = 6.8, 2.8 Hz, 1 H), 7.80-7.76 (m, 2 H), 7.46 (appt t, J = 9.2 Hz, 1 H), 
7.20 (s, 1 H), 3.97 (s, 3 H); 13C NMR (400 MHz, DMSO-d6) δ 158.1, 155.2, 153.6, 152.8, 147.5, 
136.6, 124.2, 123.0, 119.4, 119.2, 117.2, 117.0, 108.3, 106.3, 56.6; 19F NMR (376 MHz, DMSO-





morpholinopropoxy)-quinazolin-4-amine (2-4). A solution of 2-chloro-4-((3-chloro-4-
fluorophenyl)amino)-7-methoxy-quinazolin-6-ol (4.38 g, 12.4 mmol), 4-(3-
chloropropyl)morpholine (2.12 mL, 13.6 mmol), and cesium carbonate (8.14 g, 24.7 mmol) in 
DMSO (35 mL) was stirred at 40 °C and monitored by TLC (2% MeOH/CH2Cl2; starting material 
Rf=0.3; product Rf=0.2). After 3 h, the mixture was cooled to rt, diluted with EtOAc (350 mL) 
and water (100 mL), and extracted. The organic layer was washed with sat. NaHCO3 (2 x 85 mL), 
1M LiCl (25 mL) and 2M NaOH (25 mL). The aqueous layer (pH 12) was then back-extracted 
with EtOAc (2 x 175 mL) and the combined organic layers were dried (Na2SO4, 55 g), filtered, 
rinsed with EtOAc (100 mL) and concentrated. The crude residue (7.3 g) was heated at reflux in 
MeOH (70 mL) for 10 min and then allowed to precipitate at rt for 5 h. The solids were collected 
by filtration, washed with MeOH (35 mL), and dried in vacuo (0.5 Torr, 20 °C) to afford 2-4 (2.18 
g, 4.53 mmol, 37%) as a colorless solid: TLC (2% MeOH:CH2Cl2) Rf= 0.2; Mp 216.2-218.9 C; 
IR (ATR, neat) 3329, 2946, 2812, 1623, 1579, 1494, 1431, 1290, 1256, 1221, 1149, 1110, 1057, 
1014, 961, 853, 798, 776, 736, 695; 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1 H), 8.01 (dd, J = 
6.8, 2.8 Hz, 1 H), 7.83 (s, 1 H), 7.76-7.72 (m, 1 H), 7.50 (app t, J = 9.2 Hz, 1 H), 7.19 (s, 1 H), 
4.17 (t, J = 6.4 Hz, 1 H), 3.93 (s, 1 H), 3.58 (app t, J = 6.4 Hz, 1 H), 2.47-2.45 (m, 2 H), 2.38 (brd 
s, 4 H), 2.01-1.98 (m, 2 H); 13C NMR (100 MHz, DMSO-d6) δ 158.2, 155.7, 154.4, 148.9, 148.6, 
136.3, 124.8, 123.6, 123.5, 119.4, 117.3, 117.1, 107.6, 107.2, 103.3, 67.7, 66.6, 55.6, 55.4, 53.9, 
26.3; 19F NMR (376 MHz, DMSO-d6) δ -121.8;  HRMS (LCMS ESI+) m/z calcd for 




morpholinopropoxy)quinazolin-4-amine (2-5, Gefitinib).68 To a suspension of zinc dust (2.96 
g, 45.3 mmol, 10 equiv) and TMEDA (6.9 mL, 45 mmol, 10 equiv) in MeOH (110 mL) at 0 °C 
was added dropwise acetic acid (5.2 mL, 90.6 mmol, 20 equiv) followed by 2-chloro-N-(3-chloro-
4-fluorophenyl)-7-methoxy-6-(3-morpholino-propoxy)-quinazolin-4-amine (2.18 g, 4.53 mmol). 
The temperature was monitored with an internal and external thermometer. The reaction mixture 
was heated at 40-45 °C for 24 h, cooled to rt, and diluted with MeOH (115 mL). To this solution 
was added 2-mercaptonicotinic acid (3.58 g, 22.6 mmol, 5 equiv). The suspension was vigorously 
stirred at rt for 30 min, diluted with MTBE (190 mL), and washed with 2 M NaOH (2 x 190 mL). 
The combined aqueous layers were back-extracted with MTBE (2 x 190 mL), and the combined 
organic layers were washed with sat. NaHCO3 (190 mL), dried (Na2SO4, 65 g), filtered, and 
concentrated to give a white-yellow solid residue (7.25 g). The solid was dissolved in hot MeOH 
(55 mL) and allowed to crystallize for 3 h at rt. The colorless needles were collected by filtration, 
washed with MTBE (20 mL), and dried in vacuo (0.5 Torr, 20 °C) to provide a first batch of 
crystalline product (1.35 g). The mother liquor was concentrated (~30 mL) and allowed to 
crystallize overnight at rt. The resulting crystals were filtered and dried in vacuo (0.5 Torr, 20 °C) 
to provide a second batch of product (0.240 g) that was combined. The product was further dried 
in vacuo (0.5 Torr, 80 °C) for 24 h to provide (2-5, Gefitinib, Iressa®) as a colorless solid (1.51 g, 
3.38 mmol, 75%): TLC 1:2:2, EtOH:EtOAc:Hex Rf=0.2; Mp 195.2-197.3 C; IR (ATR, neat) 
3365, 3160, 1873, 2816, 1622, 1578, 1530, 1497, 1472, 1426, 1393, 1353, 1280, 1217, 1112, 1044, 
993, 957, 850, 772 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.57 (s, 1 H), 8.50 (s, 1 H), 8.12 (dd, J 
= 6.8, 2.4 Hz, 1 H), 7.81-7.77 (m, 2 H), 7.45 (app t, J = 9.2 Hz, 1 H), 7.20 (s, 1 H), 4.18 (t, J = 6.4 
Hz, 1 H), 3.94 (s, 3 H), 3.58 (app t, J = 4.4 Hz, 4 H), 2.48-2.46 (m, 2 H), 2.39 (brd s, 4 H), 2.03-
1.96 (m, 2 H); 13C NMR (100 MHz, DMSO-d6) δ 156.5, 155.0, 153.1, 148.8, 124.0, 122.9, 122.8, 
117.1, 116.9, 109.2, 107.8, 103.0, 67.6, 66.6, 56.4, 55.4, 53.9, 26.3; 19F NMR (376 MHz, DMSO-
d6) δ -123.3; HRMS (LCMS ESI+) m/z calcd for C22H25ClFN4O3 [M+H] 447.1594, found 
447.1594. 
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3.0 Synthesis of JP4-039 Analogs Through a Vinylogous Mannich Reaction and Their In 
Vitro Activity as Ferroptosis Inhibitors 
3.1 Introduction 
3.1.1 Mitochondria Targeting Nitroxides and Their Therapeutic Indications 
Our group has a great interest in mitochondria-targeting therapeutics. Our strategy is to use 
a mitochondrial-targeting moiety to deliver a potent payload across the membrane.77-79 The 
mitochondrial-targeting fragment is designed based on gramicidin S (Figure 3-1), a 
cyclodecapeptide natural product combining natural and unnatural amino acids that has activity 
against Gram-positive and Gram-negative bacteria.80 
 
 
Figure 3-1 Structure of gramicidin S 
 
Gramicidin S is amphipathic with an antiparallel -sheet secondary structure that positions 
hydrophilic and hydrophobic amino acids on opposite sides of the molecule.80 The biological 
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activity of gramicidin S derives from favorable interactions with cell membranes, however, as a 
single agent it has limited practical therapeutic value because of cytotoxic side effects such as 
hemolysis.81 In our peptide mimics, we have replaced a polar, internal amide bond with an alkene 
dipeptide isostere (Figure 3-2).77-79, 82 (E)-Alkene peptide isosters are innately rigid and, unlike 
amides, not susceptible to peptidase cleavage, thus increasing bioavailability.80 
 
 
Figure 3-2 (E)-alkene is an isostere of an amide 
 
We have utilized a nitroxide moiety, specifically 2,2,6,6-tetramethylpiperidin-N-oxyl 
(TEMPO) (Figure 3-3), as the payload in our design. Nitroxides are stable compounds that contain 
a nitroxyl moiety with an unpaired electron.83 The most commonly utilized heterocyclic nitroxides 
have substitutions at each of the -carbons of the nitroxide to enhance stability.83 4-Hydroxy-
TEMPO (TEMPOL) is one example of a simple nitroxide that has been shown to increase insulin 
responsiveness, provide protective effects in neurodegenerative models, and counteract oxidative 
stress (Figure 3-3).84 Other nitroxide bearing compounds have shown efficacy in lung, breast, 
thyroid, and ovarian cancer.83  
 
 
Figure 3-3 Structures of TEMPO and TEMPOL 
 
Nitroxides act as radical-scavenging antioxidants.85 An antioxidant is any compound that 
inhibits oxidation in the body.86 Innate antioxidants to the body include ubiquinol (coenzyme Q), 
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glutathione (GSH) (Figure 3-4), and superoxide dismutase.87 Vitamin C and vitamin E are 
examples of dietary antioxidants (Figure 3-4).87  
 
 
Figure 3-4 Structure of natural and dietary antioxidants 
 
In the body, oxidation plays a critical role in cell signaling, the electron transport chain of 
the mitochondria, and a variety of other enzymatic and nonenzymatic reactions including the 
cytochrome P-450 system.88 The majority of oxidation chemistry occurs in the mitochondria.89 
Reactive oxygen species (ROS) are a byproduct of these processes. The most common ROS are 
the superoxide anion (O-2•), hydrogen peroxide (H2O2), hydroxyl radical (•OH), organic 
hydroperoxide (ROOH), and alkoxy or peroxy radicals (RO• or ROO•).87 These species donate 
oxygen to other substances in the body. If the cell cannot properly break down these free radicals, 
oxidative stress occurs. Lipids, proteins, and DNA can be affected by oxidative stress driving age 
related diseases and cancers.90 Nitroxides are able to quench ROS through a catalytic one- and 
two-electron redox cycle (Figure 3-5 A).84 This process is reversible and occurs at physiological 
pH with rapid rate constants. Pratt and coworkers have proposed a redox cycle of nitroxides to 
quench peroxyl radicals (Figure 3-5 B).91 The catalytic redox cycle of nitroxides consists of 
electron transfer with peroxyl radicals (ROO•) to form oxammonium ions. This species can 
undergo hydride transfer to form a hydroxylamine, and in turn regenerate the nitroxide.91 Although 
they do not possess a nitroxide moiety, effective antioxidants such as vitamin E and liproxstatin-1 
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(Lip-1) are believed to proceed through a nitroxide moiety as part of their catalytic cycle 
supporting the general conception of nitroxide therapeutics.92 
 
 
Figure 3-5 A) TEMPO catalytic cycle B) Proposed nitroxide catalytic cycle to quench peroxyl radicals91 
 
The first hemigramicidin-TEMPO conjugate therapeutics in our lab were developed 
through a 10-step synthesis sequence involving chromatographic resolution (Scheme 3-1).77 (S)-
((2-Benzylbut-3-yn-1-yl)oxy)(tert-butyl)diphenylsilane (3-1) was subjected to hydrozirconation 
and subsequent transmetallation to dimethylzinc followed by addition to N-Boc-isovaleraldimine 
to provide 3-2 as a mixture of diastereomers. The diastereomers were acylated, separated, and 
deprotected to provide 3-3 which then underwent a two-step oxidation procedure consiting of a 
Dess-Martin periodinane (DMP) oxidation to provide the aldehyde and a Pinnick oxidation to 
provide carboxylic acid 3-4. This key intermediate was then coupled with tri-peptide H-Pro-Val-
Orn(Cbz)-OMe and 4-amino-Tempo (4-AT) to provide the alkene isostere analog of gramicidin S, 
XJB-5-131. X-ray analysis confirmed the major diastereomer assignement.77 This analog was 
characterized by quantitative mass spectrometry to preferentially locate to the mitochondria and 
protect cells against apoptosis.93 The mitochondrial membrane has a unique negative potential, -
180 mV, preferentially attracting cations; the resonance stabilized triphenylphosphonium ion is 
the most common mitochondrial targeting moiety for this reason.94 XJB-5-131 can cross the 
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mitochondrial membrane in spite of the absence of a positive charge, through mechanisms that are 
not yet fully elucidated. Once inside the organelle, the nitroxide payload is able to scavenge for 
ROS and electrons escaping the oxidative phosphorylation process.78, 95 
 
 
Scheme 3-1 Synthesis of XJB-5-13177 
 
In addition to efficiently locating to the mitochondria, these first analogs showed promise 
in bioassays of radiation, traumatic brain injury (TBI), hematopoietic syndrome, Huntington’s 
disease, and in head and neck irradiation of Fanconi anemia models, among others.77, 96-98 
Promising biological activity lead to the desire to produce new analogs possessing superior 
potency and improved pharmacological properties. XJB-5-131 does not meet three out of four of 
Lipinski’s rule of five to determine the drug-likeness of a chemical compound.99 While XJB-5-
131 has only 5 hydrogen bond donors, it has more than 10 hydrogen bond acceptors, a molecular 
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weight greater than 500, and an octanol-water partition coefficient (logP) greater than 5. Solubility 
and lipophilicity greatly limit the practicality of XJB-5-131 as a therapeutic. For analog 
development purposes, a new, more efficient route, was necessary to generate sufficient amounts 
of analogs with improved pharmacological properties for in vitro and possible in vivo testing. JP4-
039, a smaller alkene dipeptide isostere composed of leucine and glycine residues, was synthesized 
in large quantity during this second campaign (Figure 3-6).79  
 
 
Figure 3-6 Structure of JP4-039 
 
The synthesis of JP4-039 proceeded through a key coupling of an imine with a 
trimethylaluminum species (Scheme 3-2).79 Isovaleraldehyde (3-5) was reacted with sulfinamide 
3-6 at room temperature to provide stable imine 3-7. This intermediate was then coupled with 
TBDPS protected alcohol 3-9 through a hydrozirconation and transmetallation via 
trimethylaluminum to provide the allylic amine 3-10 in >95:5 dr. The allylic amine was cleaved 
with HCl in diethyl ether to the hydrochloride 3-11. Subsequent Boc-protection of the amine gave 
3-12 and TBAF mediated deprotection of the silyl ether provided the desired alcohol 3-13. This 
key alcohol was used to make a variety of derivatives including JP4-039. Jones oxidation with 
chromium trioxide provided carboxylic acid 3-14 that was then coupled with 4-AT to provide JP4-
039 in >98% purity as determined by supercritical fluid chromatography (SFC). The final 
purification of JP4-039 has been accomplished through recrystallization in heptane. Recently, this 
synthetic route by Wipf and Pierce was successfully employed to synthesize 275 g of JP4-039 at 
Albany Molecular Research Inc. (AMRI). 
50 
 
Scheme 3-2 Synthesis of JP4-039 through a hydrozirconation/transmetalation reaction79 
 
There are several drawbacks to the synthetic route. The linear sequence is eight steps and 
the leucine side chain is introduced early in the sequence. To generate analogs with functional 
group substitutions for the leucine residue, there is not a common intermediate to build from. Even 
if these side-chain modifications must be introduced early in the synthesis, a shorter, four- to five-
step sequence would be a great improvement for diverse analog development. An obvious way to 
reduce the synthesis length is to eliminate the need for the protecting group interchange from a 
sulfinylamine to a Boc-amine as well as a protection and deprotection of the primary alcohol. 
Another drawback to the synthetic route is the use of pyrophoric (trimethylaluminium, Me3Al, and 
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toxic (Jones’ reagent) chemicals.100-101 Especially without a common intermediate, the repeated 
use of these reagents in analog development is not ideal from a safety perspective. 
Similar to XJB-5-131, JP4-039 has shown efficacy in a selection of bioassays; the greatest 
therapeutic indication is as a potent radiation mitigator.102-106 In total body irradiation models, JP4-
039 is hypothesized to reduce oxidative stress events in the mitochondrial membrane which in turn 
limits signaling events that drive cell death.107 Unlike XJB-5-131, JP4-039 conforms to all of 
Lipinski’s rules, making it much more drug-like.99 JP4-039 is more water soluble and thus easier 
to formulate for delivery.  
Both mitochondrial targeting peptide-conjugates, XJB-5-131 and JP4-039, have been used 
as probes in oxidative cell death phenotypes.77, 98, 108-109 Cell death is essential for life. In the first 
stages of life it is a necessary part of morphogenesis and development of the immune and nervous 
systems.110 Throughout life, cell death maintains homeostasis, plays an active role in metabolism, 
and serves as an anti-cancer defense mechanism.110-111 Unfortunately, uncontrolled cell death can 
drive tumor evolution by killing healthy cells and allowing the proliferation of cancer cells in their 
place (Figure 3-7).112 
 
 
Figure 3-7 Uncontrolled cell death can drive tumor evolution 
 
Several parallel cell death pathways can be activated independently. Death triggers a loss 
of cell membrane integrity, fragmentation of DNA, or activation of extracellular death receptors.113 
The Nomenclature Committee on Cell Death have defined over 34 different modes of regulated 
cell death.114 A variety of internal or external perturbations such as Ca2+ overload, pathogen 
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invasions, inflammatory cues, and hypoxia provide unique cellular morphology features.114-115 
Cells also have compensatory survival pathways, such as the heat shock response, leading to a 
variety of different and distinct cell death phenotypes.  
In 2012 Brent Stockwell and coworkers discovered a new, iron-dependent cell death 
phenotype, ferroptosis.116 As our nitroxide conjugates have shown efficacy in other oxidative cell 
death phenotypes, we also wanted to probe their role in ferroptosis. 
3.1.2 Ferroptosis, an Iron-Mediated Cell Death Pathway 
Ferroptosis is distinct from other regulated cell death pathways, particularly apoptosis and 
necroptosis (regulated necrosis).116 Apoptosis is a caspase dependent process. Caspases (cysteine-
aspartic proteases) are a group of twelve endoproteases that utilize a catalytic cysteine residue in 
the active site to hydrolyze peptide bonds after an aspartic acid residue to drive apoptosis or 
inflammation.117 Apoptosis is characterized by nuclear fragmentation, an intact plasma membrane 
at an early stage, and a decrease in cellular size (Figure 3-8).118-119 It can occur as a result of internal 
factors that lead to mitochondrial outer membrane permeabilization (MOMP) or external factors 
driven by the binding of ligands to death receptors or the decrease in binding to dependence 
receptors on the plasma membrane.119 The deregulation of inhibitor of apoptosis proteins (IAP) is 
a frequent driver of cancer and often a target for therapy.120 Inhibitors of apoptosis include 
navitoclax, ABT-199, and obatoclax mesylate among others.121  
Necroptosis is a pro-inflammatory, passive process that generally affects large pockets of 
cells and is characterized by an increase in cellular volume, plasma membrane protrusions, and 
lack of nuclear fragmentation (Figure 3-8).114 Necroptosis is dependent on receptor-interacting 
protein kinase 1 and 3 (RIPK1/RIPK3) and mixed lineage kinase domain like (MLKL); it is 
caspase independent.122-123 Necroptosis cell death progression has been implicated in systemic 
inflammation, neurodegeneration, and ischemic reperfusion injury.124 Necrostatin 1 (Nec-1), an 
inhibitor of RIPK1, and necrosulfonamide (NSA), an inhibitor of MLKL, are small molecules that 





Figure 3-8 Comparison of apoptosis, necroptosis, and ferroptosis114 
 
Ferroptosis was coined in 2012 to describe a distinct cell death pathway that occurred in 
RAS-mutated tumor cells.116 RAS is a class of small GTPase proteins that have critical roles in 
cell signaling.126 RAS mutations cause uncontrolled cell growth, which allow cells to avoid death 
signals and become immune to drug treatments; they are frequently used in biological models. 
When the Stockwell group exposed RAS-mutated cells to the small molecules erastin or RSL3, 
the cells did not undergo typical apoptotic (nuclear fragmentation) or necroptotic (plasma 
membrane protrusions) death phenotypes. Ferroptotic cell death was manifested through a 
decrease in cellular volume, mitochondrial shrinkage, and an increase in mitochondrial membrane 
density (Figure 3-8).116  
The defining feature of ferroptosis is the accumulation of iron dependent lipid peroxides.114, 
116, 127 This distinguishing feature has been confirmed through LCMS oxidative lipidomics.127 
Ferroptosis has been implicated in ischemia reperfusion injury, traumatic brain injury, 
Huntington’s disease, stroke, acute kidney injury, and several cancers, among others.128-130 
As the defining feature of ferroptosis, it is important to understand what lipid peroxidation 
is, what drives it, and what counteracts it. Lipid peroxidation is the destruction of lipids in cell 
membranes by free radicals.131 Polyunsaturated fatty acids (PUFAs) are highly prone to 
peroxidation because of the weak C-H bonds of the bisallylic carbons in the backbone structure.132 
LCMS oxidative lipidomics revealed three main PUFA classes prone to peroxidation: 
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phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol.127 The specific length 
and location of double bonds in the lipid tails of these phospholipids are believed to be the reason 
why they are more prone to oxidation.127 Although the mechanism for initiation of lipid 
peroxidation is not fully understood (it has been attributed to both enzymatic and non-enzymatic 
factors), it is generally hypothesized that the initiation event is a result of the removal of a bis-
allylic hydrogen atom from PUFA phospholipids (Figure 3-9).131, 133 This generates a carbon-
centered phospholipid radical (PL•) that can react with molecular oxygen in the cell to form a 
phospholipid peroxyl radical (PLOO•).134 This peroxy radical can then remove another hydrogen 
atom from PUFA phospholipids to form a phospholipid hydroperoxide (PLOOH), the propagating 
species in the destructive cycle.131 PLOOH react with labile iron in the cell through Fenton 
chemistry (Scheme 3-3) to generate further radical species (PLO• and PLOO•) that can participate 
in the cycle (Figure 3-9).135-136 
 
 
Figure 3-9 Phospholipid peroxidation cycle 
 
Just as the mechanism of initiation is attributed to several possible cellular events, the 
termination event of lipid peroxidation is not fully elucidated. Ferroptotic cell death occurs when 
the amount of PLOOH reaches a level that causes a breakdown of organelle or cell membrane 
integrity. Depending on the level of PUFA phospholipids in their structure, the mitochondria, 
endoplasmic reticulum, and lysosome membranes have been shown to be affected by lipid 
peroxidation.131 Recently, cathepsin B, a lysosomal cysteine protease, has been implicated as an 





Other proposed initiators and drivers of lipid peroxidation include lipoxygenases (LOXs) 
and cytochrome P450 oxidoreductase (POR). LOX are iron-dependent dioxygenases that can 
directly oxygenate PUFAs and increase the amount of lipid hydroperoxides.138 Knockout studies 
of GPX4 demonstrate that LOX are not essential drivers of ferroptosis, but potentially contribute 
to initiation and propagation of lipid peroxidation139-140 POR are ubiquitous in the cell and required 
for electron transfer from NADPH to cytochrome P450.141 After accepting an electron, reduced 
cytochrome P450 is hypothesized to be able remove a hydrogen from PUFAs to contribute to lipid 
peroxidation or, alternatively, contribute to the conversion of Fe3+ to Fe2+ as part of the Fenton 
reaction (Scheme 3-3).141 
 
 
Scheme 3-3 The Fenton reaction136 
 
As evidenced by the Fenton reaction, iron is an essential driver of ferroptosis. The more 
cellular labile iron in the cell, the greater the propagation of lipid peroxidation. Extracellular iron 
is bound to transferrin, a glycoprotein that can bind two Fe3+ tightly but reversibly with high 
turnover (Figure 3-10).142 Transferrin is the most vital source of iron for the body.142 Transferrin-
bound iron enters the cell through endocytosis by Transferrin receptor 1. Transferrin receptor 1 
has greater affinity for diferric bound transferrin as compared to monoferric bound transferrin and 
apo-transferrin.143 At serum pH 7.4, Fe3+ complexation to transferrin receptor 1 is favorable. 
However, inside the endosome, ATP-dependent H+ pumps lower the pH to 5.6 facilitating the 
release of Fe3+ from transferrin receptor 1.143 Once uncomplexed, free Fe3+ is reduced to Fe2+ by 
transmembrane ferrireductase STEAP3 and it then enters the cytosol through solute carrier family 
11 member 2 (SLC11A2).142 In the cytosol, Fe2+ is further stored in an inactive complex by the 
protein ferritin thus limiting oxidative damage.144 To uncomplex Fe2+, the selective cargo receptor 
nuclear receptor coactivator 4 (NCOA4) binds ferritin and transports it to the lysosome for 
degradation (Figure 3-10).144-145 When this process is overactivated or mis-regulated, an increased 
amount of ferritin is degraded through a process known as ferritinophagy, releasing large amounts 
of uncomplexed, reactive Fe2+.137 In the cell, free iron is also regulated by phosphorylase kinase 
catalytic subunit gamma 2 (PHKG2), heat shock protein beta-1 (HSPB1), and iron responsive 
element binding protein 2 (IREB2) among others (Figure 3-10).132, 146 Misregulation of any of 
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these storage elements increases the amount of intracellular reactive iron that participates in the 
Fenton reaction to drive lipid peroxidation. 
 
 
Fe3+ is bound to transferrin at serum pH 7.4; transferrin receptor 1 has great affinity for diferric bound transferrin 
and at pH 5.6 uncomplexes Fe3+ from transferrin; STEAP3 reduces Fe3+ to Fe2+; solute carrier family 11 member 2 
(SLC11A2) facilitates entry of Fe2+ to the cytosol; phosphorylase kinase catalytic subunit gamma 2 (PHKG2) 
regulates free iron; heat shock protein family B (Small) Member 1 (HSPB1) reduces iron-mediated production of 
lipid ROS; iron responsive element binding protein 2 (IREB2) encodes a regulator of iron metabolism and 
homeostasis; nuclear receptor coactivator 4 (NCOA4) drives ferritin degradation; Fenton reaction converts labile 
Fe2+ and hydrogen peroxide to Fe3+ and highly reactive hydroxy radicals; Fe3+ then reacts with H2O2 to form 
hydroperoxyl radicals that lead to lipid peroxidation; deferoxamine (DFOA) and 2,2’-bipyridine chelate iron. 
 
Figure 3-10 Mechanisms to regulate iron in the cell  
 
Under optimal biological conditions, the cell has well-defined mechanisms to counteract 
lipid peroxidation (Figure 3-11).116, 144 Mechanisms discovered to date revolve around glutathione 
peroxidase 4 (GPX4) and more recently ferroptosis suppressor protein 1 (FSP1). GPX4 is a 
selenium-containing enzyme. It is the major enzyme responsible for the detoxification of PLOOHs 
in cells. While all members of the glutathione peroxidase family can degrade peroxides, only 
GPX4 can break down hydroperoxides in complex lipids. The absence of a twenty amino acid 
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sequence in the surface-exposed structural loop is hypothesized to contribute to this unique 
reactivity.147 Before ferroptosis was officially recognized, GPX4 knockout studies revealed a non-
apoptotic, lipid peroxidation driven cell death.148 Activation of GPX4 is glutathione (GSH) and in 
turn cystine dependent. Cystine enters the cell through System Xc-, a membrane-bound Na+ 
dependent exchange antiporter that shuttles cystine into the cell in exchange for glutamate.149 Once 
in the cell, cystine is converted to cysteine which is then further converted to GSH by glutamate 
cysteine ligase (γ-GCS).144, 149 GSH, a tripeptide consisting of glutamate, cysteine, and glycine, is 
a potent reductant critical for GPX4 mediation of lipid peroxidation.144 At the selenocysteine 
catalytic center of GPX4, two molecules of GSH are used to convert lipid hydroperoxides to 
glutathione disulfide and the associated lipid alcohol and water (Figure 3-11). The selenol in the 
active site is oxidized by the lipid hydroperoxide to selenenic acid, reduced with GSH to form a 









System Xc- brings cystine into and glutamate out of the cell; erastin is a system Xc- inhibitor; glutamate cysteine 
ligase (γ-GCS) catalyzes the first and rate-limiting step to form gamma-glutamylcysteine (γ-GC) in the conversion 
of cysteine to glutathione; glutathione (GSH) activates glutathione peroxidase 4 by donating two electrons; 
glutathione peroxidase 4 (GPX4) reduces lipid hydroperoxides to lipid alcohols effectively slowing the lipid 
peroxidation chain reaction; cathepsin B is proposed as a GPX4 independent executioner of ferroptosis through 
hypothesized histone H3 cleavage; histone H3 maintains the structure of chromatin in cells. 
 
Figure 3-11 Mechanisms to regulate lipid peroxidation and ferroptosis in the cell 
 
There are two main checkpoints for a small-molecule induction of ferroptosis. The first, 
most direct way is through inhibition of GPX4. The chloroketone RSL3 directly blocks GPX4 
leading to uncontrolled lipid peroxidation and ferroptosis cell death (Figure 3-12).116 The second, 
more indirect mechanism is through system Xc- inhibition. Inhibition of system Xc- deprives the 
cell of cystine. Without cystine, GSH cannot be synthesized and furthermore, GPX4 is not 




Figure 3-12 Two ferroptosis inducers, erastin and RSL3 
 
A GPX4-independent pathway that was recently implicated in ferroptosis involves the 
flavoprotein apoptosis-inducing factor mitochondria-associated 2 (AIFM2), which was renamed 
ferroptosis-suppressor protein 1 (FSP1) (Figure 3-11). This gene was discovered through a genetic 
suppressor screen and shown to prevent ferroptosis driven by GPX4 deletion.151 FSP1 is 
hypothesized to control lipid peroxidation as part of the oxidation-reduction cycle of the 
antioxidant ubiquinol (Figure 3-4). Ubiquinol quenches lipid peroxides to terminate autoxidation. 
FSP1 catalyzes the regeneration of ubiquinol from ubiquinone with NADP(H) so the cycle can 
continue.151 Importantly, this pathway points to the critical role of radical-trapping antioxidants in 
preventing ferroptotic cell death induced by GPX4 inhibition. Other proteins and pathways critical 
to the overall antioxidant potential of the cell, including tumor protein 53 (Figure 3-11), continue 
to be investigated for their role in ferroptosis.152  
Several classes of small, organic molecules have been developed to inhibit ferroptosis. 
Some of these compounds act as iron-chelators or as antioxidants based on the critical role iron 
and radical species have in driving ferroptosis. The first class, consisting of deferoxamine (DFOA) 
and 2,2’-bipyridine (Figure 3-10 and Figure 3-13), inhibits the accumulation of iron in the cell 
through chelation. Thus, iron-chelators limit lipid peroxidation resulting from the Fenton reaction 
and the iron-dependent LOX mediated oxidation of PUFAs.116 The therapeutic benefit of iron 
chelators is limited because iron is essential to a variety of critical functions in the body. The 
second class of compounds are antioxidants, which can directly inhibit lipid peroxidation. Some 
examples are vitamin E, liproxstatin-1 (Lip-1), and ferrostatin-1 (Fer-1) which act as radical-
trapping antioxidants (Figure 3-11 and 3-13).92 Lip-1 and Fer-1 were discovered through high-
throughput screens and have a half maximal effective concentration (EC50) in an erastin-induced 
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ferroptosis cell death model of 38 nM and 70 nM respectively.92 Recently, a group from Sichuan 
University demonstrated a lead phenothiazine compound (Figure 3-13) with strong intrinsic 
antioxidant potential that has an EC50 of 0.5 nM in an erastin-induced ferroptosis assay. This is one 
of the most potent ferroptosis inhibitors to date.153 
 
 
Figure 3-13 A) Iron chelators DFOA and 2,2’-bipyridine B) Antioxidants Fer-1, Lip-1, and phenothiazine #51 
 
There remains a strong need for the further investigation of ferroptosis. Over the last eight 
years, mechanistic work has revealed interesting contrasting roles for ferroptosis in disease. For 
example, it has recently been proposed that certain classes of cancer cells are more likely to 
undergo ferroptotic cell death because they have a higher ROS load and iron requirement.131, 154 In 
this scenario, ferroptosis inducers are attractive as they could be developed to selectively induce 
cell death in cancer cells which are prone to lipid peroxidation. Conversely, in ischemic diseases 
ferroptosis negatively contributes to the pathogenesis of the disease. In these indications, 
ferroptosis inhibitors are necessary to prevent stroke and heart injury.155 Not only can ferroptosis 
inhibitors serve therapeutic purposes, they can also help elucidate the various biological pathways.  
In 2016, in collaboration with the Stockwell laboratory, the radical-scavenging compounds 
XJB-5-131 and JP4-039 were tested in an erastin-induced ferroptosis assay in the fibrosarcoma 
cell line HT-1080.156 Not only was the Wipf group interested in the therapeutic potential of these 
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compounds, they were also interested in using these compounds to probe the role of mitochondrial 
lipid peroxidation in ferroptosis. XJB-5-131 and JP4-039 both preferentially locate in the 
mitochondria over the cytosol; XJB-5-131 has a 600-fold enrichment factor while JP4-039 has 
only a 20-30 fold enrichment factor.93 If XJB-5-131 and JP4-039 showed activity as ferroptosis 
inhibitors, this would indicate that protection of mitochondrial lipids was sufficient to prevent 
ferroptosis. The results supported this hypothesis. Owing to its efficiency in crossing the 
mitochondrial membrane and enriching in the mitochondria, XJB-5-131 exhibited superior 
protective effects with an EC50 of 114 nM while JP4-039, which is less concentrated in the 
mitochondria, had an EC50 of 3.6 µM.
156 In this report, ten analogs of XJB-5-131 and JP4-039 
were synthesized and examined for anti-ferroptotic activity. Most of these analogs were not more 
active than XJB-5-131 or JP4-039. Surprisingly, an exception was the bis-nitroxide analog of JP4-
039 (Figure 3-14) with an EC50 of 915 nM. The authors speculated to its enhanced ability to 
scavenge reactive oxygen species in the mitochondria. Importantly, there was no correlation 
between protective activity and lipophilicity. 
 
 
Figure 3-14 JP4-039 bis-nitroxide anlaog 
3.1.3 SAR In Vitro Assay and JP4-039 Zones for Modification 
Based on this early effort, there remained significant room for improvement in the activity 
of the JP4-039 scaffold. We chose to pursue the smaller JP4-039 scaffold because of its better drug 
like properties, including lower molecular weight and logP compared to XJB-5-131. The logP of 
JP4-039 is 2.76 while the logP of XJB-5-131 is 7.61. It has been difficult to pursue XJB-5-131 in 
other therapeutic indications because its lipophilicity and molecular weight make it hard to dose. 
Based on our previous work, it was hypothesized that XJB-5-131 is an effective ferroptosis 
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inhibitor because it locates to the mitochondria and specifically inhibits the peroxidation of 
mitochondrial lipids. JP4-039 is a less effective ferroptosis inhibitor because it is largely 
untargeted.156 Based on this finding, to improve the anti-ferroptosis activity of the truncated series 
of nitroxides, we should improve the ability of these compounds to cross the mitochondrial 
membrane or their efficiency as global cellular antioxidants. We hypothesized that structural 
modifications that affect the secondary structure of the truncated analogs may improve their 
mitochondrial targeting ability. Structural modifications that affect lipophilicity and polar surface 
area may also improve global cellular antioxidant activity. Ultimately, our goal was to generate 
compounds with improved activity and determine whether the increase in activity was 
conformation- or lipophilicity-dependent. 
To build a structure activity relationship (SAR), we utilized a CellTiter-Glo® ferroptosis 
assay in HT-1080 cells at the contract research organization (CRO) Pharmaron. CellTiter-Glo® is 
a method to measure the number of viable cells in a culture by measuring the amount of ATP, a 
metabolic marker, that is present. We chose to determine the 80% effective concentration (EC80) 
for each compound. EC80’s have been used previously to screen large libraries of compounds for 
ferroptosis activity.157 For our compounds, EC80 determinations were a more accurate 
representation of the data based on the concentration points screened and the resulting curves 
generated. 
We analyzed the previously reported EC50 data obtained in collaboration with the 
Stockwell laboratory to determine EC80 values. The EC80  for JP4-039 was between 4000-7000 nM 
in erastin (10 µM) induced ferroptosis cell death in the fibrosarcoma cell line HT-1080.156 The 
control Fer-1 had an EC80 range of 80-100 nM. The assay utilized by the Stockwell group was 
fluorescence based; the greater the apparent fluorescence intensity, the greater the protective effect 
of the compound. Fluorescent assays measure the conversion of a substrate to a reaction product 
that fluoresces when excited by light of a certain wavelength.158 In the assay at Pharmaron, JP4-
039 had an EC80 range of 4000-8500 nM while the control Fer-1 had an EC80 of 39 ± 19 nM. The 
assay conducted at Pharmaron was luminescence-based. Luminescence-based assays have a wide 
dynamic range and are one of the most sensitive detection methods used (significantly more 
sensitive than fluorescence) because of signal multiplication and amplification capabilities. In 
luminescent assays, a substrate is converted to a reaction product that emits photons of light as it 
returns from an electronically excited state to a ground state.158 Across the two assay types, the 
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EC80 values for JP4-039 were within error range. The EC80 values for Fer-1 showed approximately 
a two-fold difference but we believe this difference falls into the assay error range, considering 
that the two assays are fundamentally different and were run in different labs. The advantage of 
the luminescence-based assay at Pharmaron is that we are more likely to discern subtle changes in 
activity and better observe the rank ordering of our compounds from most potent to less potent. 
We targeted five zones for chemical modification on JP4-039 (Figure 3-15). We 
investigated replacements of the leucine side chain (Zone I - red), the chirality at the amine center 
(Zone II - blue) and substitutions at the α-position of the amide (Zone III - green). We also 
considered the location of nitroxide, specifically relocating it from Zone IV (gold) to Zone V 
(purple). Finally, we looked at a replacement of the protecting group of the amine (Zone V - purple) 
as a way to introduce a second scavenging moiety to the molecule. These modifications were 
designed to improve the overall activity and analyze whether the improvement in activity was a 
result of structure conformation or lipophilicity. Thus, we were careful to consider the logP as part 
of our synthesis efforts. Generally, logP should not exceed 5.99 There are several exceptions to this 
rule, especially when a portion of the molecule is a targeting moiety, as is the case with XJB-5-
131.159 We were concerned with logP to ensure that the activity was not corelated purely to how 
lipophilic the molecule was. Lipophilic antioxidants such as vitamin E are known to rescue cells 
from ferroptosis through a different mechanism than our compounds. Vitamin E is fat soluble and 
thus incorporated into cell membranes.160 
 
 
Figure 3-15 SAR zones of JP4-039  
 
To make and test these structural modifications efficiently, a new synthetic route was 
required. The new route needed to be shorter so that we could more readily introduce substitutions 
for the leucine side chain (Zone I). It also needed to avoid the use of pyrophoric and toxic reagents 
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in order to facilitate scale-up when needed. A more robust and less water- and air-sensitive 
methodology for setting the chiral amine center would also be beneficial. 
As the key step in our new synthesis, we proposed a vinylogous Mannich reaction, inspired 
by a 2017 report from the Yin group at the Chinese Academy of Sciences (Scheme 3-4).161 With 
this carbon-carbon bond forming reaction we could avoid the use of a hydrozirconation step to set 
the stereocenter and eliminate the need for a change in the nitrogen protecting group. It would also 
avoid the use of toxic reagents. Most importantly, we believed we could rapidly synthesize a 
structurally diverse set of analogs to test for anti-ferroptotic activity. 
 
 
Scheme 3-4 Proposed vinylogous Mannich reaction towards JP4-039 
3.1.4 The Vinylogous Mannich Reaction 
The Mannich reaction is one of the most useful carbon-carbon bond forming reactions in 
synthetic chemistry. The reaction is named after Carl Mannich who first described the mechanism 
in 1912.40 The Mannich reaction is the reaction between a primary or secondary amine, a 
nonenolizable aldehyde, and an enolizable carbonyl compound (Scheme 3-5 A); the amine and 
aldehyde can also be pre-condensed to form the imine prior to reaction with an enolizable carbonyl 
compound (Scheme 3-5 B). The key to the reaction is the presence of a resonance-stabilized 




Scheme 3-5 A) Three-component Mannich reaction and B) Two-component Mannich reaction 
 
The utility of the Mannich reaction is derived from not only the generality of the 
mechanism and reaction components but also from the vast number of specialized protocols 
applicable for numerous functional groups through specialty catalyst design and auxiliary 
incorporation. With optimized conditions, reactions are highly chemo- and stereospecific. Much 
of the innovation in Mannich reactions stems from the utility of the β-amino-carbonyl product as 
a precursor for natural products and pharmaceuticals.162-163 β-Amino-carbonyl synthons are readily 
transformed to Michael acceptors, amino alcohols, and a variety of carbonyl derivatives.163 In the 
early 2000’s Shibaski164, Jorgensen165, and Trost166 introduced catalytic asymmetric Mannich 
reactions using chiral organometallic systems. Most of this work built on asymmetric aldol 
chemistry. 
The vinylogous Mannich reaction is a logical two carbon extension of the Mannich reaction 
(Scheme 3-6). The term vinylogous describes functional groups where the standard moieties are 
separated by a double bond.167 In the traditional Mannich reaction, addition occurs at the α-position 
of the enolizable carbonyl compound. In the vinylogous equivalent, addition takes place at the γ-
position of a dienol. The conjugated double bonds serve as an electron conducting channel in the 
molecule.168 Both cyclic and acyclic as well as direct (dienolate not pre-formed) and indirect 
(Mukaiyama-Mannich reaction where the dienolate is pre-formed) variants have been extensively 
explored. Stephen F. Martin at the University of Texas is a pioneer in the field of vinylogous 




Scheme 3-6 Acyclic, indirect vinylogous Mannich reaction 
 
Asymmetric vinylogous Mannich reactions were first introduced in 1999 and continue to 
be investigated today.170 Asymmetric induction can occur in three ways: 1) chiral catalyst/ligand 
design; 2) introduction of a chiral auxiliary on the imine; and 3) introduction of a chiral auxiliary 
on the carbonyl component. To date, no vinylogous Mannich methodology has integrated two of 
these components in a cooperative system. Reaction development is significantly behind that of 
the closely related vinylogous aldol variant.168 
The first catalytic, asymmetric indirect vinylogous Mannich reaction was demonstrated by 
the Martin group in 1999 (Scheme 3-7).170 The reaction involved an aryl aldimine and 
silyloxyfuran with 20 mol% of an optimized titanium-BINOL catalytic system. Yields were 
modest and the ee ranged from 28-54%. Martin noted that the hydroxy group on the aromatic ring 
of the imine was critical for the enantioselectivity of the reaction. The hydroxy group was 
hypothesized to coordinate to the titanium Lewis acid species in the proposed transition state. The 
catalyst system was prepared in a 2:1 ratio of (S)-BINOL to Ti(i-PrOH)4 in a coordinating solvent. 
When the chiral ligand was omitted from the reaction, the yield remained high but the 
diastereomeric ratio was reduced from up to 91:9 to 2:1. 
 
 
Scheme 3-7 Martin et al. vinylogous Mannich reaction170 
 
The next major advancement in catalytic and asymmetric vinylogous Mannich 
methodology was not until 2006 when Hoveyda at Boston College disclosed a silver-catalyzed 
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transformation of protected aldimines and silyloxyfurans that proceeded with >98% de, >90% ee, 
and 60-95% yield (Scheme 3-8).171 A chiral phosphine ligand (1-15 mol%) and AgOAc with i-
PrOH (1.1 equiv) as an additive in THF was an effective catalytic system for a variety of aryl 
substituted aldimines and methyl substituted silyloxyfurans. i-PrOH was a necessary proton source 
additive for reaction turnover. In the proposed mechanism, Ag(I) is coordinated to both the ligand 
(phosphorus and nitrogen atoms) and the aldimine (nitrogen and methoxy group) substrate. The 
substrate was bound anti to the bulky R substituent on the ligand. An endo-type addition was 
followed by an intramolecular desilylation by the Lewis basic amide end of the ligand through a 
process facilitated by the alcohol additive (i-PrOH). The amide moiety of the ligand was key for 
both yield and enantioselectivity. When a less Lewis basic substituent (OMe) or a less electron 
rich (N(H)-p-CF3C6H4) group was used, both the yield and ee decreased. Hoveyda hypothesized 




Scheme 3-8 Hoveyda et al. Ag(I) catalyzed indirect vinylogous Mannich reaction171 
 
Also in 2006, the first direct, catalytic, asymmetric vinylogous Mannich reaction was 
disclosed by the Chen group (Scheme 3-9).172 The reaction components were a N-Boc aldimine 
and an α,α-dicyanoolefin activated by a chiral bifunctional thiourea-tertiary amine organocatalyst. 
Berkessel’s thiourea catalyst delivered product in nearly quantitative yield and >98% ee with only 
2 mol% of catalyst. The group previously demonstrated the facile γ-deprotonation of α, α-
dicyanoolefin under mildly basic conditions in the context of vinylogous Michael reactions. A 




Scheme 3-9 Chen et al. direct vinylogous Mannich reaction172 
 
The first catalytic, enantioselective vinylogous indirect Mukaiyama-Mannich reaction of 
acyclic silyl dienolates and aldimines was accomplished by Schneider at the University of Leipzig 
in 2008 (Scheme 3-10).173 Solvent selection was critical for the reaction, using a 1:1:1 mixture of 
THF:t-BuOH:2-Me-2-BuOH with 1 equivalent of water. THF was critical for enantioselectivity, 
the alcohol solvent for the reaction rate, 2-methyl-2-butanol for solubility, and water for turnover 
in the catalytic cycle. An er of 90:10 to 96:4 was achieved with aromatic imines; aliphatic imines 
were not tolerated. A key finding from the methodology was the formation of a contact ion pair 
through monocoordination of the phosphoric acid to the imine which could be detected and 
characterized by ESI(+)-MS/MS.  
 
 
Scheme 3-10 Schneider et al. acyclic vinylogous Mannich reaction173 
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Schneider also disclosed the first example of a vinylogous Mukaiyama-Mannich reaction 
to produce enantioenriched amides (Scheme 3-11).174 A selection of silyl N,O-acetals were 
screened, including N,N-dimethyl-, N,N-diisopropylamide-, pyrrolidide-, piperidide-, and 
morpholide-, as nucleophiles in the reaction with aryl substituted PMP-protected aldimines. The 
alkyl substituted acetals were low yielding (19-34%) and had a poor ee. The piperidide substituent 
was optimal, providing amide products with yields from 52-99% and ee from 59-92%. While only 
1 mol% of phosphine catalyst was required, a typical reaction took 9 days at -30 °C. Similar to the 
group’s previous reports, alcohol or water in the solvent mixture was critical to trap the TBS 
species as the silanol (water) or silyl ether (alcohol) and to reprotonate the phosphate counterion 
to ensure catalyst turnover. The silyl N,O-acetal was used in three-fold excess in the reaction. 
Subsequent transformations of the amide product included conversion to the allylic alcohol with 




Scheme 3-11 Schneider et al. vinylogous Mannich reaction ot form amides174 
 
Several other groups published variants of the asymmetric vinylogous Mannich reaction of 
acyclic silyl dienolates and imines following these seminal works. Carretero at the University of 
Madrid disclosed the first copper catalyzed variant with N-2-thienylsulfonylimines and an in-situ 
catalyst (10 mol%) generated from CuBr2 and a bulky Fesulphos ligand.
175 The Schneider group 
built on their previous work with PMP protected imines, silyl dienolates, and phosphoric acid 
catalysts to showcase improved yields, enantiomeric ratios (88-97%), and applicability to a three-
component reaction. They were able to gain further mechanistic insights by obtaining a crystal 
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structure of their imine-bound phosphoric acid catalyst.176 Schneider also used the methodology 
as a key step to generate the tobacco alkaloid (S)-anabasine177 in the synthesis of four indolizidine 
based alkaloids (IBAs)178, and later in the synthesis of an additional 16 IBAs.179 The Feng group 
at Sichuan University utilized a scandium(III)-N,N’-dioxide complex in a three-component 
vinylogous Mannich reaction with a benzaldehyde derivative, 2-aminophenyl, and silyl dienol 
ethylester.180 Finally, in 2014 the List group used a dioxinone-derived silyl dienolate with a N-Boc 
aldimine and bulky disulfoniminde catalyst derived from BINOL (1 mol%) to provide γ-selective 
products with high yields and modest er (80:20 to 99:1) after 3 days of reaction time.181 
In 2017, the Yin group at the Chinese Academy of the Sciences disclosed the first direct, 
catalytic vinylogous Mannich reaction of β,γ-unsaturated amides (Scheme 3-12).161 Steric bulk 
provided by the amide substrate (3,5-diphenyl pyrazole), copper species ([Cu(CH3CN)4]PF6), and 
ligand ((R)-DTBM-SEGPHOS) resulted in a γ-selective reaction with ee up to 99%. The reaction 
proceeded with only 1 mol% of the catalyst/base system. It should be noted that alkyl substituents 
on the imine resulted in much more modest ee values between 83-89%. The reaction was not 
successful with the analogous α,β-unsaturated amides because of the high pKa values of the γ-
proton necessary for deprotonation for the reaction to occur. The pKa of protons α to amides 
(where deprotonation is necessary for β,γ-unsaturated amides) is approximately 30.182 The authors 
extended the β,γ-unsaturated amide methodology to the ε-position for a bisvinylogous Mannich 
reaction. Re-optimization of the reaction was required, however, and the authors did not provide a 
rationale as to why the 3,5-di-p-tolyl pyrazole or TANIAPHOS ligand were optimal. 
 
 
Scheme 3-12 Yin et al. vinylogous and bisvinylogus Mannich reaction of β,γ-unsaturated amides161 
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Acyclic vinylogous Mannich reactions lead to a -amino-,-unsaturated carbonyl 
compound.161 Isomerization of the double bond to the -amino-β,γ-unsaturated carbonyl 
compound generates the backbone of JP4-039. The recent work from the Yin group matches up 
quite closely with JP4-039 because it utilizes a Boc-protecting group on the imine. While we could 
use the same pyrazole system to generate the backbone of JP4-039, we hypothesized that the 
introduction of a different auxiliary would further enhance the stereochemical outcome of the 
reaction and also be a useful directing group for our proposed -substitutions in Zone III (Figure 
3-15). For this reason, we were interested in using the Evans oxazolidinone auxiliary in the 
vinylogous Mannich reaction with imines.   
3.1.5 Oxazolidinone Auxiliaries in (Vinylogous) Mannich Reactions 
To date, there has not been a report of a selective vinylogous Mannich reaction with a chiral 
auxiliary attached to the carbonyl nucleophile. The Liu and Chen groups at the Chinese Academy 
of Sciences incorporated chirality through a N-tert-butanesulfinylimino group on the imine while 
the Chen group at Nankai University used an O-pivaloylated D-galactosylamine as a chiral 
auxiliary on an imine to carry out a vinylogous Mannich reaction.183-184 There are several examples 
for a nucleophilic chiral auxiliary in the more traditional Mannich reaction.185-187 Evans’ 
oxazolidinone is one of the most common auxiliaries. 
Chiral auxiliaries gained attention in 1975 when E.J. Corey used 8-phenylmenthol in the 
synthesis of an enantiomerically enriched key prostaglandin intermediate.188 For an aldol-type 
chiral auxiliary to be effective it must be: 1. easy to introduce; 2. predisposed to highly-selective 
enolizations; 3. provide a high degree of facial selectivity for addition post-enolization; and 4. easy 
to cleave without erosion of stereochemistry.189 The N-acyloxazolidinone with a benzyl directing 
group at the 4-position was the first chiral oxazolidinone auxiliary developed by the Evans group 
at Harvard University in 1981 and has since become the gold standard in chiral auxiliaries.190 
Numerous variations with different directing groups and heteroatoms have since been developed 




Figure 3-16 Oxazolidinone derived chiral propanoates 
 
The oxazolidinone auxiliary is easy to introduce through coupling reactions with 
carboxylic acids or acyl chlorides (Figure 3-17). The oxazolidinone itself can be purchased or 
synthesized in two steps from an amino acid.191 Generally, they direct highly selective (Z)-
enolizations and permit high facial selectivity post-enolization through a substituent at the 4-
position. Finally, they are easy to cleave through saponification or reduction conditions. The 
auxiliary has shown great utility in asymmetric alkylations, asymmetric syn- and anti-aldol 
reactions, and in Diels-Alder reactions.189, 192 The discussion of oxazolidinones as chiral auxiliaries 
in asymmetric aldol reactions has been included in numerous review articles,193-196 however, they 
have found very limited utility in Mannich reactions; they have not been used in vinylogous 
Mannich reactions.  
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Figure 3-17 Oxazolidinone auxilaries are the gold standard in chiral auxilaries 
 
Dr. Reddy’s Laboratories, a pharmaceutical company in India, used chiral oxazolidinone 
chemistry to set the stereochemistry in a Mannich reaction towards the process scale synthesis of 
the anti-hypercholesterolemia drug, Ezetimibe (Scheme 3-13).185 The reaction was performed on 
a 100-gram scale to provide product in 48% yield with dr 97:3. 
 
 
Scheme 3-13 Praveen et al. Mannich reaction with chiral phenyl-substituted oxazolidinone185 
 
The Olivo group at the University of Iowa reported the Mannich type addition of a carbonyl 
compound bearing a thiazolidine auxiliary to in situ prepared N-substituted N-acyl iminum ions 
(Scheme 3-14).186 A group of six imines provided the anti-product in modest yields and a dr from 
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7:3 to 9:1. The investigators proposed a reaction mechanism that proceeded through an open 
antiperiplanar transition state.  
 
 
Scheme 3-14 Olivo et al. Mannich reaction with chiral thiazolidine auxiliary186 
 
The Feng group at Sichuan University used an achiral oxazolidinone substituted 
isothiocyanate in a Mannich-type reaction with various sulfonyl imines (Scheme 3-15).197 The 
phenyl imines all proceeded in >80% yield, and ee 90-99%. The reaction was catalyzed by a chiral 
bisguanidine derived from benzene-1,3-diamine. The Brønsted basicity of the guanidine was 
critical for initial activation of the isothiocyanate. The additive 4-cyanobenzoic acid provided an 
incremental improvement in enantioselectivity. This was hypothesized to occur by acid 
protonation of the guanidine catalyst to form a guanidinium salt which in turn activated the tosyl 
protected imine through H-bonding interactions. 
 
 
Scheme 3-15 Feng et al. Mannich reaction with achiral unsubstituted oxazolidinone197 
 
The Praveen, Olivio, and Feng groups have demonstrated that with proper reaction 
conditions, oxazolidinone auxiliaries can direct highly stereoselective Mannich reactions. We 
hypothesized that this control would translate to vinylogous Mannich reactions. Specifically, we 
believed the incorporation of Evans’ oxazolidinone auxiliary onto our nucleophile could improve 
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enantiomeric outcome in an asymmetric reaction or more ambitiously diastereomeric outcome in 
a double asymmetric reaction.  
Double asymmetric reactions are controlled by two chiral sources.198 The chiral sources 
can be two chiral substrates that combine in such a way to form a new stereogenic center or one 
chiral substrate and one prochiral substrate that utilize a chiral reagent to generate a new 
stereogenic center in the product (Figure 3-18).  
 
 
Figure 3-18 Double asymmetric reaction to form product with new stereogenic center 
 
The Davies group at the University of Oxford has examined double asymmetric reactions 
between two chiral substrates. In 2010, they disclosed the double diastereoselective addition of 
enantiopure lithium amines to chiral oxazolidinones (Figure 3-19).199 In a representative example, 
(S,E)-4-benzyl-3-(but-2-enoyl)oxazolidin-2-one formed a matched pair with lithium (S)-N-benzyl-
N-(α-methylbenzyl)amine to provide the major (S,S)-enantiomer with a dr 96:4. With the 
mismatched (R)-lithium amine, the major product was the (R,R)-enantiomer with a dr of 80:20. 
The (S)-oxazolidinone, (R)-amine system was determined to be the mismatched pair because of 
the reduction in overall dr. When the (S)-oxazolidinone was reacted with an achiral Li-amine, the 
major product was the (S)-enantiomer with an er 76:24, indicating that the double asymmetric 
catalytic system provided a distinct advantage. The group did not report selectivity when only a 






















Figure 3-19 Analysis of matched/mismatched product outcome in a conjugate addition reaction199 
 
While some matched-mismatched pairs result in equally high yielding reactions, albeit with 
lower dr, this is not always the case. Work by Fernandez-Mayoralas and Houk investigating aldol 
reactions of an α-chiral azide-substituted aldehyde, ketone, and chiral proline catalyst resulted in 
a 5-membered ring azasugar in 60% yield (dr >20:1) in the matched scenario and only a 10% yield 
(dr 5:1) in the mismatched scenario.200 
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An advantage of double asymmetric reactions is that the diastereomeric ratio can often be 
improved by chromatography. In many cases, the desired diastereomer can be purified from the 
undesired diastereomer through silica gel chromatography to enhance the overall dr.201 This type 
of separation is not possible with enantiomers.  
Although Evans’ oxazolidinone auxiliaries have not been used in vinylogous Mannich 
reactions, we were encouraged by the reactivity and stereocontrol in Mannich reactions. Chiral 
appendages of various sizes and flexibilities at the 4-position or 5-position of the oxazolidinone 
can be screened in order to optimize the selectivity. We also hypothesized that the carbonyl group 
of the oxazolidinone may coordinate more strongly than the pyrazole to copper(I), stabilizing the 
enolate and allowing for greater control of the enantio- or diastereochemical outcome. With the 
right substituent we believed the auxiliary would be sufficiently bulky to block α-attack. 
3.2 Results and Discussion 
3.2.1 Synthesis of JP4-039 Through a Vinylogous Mannich Reaction with a Pyrazole 
Auxiliary 
We designed a new synthesis of JP4-039 with a vinylogous Mannich reaction as the key 
transformation. In a retrosynthetic analysis from JP4-039, we envisioned three requisite 
transformations: a direct (or indirect) amide coupling, isomerization of the backbone double bond 
from a ,-unsaturated carbonyl compound to ,-unsaturated carbonyl compound, and a carbon-
carbon bond forming vinylogous Mannich reaction (Figure 3-20). Before exploring oxazolidinone 
auxiliaries, we first set out with a proof of concept synthesis of JP4-039 using the same pyrazole 




Figure 3-20 Retrosynthetic analysis of JP4-039 
 
The formation of protected imines is not a trivial step. N-Boc protected alkyl substituted 
imines, especially, are highly prone to decomposition even upon exposure to room temperature for 
a few minutes.202 We began with the synthesis of sulfone 3-15 from benzaldehyde, t-butyl 
carbamate, and sodium benzenesulfinate under acidic conditions in good yields (Scheme 3-16).203 
This procedure was also amenable for the synthesis of sulfone 3-16 from 3-methylbutanal, t-butyl 
carbamate, and sodium benzenesulfinate. 
 
 
Scheme 3-16 Synthesis of sulfones 3-15 and 3-16 
 
Following protocols similar to Greene and Shibasaki,204-205 exposure of sulfone 3-15 to 
cesium carbonate at reflux or at room temperature in CH2Cl2 for extended periods of time (4-5 h) 
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led to inconsistent product formation, most often contaminated with large amounts of 
benzaldehyde. There have been multiple reports that even trace impurities from the imine 
formation step can suppress reactivity in subsequent reactions.206 We tried including magnesium 
sulfate (MgSO4) as a drying reagent in the reaction, but that did not improve reproducibility or the 
reaction profile. A report from Pihko in 2014 noted the use of Hyflo® Super Cel® as the filter aid 
in the reaction.202 Hyflo® Super Cel® has a pH of 10.0 as a 10% solution in water and a pore size 
of 7.0 microns.207 Our previous trials involved simple filtration through a medium coarse filter frit. 
The authors noted that, in their hands, this type of filtration resulted in isomerization of the imine 
and dimerization. Based on this report, sulfone 3-15 and cesium carbonate were dried under high 
vacuum for 1 h, stirred for 45 min at 40 °C in CH2Cl2, and filtered through a plug of Hyflo® Super 
Cel® two times (Scheme 3-17). 1H NMR indicated that the formation of imine 3-17 was clean 
without any dimerization or decomposition. This pre-drying/filtration protocol was also 
compatible with alkyl substituted sulfone 3-16 to provide imine 3-18 without decomposition or 
isomerization to the enamine (Scheme 3-17). This two-step sequence (synthesis of sulfone and 
conversion to imine) was later used to synthesize a selection of imines. 
 
 
Scheme 3-17 Synthesis of aryl- or alkyl-substituted Boc-protect imines 
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With a reliable synthesis of protected imines, we first set out to see if we could use the 
methodology developed by the Yin group in 2017 with a β,γ-unsaturated pyrazole amide to 
synthesize the backbone of JP4-039 (Scheme 3-18).161 β,γ-Unsaturated carbonyl compound 3-19 
was formed through an EDC coupling of but-3-enoic acid with 3,5-dipheny-1H-pyrazole in 74% 
yield. A freshly prepared N-Boc protected i-butyl substituted imine 3-18 was reacted with 3-19 in 
the presence of base (Et3N) and the pre-formed catalyst solution of (S)-DTBM-SEGPHOS and 
[Cu(CH3CN)4]PF6 at -50 °C to form the vinylogous Mannich product (S)-3-20 in 98% yield with 
an er of 81:19 determined by chiral HPLC analysis (Scheme 3-18). The pyrazole auxiliary was 
highly activating and sufficiently bulky to allow for selective γ-attack. The bulky copper catalyst 
system also contributed to selective γ-attack; however, the er was lower than the authors’ report 
of 92:8 with the leucine substituted imine. 
 
 
Scheme 3-18 Vinylogous Mannich reaction with pyrazole auxiliary to form JP4-039 backbone 
 
We attempted to optimize the formation of vinylogous Mannich product 3-20 (Table 3-1). 
After 4.5 h at -40 °C with 2% catalyst loading we obtained 90% of the desired product with an er 
of 80:20 (entry 1). Longer reaction times at a slightly lower temperature of -50 °C increased the 
yield slightly to 98% but did not improve the selectivity (entry 2). We increased the catalyst 
loading in an attempt to improve the er, but an increase from 2% to 5% did not enhance the 
selectivity (entry 3). Despite maintaining nearly quantitative conversion and excellent 
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regioselectivity, the reaction was very temperature sensitive, perhaps contributing to why we were 
not able to achieve an er of >9:1.  
 
Table 3-1 Vinylogous Mannich reaction optimizaitons with (S)-DTBM-SEGPHOSa 
Entry Catalyst loading (%) Temperature (°C) Time (h) Yield (%)b erc 
1 2 -40 4.5 90 80:20 
2 2 -50 17.5 98 81:19 
3 5 -50 18 98 78:22 
aConditions: 3-19 (1 equiv), 3-18 (4 equiv), THF, (S)-DTBM-SEGPHOS, [Cu(CH3CN)4]PF6, Et3N (ligand, Cu, and 
Et3N all 2 mol% or all 5 mol%) 
bIsolated yield 
cDetermined by chiral HPLC 
 
Although the er was not as high as anticipated, we proceeded with our synthesis of JP4-
039 as a proof of principle of the methodology originating from the vinylogous Mannich reaction 
of amides. From the vinylogous Mannich product there were two key steps remaining to obtain 
the final compound: an isomerization from the conjugated to the skipped alkene and coupling to 
4-AT (directly or indirectly through saponification). Our initial approach was to isomerize and 
then couple to 4-AT. We first attempted a base mediated isomerization with LiOH saponification 
conditions; we had success synthesizing analogs of JP4-039 with this methodology previously. 
However, under these conditions we saw a trace to no conversion and partial loss of the pyrazole 
functionality that complicated the reaction profile. We next used a protocol from a 1985 paper that 
disclosed the photochemical deconjugation of α,β-unsaturated esters to their β,γ-unsaturated 
isomers.208 In the presence of the weak base, 1,2-dimethylimidazole, a wide range of substrates 
underwent isomerization under mercury lamp irradiation. The protocol from Duhaime et al. was 
shown to be applicable on multi-gram scale reactions. For our substrate, we envisioned an initial 
trans/cis isomerization of the vinylogous Mannich product (Scheme 3-19). The isomerization sets 
up a photochemical 1,5-sigmatropic hydrogen shift to the enol. The base serves as a proton shuffle, 
deprotonating the hydroxy group and reprotonating the α-position. If reprotonation occurs at the 
γ-position, then the cycle continues. α,β-Unsaturated esters typically possess strong absorption 
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bands in the 220-250 nm region while the β,γ-unsaturated isomers do not absorb strongly above 
220 nm, so with the proper lamp, the reaction is non-reversible.208  
 
 
Scheme 3-19 Proposed photochemical isomerization mechanism 
 
We believed these conditions would be feasible on our system, but we needed to determine 
what species would be most amenable to the transformation (Table 3-2). First, we tried to directly 
isomerize 3-20. We thought the pyrazole substrate may be sufficiently basic to catalyze the 
reaction without the addition of 1,2-dimethylimidazole. However, it did not catalyze the reaction; 
rather we saw loss of the pyrazole moiety in both methanol and t-butylmethylether (TBME) 
solvents (entries 1, 2). Inclusion of the weak base 1,2-dimethylimidazole also did not improve the 
reaction profile (entry 3). Since the pyrazole functionality has a strong UV absorbance, we 
hypothesized that it may be a liability for the photochemical process. Accordingly, 3-20 was 
converted to corresponding methyl ester 3-21 in 82% yield by stirring in methanol at 60 °C for 18 
h.161 Encouragingly, with the methyl ester derivative we were able to obtain the desired β,γ-
unsaturated isomer in 36% yield after purification of the 5:1 - trans:cis isomer mixture (entry 4). 
The ratio of trans:cis isomers was determined by 1H coupling constants and integration of the 
alkene peaks. We analyzed these three species by UV-Vis spectroscopy and, as proposed by 
Duhaime, only the α,β-unsaturated ester 3-21 showed absorbance in the 220-250 nm range; trans- 
and cis-isomers 3-23 did not have absorbance in this region. If desired, we could re-subject the 
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cis-isomer to the photochemical isomerization conditions, but, on a small scale, this yield was 
satisfactory. To obtain JP4-039, we had to convert the methyl ester to the carboxylic acid before 
coupling to 4-AT. With a goal of reducing the total number of steps, we speculated we could 
convert 3-20 to a species amenable for direct coupling with 4-AT following isomerization. Several 
groups have demonstrated the direct conversion of activated esters to amides.209 Therefore, 3-20 
was stirred in 2,2,2-trifluoroethanol for 7 h at 75 °C to provide activated ester substrate 3-22 in 
84% yield. Under mercury lamp irradiation for 24 h, we obtained isomerized activated ester 
product 3-24 in 34% yield after purification of the 5:1 – trans: cis isomer mixture (entry 5). 
Overall, however, photochemical isomerization conditions proved time intensive and did not 
provide a high yield of β,γ-unsaturated product (without requiring re-subjection of the cis-isomer). 
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Simultaneously, we explored isomerization conditions of the vinylogous Mannich product 
3-20, and evaluated direct coupling reactions of 3-20 to 4-AT (Scheme 3-20). Conventional 
heating at 90 °C with 2 equiv of 4-AT provided a 1:2 ratio of product:SM, but the reaction seemed 
to stall as reaction times >24 h did not promote additional conversion. The addition of DMAP also 
did not improve the conversion. However, we were able to obtain 45% of the desired coupled 
product 3-25 through microwave heating conditions with 4 equiv of 4-AT at 90 °C in THF for 1 
h. Since the starting material was entirely consumed, we believe the lower yield was a result of a 
retro-Mannich process. We investigated catalytic conditions for the coupling that would be milder 
and possibly promote a clean reaction. Unfortunately, boric acid210, scandium triflate211, and 
iron(III) nitrate212 did not provide sufficient conversion to 3-25 at temperatures below 60 °C.  
We used the most promising isomerization conditions developed to synthesize JP4-039 
(Scheme 3-20). With 1,2-dimethylimidazole (1.4 equiv) in methanol under mercury lamp 
irradiation for 24 h, we were able to isolate JP4-039 as the hydroxylamine species in 34% yield. 
Irradiation in the presence of weak base at least partially converted the 4-AT radical to the 
hydroxylamine. Fortunately, we were able to oxidize the hydroxyl amine to JP4-039 with 5 equiv 
of potassium ferricyanide at rt for 2.5 h in quantitative yield (Scheme 3-20).213 
 
 
Scheme 3-20 Coupling of vinylogous Mannich product to 4-AT and isomerization/oxidation to JP4-039 
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We attempted to convert 3-25 to the hydroxylamine prior to isomerization. We 
hypothesized that this would improve the overall yield. We suspended the crude reaction product 
3-25 in various reducing agents, including sodium dithionite (Na2S2O4)
214, a solution of zinc and 
ammonium chloride (Zn/NH4Cl)
215, and ascorbic acid.79 However, we were not able to see full 
conversion to the hydroxylamine.  
With a pyrazole amide starting material we achieved proof of concept that a vinylogous 
Mannich reaction could be used to synthesize JP4-039 in 5 linear steps with 11% overall yield and 
er 81:19. The yield and selectivity were both reduced compared to the previous synthesis which 
was completed in 53% overall yield with er >99:1. The advantage of the vinylogous Mannich route 
is that it did not require moisture or air sensitive reagents. The use of pyrophoric or toxic chemicals 
was also not necessary. We hypothesized that the double bond isomerization protocol and the 
selectivity of the vinylogous Mannich reaction could improve through incorporation of an 
oxazolidinone nucleophile chiral auxiliary. The chiral auxiliary would provide a second source of 
stereochemical control for the vinylogous Mannich reaction and would allow us to investigate 
subsequent isomerization/alkylations controlled by the auxiliary. Arguably, this optimization 
should further facilitate the goal of a rapid synthesis of structurally diverse JP4-039 analogs for 
the study of ferroptosis. 
3.2.2 Vinylogous Mannich Reaction with an Oxazolidinone Auxiliary 
To investigate the second approach to JP4-039, we synthesized a selection of substituted 
analogs through a pivaloyl chloride, n-butyl lithium coupling reaction (Table 3-3). The auxiliaries 
included the more traditional Evans auxiliaries: i-propyl (entry 1-2), (1H-indol-2-yl)methyl (entry 
3), and benzyl (entry 4-5). We also explored a much more bulky auxiliary with phenyl groups in 
the R2 positions (entry 6) as well as a thiazolidinethione auxiliary introduced by Fujita and Nagao 







Table 3-3 Synthesis of oxazolidinone derivativesa 
 
Entry X R1 R2 Product Yield (%)b 
1 O i-Propyl H (R)-3-26 47 
2 O i-Propyl H (S)-3-26 60 
3 O (1H-Indol-2-yl)methyl H (R)-3-27 74 
4 O Benzyl H (R)-3-28 45 
5 O Benzyl H (S)-3-28 40 
6 O Benzyl Phenyl (R)-3-29 28 
7c S Benzyl H (R)-3-30 66 
8 O H H 3-31 43 
aConditions: oxazolidinone (1 equiv), but-3-enoic acid (1.4 equiv), PivCl (1.4 equiv), Et3N (1.4 equiv), n-BuLi (1.15 
equiv), THF (0.2 M) 
bIsolated yield 
cConditions: oxazolidinone (1 equiv), but-3-enoic acid (1.4 equiv), DCC (1.4 equiv), DMAP (0.1 equiv), CH2Cl2 (0.2 
M) 
 
We obtained inconsistent and often lower than expected yields when acylating the 
auxiliaries because of the formation of an isomerized, conjugated side-product. The conjugated 
side-product was impossible to separate from the desired product. Similar limitations have been 
reported for β,γ-unsaturated acids in the literature.216 In these examples, using N-
methylmorpholine (NMM) as the base, opposed to the more classical base triethylamine, provided 
exclusively the deconjugated product. NMM is a nucleophilic but weaker base that is often used 
in peptide coupling reactions because it leads to reduced racemization and isomerization in the 
activation of acids.217 The pKa’s of protonated triethylamine and protonated NMM are 10.75 and 
7.61 respectively.217 As a weaker base, NMM  is less prone to deprotonate the α-position of the 
activated carbonyl compound which results in isomerized, conjugated side product. We were able 
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to reproduce the conditions with NMM to obtain β,γ-unsaturated amides in consistently higher 
yields with no isomerized side-product (Scheme 3-21).  
 
Scheme 3-21 N-Methylmorpholine mediated synthesis of β,γ-unsaturated oxazolidinone 
 
We evaluated each β,γ-unsaturated acyl oxazolidinone using the same reaction conditions 
as for the pyrazole-substituted derivatives (Table 3-4). With i-propyl-substituted oxazolidinone 3-
26 and i-butyl imine 3-18, vinylogous Mannich product 3-32 was obtained in 60% yield but with 
a dr of only 60:40 determined by chiral HPLC analysis (entry 1). With the same i-butyl imine 3-
18, we observed trace product with (1H-indol-2-yl)methyl-substituted compound 3-27 (entry 2) 
and no product formation with the much more bulky 5,5-diphenyl-4-benzyl-substituted 
oxazolidinone 3-29 (entry 3). We explored the vinylogous Mannich reaction between the phenyl-
substituted imine and thiazolidine substrate 3-30 but only isolated trace amounts of product (entry 
4); possibly the sulfur atoms of 3-30 were not favorable for copper coordination. When we 
switched to the benzyl-substituted auxiliary 3-28 with i-butyl imine 3-18, we obtained 50% of 
desired vinylogous Mannich product 3-33 with a dr 70:30 (entry 5). With phenyl-substituted imine 
3-17, the yield of product 3-34 dropped to 31%, but the dr improved to 86:14 as determined by 
SFC analysis (entry 6). With this encouraging diastereomeric ratio, we pursued further 






Table 3-4 Oxazolidinone auxiliary screen in the vinylogous Mannich reactiona 
 




1d O i-Propyl H i-Butyl 60, (3-32) 60:40 
2 O Indolylmethyl H i-Butyl Trace NA 
3 O Benzyl Phenyl i-Butyl 0 NA 
4 S Benzyl H Phenyl Trace NA 
5 O Benzyl H i-Butyl 50, (3-33) 70:30 
6 O Benzyl H Phenyl 31, (3-34) 86:14 
aConditions: Oxazolidinone (1 equiv), imine (2 or 4 equiv), THF (0.1 M), catalyst solution ((S)-DTBM-SEGPHOS, 
[Cu(CH3CN)4]PF6, Et3N) (0.15 equiv) 
bIsolated yield 
cDetermined by chiral HPLC or SFC 
d((S)-DTBM-SEGPHOS, [Cu(CH3CN)4]PF6) (0.1 equiv), Et3N (1.0 equiv) 
 
With (R)-benzyl oxazolidinone 3-28, we screened various ligands, copper sources, 
additives, the inclusion of water, solvents, and reaction temperatures without significant 
improvement in yield or diastereomeric outcome. For example, increasing catalyst loading from 
0.15 equiv to 0.25 equiv was slightly beneficial for the yield.  
One key finding was that only the very bulky DTBM-SEGPHOS ligand efficiently 
catalyzed the reaction. We hypothesized that the reactivity was dependent on more than just ligand 
dihedral- and bite-angle. The Liu group at the University of Pittsburgh and the Buchwald group at 
MIT recently reported the success of the DTBM-SEGPHOS ligand in the hydroamination of 
unactivated olefins.218-219 Through experimental calculations they confirmed that stabilizing, 
“through space” ligand-substrate interactions (ΔEint-space) were responsible for the difference in 
reactivity of substrates with DTBM-SEGPHOS versus the less bulky SEGPHOS ligand. 
Dispersion interactions between the t-butyl groups of the ligand and the alkyl substituents on the 
olefin substrates were weakly stabilizing and the additive effects of these ~1 kcal/mol stabilizations 
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significantly increased the reaction rate. All of the “through bond” (ΔEint-bond) interactions for 
DTBM-SEGPHOS and SEGPHOS were nearly identical and thus did not contribute to the 
reactivity difference.218 We hypothesized that our system could benefit from these “through space” 
interactions. Unique London dispersion interactions between the bulky DTBM-SEGPHOS ligand 
and oxazolidinone nucleophile lower the activation barrier leading to increased product formation 
as compared to less sterically demanding ligands. 
While most reaction parameter optimizations were unsuccessful, a small screen of bases 
was beneficial (Table 3-5). Standard conditions with Et3N (0.15 equiv) provided vinylogous 
Mannich product (R,R)-3-34 in 31% yield (entry 1). When Et3N was increased to 0.45 equiv, we 
did not see a corresponding increase in conversion (entry 2). With the success of NMM as a base 
in the auxiliary coupling reaction, we used it in the vinylogous Mannich reaction at -20 °C but 
only obtained 16% of desired product (R,R)-3-34 (entry 3). Neither did the strong base DBU 
(pKaH 12) nor less basic pyridine (pKaH 5.2) catalyze the reaction (entries 4-5). Next, we switched 
to 1,4-diazabicyclo[2.2.2]octane (DABCO) which was shown to be selective in a vinylogous Aza-
Morita-Baylis-Hillman with Boc protected imines.220 DABCO is a cyclic, tertiary amine that is 
highly nucleophilic. Protonated DABCO has a pKaH of 8.8 making DABCO a weak base, 
however, the two nitrogen atoms of DABCO lead to unique properties including that of an 
uncharged supernucleophile.221 With DABCO (0.15 equiv) at -40 °C, we obtained product (R,R)-
3-34 in 34% yield and a much cleaner overall reaction profile; the pKaH of 8.8 was sufficient for 
the required α-deprotonation (entry 6). We increased the equivalents of DABCO to 0.5 and 1.0 
equivalents at -20 °C (entries 7-8) and observed improved results with DABCO (0.5 equiv) as the 
yield was improved to 58%. Interestingly, when we switched to the very strong, non-nucleophilic 
phosphazene bases P4-t-Bu (entry 9) and P2-t-Bu (entry 10), we obtained the α-addition product 








Table 3-5 Base screen for the vinylogous Mannich reaction between 3-28 and 3-17a 
 
aConditions: (R)-3-28 (1 equiv), 3-17 (2 equiv), (S)-DTBM-SEGPHOS (0.25 equiv), [Cu(CH3CN)4]PF6 (0.25 equiv), 




The optimal conditions for the reaction were two equivalents of imine 3-17, a catalyst 
system of DTBM-SEGPHOS (0.25 equiv) and [Cu(CH3CN)4]PF6 (0.25 equiv), DABCO (0.5 
equiv), and THF (0.1 M) at -20 °C for 5 h. Previously, reaction times were >15 h, but with these 
optimized conditions we found that the reaction was complete in less than five hours. 
After determining the optimized conditions, we performed a systematic analysis of the 
reaction outcome to determine if the double asymmetric reaction was more selective than the single 
asymmetric reaction.  
Entry Base Base equiv Temp (°C) (R,R)-3-34 yield (%) 3-35 yield (%) 
1 Et3N 0.15 -40 31 - 
2 Et3N 0.45 -40 30 - 
3 NMM 0.15 -20 16 - 
4 DBU 0.15 -40 - - 
5 Pyridine 0.15 -40 - - 
6 DABCO 0.15 -40 34 - 
7 DABCO 0.50 -20 58 - 
8 DABCO 1.0 -20 39 - 
9 P4-t-Bu 0.50 -20 - 50 
10 P2-t-Bu 0.50 -20 - 53 
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A double asymmetric synthesis reaction can be analyzed mathematically. Masamune 
proposed that the degree of asymmetric induction obtained in double asymmetric reaction is 
approximated as (a x b) in a matched pair and (a / b) in a mismatched pair where a and b are the 
individual diastereoselectives for each of the chiral reactants.198 This equation was later fully 
derived by Nakayama.223 Noteworthy, this equation is valid in a qualitative sense for reaction 
design. There are eight total reactions that can be considered in the analysis (Figure 3-21). In 
consideration is the following scenario: 1) a substrate that exists in (S)-X and (R)-X enantiomeric 
forms along with a closely related achiral form X; 2) a prochiral substrate, Y; and 3) a reagent that 
exists in (S)-Z and (R)-Z enantiomeric forms along with a closely related achiral form Z. For the 
single asymmetric reactions, product formation can be controlled by the reagent (Figure 3-21 A) 
or by the substrate (Figure 3-21 B). Control by the reagent leads to two major enantiomeric 
products. Control by the substrate leads to two major diastereomeric products; the other two 
possible diastereomeric products will be minor. For the double asymmetric reactions, both the 
chirality of the reagent and chirality of the substrate control the stereochemical outcome (Figure 
3-21 C). From four reaction combinations, four possible diastereomeric products can form as the 
major product. The diastereomeric outcome from the single asymmetric substrate-controlled 





Figure 3-21 Experimental designs for determining the outcome of a double asymmetric synthesis 
methodology 
 
Similar to the scenario in Figure 3-21, our vinylogous Mannich reaction can proceed under 
single asymmetric control or double asymmetric control. The vinylogous Mannich reaction results 
in the formation of one new stereogenic center. When an achiral oxazolidinone substrate reacts 
with a prochiral imine under chiral DTBM-SEGPHOS ligand conditions, two major enantiomeric 
products can form (reagent control). When a chiral oxazolidinone substrate reacts with a prochiral 
imine under achiral (or racemic) reagent conditions, two major diastereomeric products can form 
(substrate control). When a chiral oxazolidinone substrate reacts with a prochiral imine under 
chiral DTBM-SEGPHOS ligand conditions, four possible diastereomeric products can form as the 
major product (reagent and substrate control). Based on the classical sense of double asymmetric 
induction as defined in Figure 3-21, two of these reaction pairs will represent a “matched” case 
and two will represent a “mismatched” case. A matched case leads to an increase in diastereomeric 
outcome while a mismatched case results in a decrease in diastereomeric outcome. The 
mismatched outcome can also manifest itself as a decrease in reaction rate/product formation. It is 
important to evaluate the single asymmetric induction scenarios for baseline selectivity values to 
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determine if a double asymmetric induction is warranted. Additionally, the selectivity ratios may 
be used to rationalize the selectivity seen in the double asymmetric induction products.  
We anlayzed these reactions with Evans’ benzyl oxazolidinone and phenyl substituted 
imine 3-17 (Table 3-6). First, we considered the single asymmetric reactions. With unsubstituted 
oxazolidinone 3-31, the (S)-ligand provided the (R)-product with an er of 4:96 (S:R) while the (R)-
ligand provided the (S)-product with an er of 96:4 (S:R) as determined by SFC analysis (Entry 1-
2) (Scheme 3-22). Both reactions resulted in conversion of starting material to product in >50% 
yield. The remaining mass balance was recovered starting material. There was no evidence of -
addition by 1H NMR analysis. 
 
 
Scheme 3-22 Single asymmetric synthesis reactions controlled by chiral ligand 
 
The absolute configuration was determined by conversion of (R)-product (entry 1) to 
primary alcohol (R)-3-36 by a two-step ozonolysis, reduction sequence and comparison of the 




Scheme 3-23 Determination of absolute configuration of (R)-3-34 
 
When the ligand rac-BINAP was used and the stereocontrol was provided by the substrate, 
(R)-3-28 or (S)-3-28, we obtained products with only 2:1 selectivity (entry 3-4). As a ligand, rac-
BINAP should not be compared directly to DTBM-SEGPHOS because of its different size and 
electronic properties; however, this result indicates that the ligand has a stronger stereochemical 
control over the reaction compared to the chiral substrate. From the single stereochemical control 
reactions, we determined that the (S)-ligand directs to the (R)-product while the (R)-ligand directs 
to the (S)-product. These results are consistent to the Yin group’s results with the pyrazole 
auxiliary.161 We also determined that the (R)-oxazolidinone directs preferentially to the (S)-product 
while the (S)-oxazolidinone directs preferentially to the (R)-product. Taken together, the (S)-ligand 
forms a matched pair with the (S)-oxazolidinone and the (R)-ligand with the (R)-oxazolidinone. 
Next, we looked at the double asymmetric synthesis conditions. (R)-Oxazolidinone, (R)-3-
28, and the (S)-ligand provided the (R)-product with a dr of 14:86 (S:R) (entry 5). The absolute 
configuration was confirmed by conversion to the primary alcohol as previously described.161, 224 
The (R)-oxazolidinone substrate with the (R)-ligand provided the (S)-product with a slightly lower 
yield (33%) but with an improved dr of 92:8 (S:R) (entry 6). The same result was achieved with 
(S)-oxazolidinone (S)-3-28: an enhanced diastereomeric outcome with the (S)-ligand that formed 
a matched-pair compared to the (R)-ligand that formed a mismatched-pair (entry 7-8).  
In our system, the ligand provides significantly more control than the substrate. 
Interestingly, even in the matched-pair double asymmetric reactions, the stereocontrol was reduced 
compared to the reaction controlled only by the ligand. These results do not conform to 
Masamune’s mathematical analysis because there was not an enhancement in stereocontrol in the 
double asymmetric reaction. We hypothesized that the flexible chiral appendage on the substrate 
interferes with the orderly transition state controlled by the ligand. The results where selectivity 
95 
was controlled only by the substrate (entry 3-4) confirms that there is interplay between the ligand 
and chiral auxiliary; the benzyl appendage has some effect on the stereochemical outcome because 
the product outcome was not racemic. The mismatched-pair occurs when the chiral auxiliary and 
ligand direct towards different amine stereocenters resulting in a lower selectivity of 86:14 
compared to the matched-pair selectivity of 92:8 where both the chiral auxiliary and the ligand 
direct towards the same amine stereocenter. Unless we intend to use the chiral substrate appendage 


























Table 3-6 Analysis of stereochemical outcome with phenyl iminea 
 
aConditions: Oxazolidinone (1 equiv), 3-17 (2 equiv), ligand (0.25 equiv), [Cu(CH3CN)4]PF6 (0.25 equiv), DABCO 
(0.5 equiv), THF (0.1 M) 
bDetermined by SFC analysis 
cAssignment of stereocenter at amine 
dConverted to primary alcohol (R)-3-36 by ozonolysis and reduction – er 5:95 
eConverted to primary alcohol (R)-3-36 by ozonolysis and reduction – er 15:85 
 








1 H 3-31 (S)-DTBM-SEGPHOS 67 (R)-3-34 4:96d  
2 H 3-31 (R)-DTBM-SEGPHOS 50 (S)-3-34 96:4  
3 (R)-Benzyl (R)-3-28 rac-BINAP 10 (S,R)-3-34  67:33 
4 (S)-Benzyl (S)-3-28 rac-BINAP 10 (R,S)-3-34  35:65 
5 (R)-Benzyl (R)-3-28 (S)-DTBM-SEGPHOS 58 (R,R)-3-34  14:86e 
6 (R)-Benzyl (R)-3-28 (R)-DTBM-SEGPHOS 33 (S,R)-3-34  92:8 
7 (S)-Benzyl (S)-3-28 (R)-DTBM-SEGPHOS 50 (S,S)-3-34  86:14 
8 (S)-Benzyl (S)-3-28 (S)-DTBM-SEGPHOS 26 (R,S)-3-34  9:91 
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We considered two other imine substrates to confirm this unique reactivity. First, we 
synthesized furan imine 3-38 from sulfone 3-37 and then subjected it to our optimized vinylogous 
Mannich conditions with oxazolidinone substrate (R)-3-28, (S)-3-28, or 3-31 (Table 3-7). The 
furan imine with unsubstituted oxazolidinone 3-31 provided product with less stereoselectivity, 
~4:1 for both chiral ligands, compared to the phenyl substituent (entry 1-2). Unfortunately, the 
control reaction with rac-BINAP did not provide any product to aid in the analysis (entry 3). For 
the double asymmetric reactions, utilizing the (R)-oxazolidinone with the (S)-ligand provided 
product that was essentially racemic at the amine stereogenic center (entry 4). The (R)-ligand was 
significantly better, as product was obtained in slightly lower yield (40%) but an improved dr of 
84:16 (entry 5). A similar improved result was achieved with the (S)-oxazolidinone and (S)-ligand 
(entry 6). These matched-pair double asymmetric outcomes (entry 5-6) were actually a slight 
improvement compared to the stereochemical outcome obtained with the single asymmetric 
reaction controlled by the chiral ligand (entry 1-2).  
The results with the furan imine demonstrate the importance of the imine substituent on 
the stereochemical outcome. The furan is slightly electron donating while the phenyl substituent 
is slightly electron withdrawing; this electronic difference may contribute to the stereochemical 
outcome when controlled only by the ligand. In the Yin group’s system with a pyrazole auxiliary, 
alkyl substituted imines and furan substituted imines resulted in decreased enantiomeric outcome 
compared to phenyl substituted imines.161 The matched, mismatched systems lead to a significant 
difference in diastereomeric outcome. This cannot be solely attributed to the interplay between the 
substrate auxiliary and ligand; if it was, the outcome would match the phenyl imine. We 
hypothesize that the furan imine size and electronic properties contribute to the difference. The 
furan imine was more reactive than the phenyl imine which may also contribute to the decreased 








Table 3-7 Analysis of stereochemical outcome with furan iminea 
 
aConditions: Oxazolidinone (1 equiv), 3-38 (2 equiv), ligand (0.25 equiv), [Cu(CH3CN)4]PF6 (0.25 equiv), DABCO 
(0.5 equiv), THF (0.1 M) 
bDetermined by SFC analysis 
cAssignment of stereocenter at amine 
 
Next, we synthesized 4-fluorophenyl imine 3-41 from sulfone 3-40 and subjected it to our 
optimized vinylogous Mannich conditions with the oxazolidinone substrate. We obtained a similar 
stereochemical outcome to that of the phenyl derivative (Table 3-8). The reaction of unsubstituted 
oxazolidinone 3-31 with (R)-DTBM-SEGPHOS provided the best stereochemical outcome with a 
dr of 94:6 (entry 1). The (R)-substrate with the (S)-ligand formed a mismatched pair resulting in 








1 H 3-31 (S)-DTBM-SEGPHOS 74 (R)-3-39 18:82  
2 H 3-31 (R)-DTBM-SEGPHOS 62 (S)-3-39 79:21  
3 (R)-Benzyl (R)-3-28 rac-BINAP NR - -  
4 (R)-Benzyl (R)-3-28 (S)-DTBM-SEGPHOS 62 (R,R)-3-39  47:53 
5 (R)-Benzyl (R)-3-28 (R)-DTBM-SEGPHOS 40 (S,R)-3-39  84:16 
6 (S)-Benzyl (S)-3-28 (S)-DTBM-SEGPHOS 34 (R,S)-3-39  17:83 
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product with a dr of 85:15 while the reaction with the (R)-ligand in the matched pair improved the 
dr to 91:9 (entry 2-3).  
 
Table 3-8 Analysis of stereochemical outcome with flurophenyl iminea 
 
aConditions: Oxazolidinone (1 equiv), 3-41 (2 equiv), ligand (0.25 equiv), [Cu(CH3CN)4]PF6 (0.25 equiv), DABCO 
(0.5 equiv), THF (0.1 M) 
bDetermined by SFC analysis 
cAssignment of stereocenter at amine 
 
Based on these experimental data, we considered the mechanism and transition state of the 
reaction. Copper(I) prefers to adopt a tetrahedral orientation coordinating to the two phosphorus 
atoms of the ligand.225 We considered a cyclic transition state with the copper species bonded at 
the α-position of the carbonyl nucleophile (Figure 3-22 A) and an open transition with the copper 
placed on the oxygen of the enolate and coordinated to the oxazolidinone carbonyl for additional 
stability (Figure 3-22 B).187, 226 The cyclic transition state model leads to the formation of a 
favorable 6-membered ring with the oxazolidinone carbonyl group oriented anti to the acyl 
carbonyl and the copper species coordinated to the imine nitrogen (Figure 3-22 A). We briefly 








1 H 3-31 (R)-DTBM-SEGPHOS 39 (S)-3-42 94:6  
2 (R)-Benzyl (R)-3-28 (S)-DTBM-SEGPHOS 34 (R,R)-3-42  15:85 
3 (R)-Benzyl (R)-3-28 (R)-DTBM-SEGPHOS 17 (S,R)-3-42  91:9 
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considered the cyclic transition state with copper coordinated to the carbonyl of the oxazolidinone 
and the imine nitrogen, however, this led to the formation of an unfavorable 8-membered ring and 
distorted bond angles of 101 and 132° for sp2-carbons in the ring. 
In the open transition state, the oxazolidinone carbonyls must be syn to one other thus 
adopting a syn-s-cis confirmation that leads to the (Z)-enolate (Figure 3-22 B). Chelation to both 
carbonyls impedes free rotation around the carbon-nitrogen sigma bond thus locking the 
oxazolidinone in place. Anti-periplanar attack occurs on the prochiral center of the imine. With 





Figure 3-22 A) Proposed cyclic transition state and B) Proposed open transition state 
 
We modeled the cyclic and open transition states with (R)-benzyl oxazolidinone substituted 
(R)-3-28 and (S)-DTBM-SEGPHOS leading to the major (R,R)-product and the minor (S,R)-
product in Scigress with MM3 force field parameters (Figure 3-23 and 3-24).161, 226-228 In the cyclic 
transition state, the chiral ligand is oriented such that it may block one face of the imine, however, 
control from the oxazolidinone auxiliary appears limited. The benzyl oxazolidinone auxiliary is 
positioned over 8.5 Å from the prochiral center so it is unlikely to have much of an effect on the 
newly formed stereocenter (Figure 3-23). Non-covalent interactions between the substrate and 
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ligand may be altered by the chiral appendage but not in a significant effect for the prochiral center. 
From our experiments, the oxazolidinone chiral appendage provides a 2:1 selectivity when a 
racemic ligand is used so it must be orientated in such a way to impact the prochiral center. 
Additionally, in the cyclic transition state there is steric clash between the Boc-protecting group 
of the imine and the large phenyl substituent of the imine. In the open transition state it is easier to 
visualize how the benzyl oxazolidinone auxiliary could have some effect on the new stereogenic 
center. The benzyl appendage is less than 5 Å from the imine center and the sp2-carbons of the 
phenyl group of the imine are 3.7 Å from then benzyl sp2-carbons (Figure 3-24). In the major 
(R,R)-product the (small) hydrogen from the imine prochiral center is on the same face as the 
benzyl directing group. In the minor (S,R)-product the (large) phenyl group of the prochiral imine 
is on the same face as the benzyl directing group leading to an unfavorable interaction. From 
modeling the antiperiplanar transition state, it is easier to rationalize how there can be matched 
and mismatched pairs leading to different stereochemical outcomes as well as how the 
unsubstituted oxazolidinone generates a simpler transition state when controlled only by the 
ligand. We hypothesize that the matched pair occurs when the ligand blocks the face that the 
oxazolidinone appendage is on while the mismatched pair occurs when the ligand blocks the face 
that the oxazolidinone appendage directs to. At this time, we cannot definitively conclude which 




Figure 3-23 Scigress modeled cyclic transition state with (R)-auxiliary and (S)-ligand leading to A) (R,R)-
major product and B) (S,R)-minor product 
 
 
Figure 3-24 Scigress modeled open transition state with (R)-auxiliary and (S)-ligand leading to A) (R,R)-















































Ultimately the vinylogous Mannich reaction allowed the rapid formation of the backbone 
of JP4-039. The previous synthesis took six-steps to get to the Boc-protected amine, whereas this 
new route only required two synthetic steps. Additionally, various imines could be used to 
diversify the molecule in Zone I (Figure 3-15). With these vinylogous Mannich products, we set 
out to accomplish our primary objective: to probe the structure-activity relationship of JP4-039 
analogs in the ferroptosis cell death pathway and determine whether activity was sequence-
dependent or lipophilicity-dependent. 
3.2.3 Synthesis of JP4-039 Analogs 
We began the analog efforts with (R,R)-vinylogous Mannich product 3-42 with a 4-
flurophenyl side chain. We attempted our optimized photochemical isomerization conditions on 
the substrate but were unable to observe any ,-unsaturated product. Instead, the oxazolidinone 
auxiliary was highly prone to eliminate which led to decomposition products. Similar to the 
pyrazole auxiliary, the benzyl side chain on the oxazolidinone likely affected the photochemistry 
of the molecule. Alternatively, we explored strong base-mediated isomerizations. In 1973, 
Herrmann demonstrated the use of an LDA-mediated deconjugation reaction of ethyl crotonate 
(Scheme 3-24).229 Herrmann and coworkers performed simple molecular orbital calculations on 
the lithium enolate of ethyl crotonate and determined that the maximum negative partial charge 





Scheme 3-24 LDA mediated deconjugation reaction229 
 
For our isomerization conditions, we replaced HMPA with the cyclic urea DMPU as it is 
less carcinogenic (Scheme 3-25).230 Our first aim was to use a hydrogen source to isomerize the 
double bond out of conjugation. The LDA reagent (3.0 equiv) was formed at -78 °C followed by 
the addition of DMPU (3.1 equiv). Vinylogous Mannich product (R)-3-42 was added and the 
solution was allowed to warm slowly from -78 °C to -40 °C and then -20 °C. Upon recooling to -
78 °C, methanol was added. Our expected product was the skipped diene with the oxazolidinone 
still in place. However, we were pleasantly surprised that under these conditions not only did we 
achieve isomerization of the double bond but also elimination of the oxazolidinone to the methyl 
ester. We believe that the LDA-DMPU complex deprotonated an allylic hydrogen which generated 
an extended enolate system and upon quenching with methanol, a hydrogen was preferentially 
added at the α-carbon. Under the strongly basic LDA conditions, methanolysis led to the formation 
of methyl ester product, (R)-3-43, in 66% yield. To the best of our knowledge, these conditions 
have not been reported to cleave an oxazolidinone auxiliary. From here only two steps were 
necessary to prepare a direct JP4-039 analog with a 4-flurophenyl side chain. Saponification 
followed by amidation with 4-AT under standard conditions used in our group provided nitroxide 
(R)-3-44 in 55% yield (Scheme 3-25). The synthetic route to (R)-3-44 required only five linear 
steps and only four purifications, however the yield was 8% because of the low yield in the 
vinylogous Mannich step. Despite the yield, this is a dramatic improvement over the previously 
developed synthesis in terms of our ability to quickly synthesize and test a diverse set of analogs 
for their anti-ferroptosis activity. It also avoids the use of experimentally challenging 




Scheme 3-25 Synthesis of analog (R)-3-44 
 
While we were interested in modifications of Zone I, we were also interested in 
substitutions at the α-position of the carbonyl in Zone III. We previously only explored a small 
number of modifications at this position and we know that these substitutions can affect how the 
molecule folds and crosses the mitochondrial membrane.79,93 Despite multiple attempts to 
isomerize and alkylate both the 4-benzyl oxazolidinone and unsubstituted oxazolidinone 3-42, we 
were unsuccessful. Conditions we attempted included: 1) replacing HMPA with DMPU; 2. 
exploring both NaHMDS and LDA; 3. modifying temperature; 4. modifying equivalents of LDA 
and DMPU; and 5. using alkylating agents of various sizes and in various equivalents. In brief, 
reactions with HMPA were not as high yielding as DMPU. Since NaHMDS is not as strong of a 
base as LDA (pKa 26 vs 36), we were not surprised to observe no reactivity under these conditions 
as most likely NaHMDS did not lead to deprotonation and formation of the enolate.231 We noted 
that when the reaction was not warmed up, alkylation did not occur. However, when the reaction 
temperature reached rt too quickly, decomposition was evident. As our substrate possessed a NH, 
we required at least two equivalents of base. In some cases, excess base drove the formation of 
decomposition products. The smaller electrophile methyl iodide or the more reactive electrophile 
methyl triflate did not lead to deconjugated alkylated product. From all these unsuccessful 
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reactions, we generally isolated starting material or alkylated oxazolidinone auxiliary along with 
decomposition products (Scheme 3-26). 
 
 
Scheme 3-26 Attempted deconjugative alkylation reaction with oxazolidinone auxiliary 
 
As the deconjugative alkylation did not work with the oxazolidinone auxiliary, we 
hypothesized that the corresponding methyl ester may be more amendable to the transformation. 
In the literature, the most common way to cleave Evans oxazolidinone auxiliary is with 
LiOH/H2O.
231 However, this method generates the carboxylic acid and we wanted to streamline 
the synthesis directly to the methyl ester. In 2018, a group at Bristol-Myers Squibb disclosed one-
pot Yb(OTf)3 conditions to convert N-acyl oxazolidinones directly to esters or amides.
232 The 
authors did not comment specifically on the mechanism but through a high-throughput screen 
determined that the smaller the ionic-radius of the Lewis acid (104.2 Å for Yb(OTf)3), the shorter 
the reaction time. According to the literature, Yb(OTf)3 does have unique reactivity with 
oxazolidinones; it has been utilized in annulations and free-radical-mediated intramolecular 
conjugate addition reactions.233-234 To our delight, the ytterbium conditions worked well for both 
4-benzyl oxazolidinone substituted (R,R)-3-42 and unsubstituted oxazolidinone substrate (S)-3-42 
(Scheme 3-27). Both methyl ester products were obtained in over 95% yield with no degradation 
in er.  
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Scheme 3-27 Ytterbium triflate catalyzed oxazolidinone cleavage 
 
With the (S)- and (R)-methyl ester products in hand, we attempted the deconjugative 
alkylation chemistry again. Upon reaction with LDA (3.0 equiv), DMPU (3.1 equiv), and 4-
fluorobenzyl bromide (3.0 equiv) at -78 °C, followed by slow warming to rt, we isolated the (S)- 
and (R)-bis alkylated product 3-46 in 94% and 71% yield respectively (Scheme 3-28). With less 
than 2 equivalents of alkylating agent, we always isolated the bis-alkylated product. Mono- versus 




Scheme 3-28 Deconjugative alkylation reaction with methyl ester 3-45 
 
From this intermediate we synthesized three analogs for direct activity comparison in a 
ferroptosis assay. Both (S)- and (R)-3-46 were saponified and coupled to 4-AT to provide (S)- and 
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(R)-3-47 (Scheme 3-29). These Zone II analogs would indicate whether one enantiomer was more 
active than the other. We also wanted to explore the location of the nitroxide in the molecule. We 
planned to replace the Boc protecting group with a carbamate possessing a nitroxide moiety to test 
this effect. If this resulting molecule, with the nitroxide relocated from Zone IV to Zone V, was 
completely inactive, we would confirm the necessity of the location of the nitroxide in the lead 
structure. The nitrogen of (S)-3-46 was deprotected with TFA and then carbonate 3-48, synthesized 
from 4-hydroxy-Tempo and N,N’-disuccinimidyl carbonate, was added along with K3PO4 to 
provide nitroxide (S)-3-49 in 48% yield (Scheme 3-30). 
 
 
Scheme 3-29 Synthesis of analogs (S)- and (R)-3-47 
110 
 
Scheme 3-30 Synthesis of anlaog (S)-3-49 
 
To reduce the logP in this series of compounds, we incorporated a hetero-atom in the α-
alkylation reagent. 5-Fluoropicolinaldehyde was reduced with sodium borohydride to benzylic 
alcohol 3-50 and converted to allylic bromide 3-51 by an SN2-substitution with the activated 
primary alcohol generated upon reaction with phosphorus tribromide (Scheme 3-31). (R)-Methyl 
ester 3-45 did not react as smoothly with alkylating agent 3-51 but did provide product (R)-3-52 
in 32% yield. Saponification followed by amide coupling with 4-AT provided nitroxide (R)-3-53 




Scheme 3-31 Synthesis of analog (R)-3-53 
 
We next turned our attention to the incorporation of a furan in Zone I that would reduce 
the overall logP. We converted (S)- and (R)-3-39 to methyl ester, 3-54, with the Yb(OTf)3 
conditions (Scheme 3-32). The enantiomeric ratios of these products (established in the vinylogous 
Mannich reaction) were much lower than that of the 4-fluorophenyl derivative. Accordingly, we 
carried out semi-preparative purification by SFC to provide the (S)-product with er of  >99:1 and 
the (R)-product with er 97:3 (Scheme 3-28). Subsequent deconjugative alkylation with 4-
flurobenzyl bromide provided (S)-3-55 in 83% yield and (R)-3-55 in 79% yield (Scheme 3-32). 
Saponification followed by amide coupling with 4-AT provided nitroxides (S)-3-56 and (R)-3-56 





Scheme 3-32 Synthesis of analogs (S)- and (R)-3-56 
 
As a single point change that would allow us to look at the SAR in Zone III, we used 3-
fluorobenzyl bromide as the alkylating reagent (Scheme 3-33). (R)-3-54 underwent deconjugative 
alkylation with 3-fluorobenzyl bromide to provide bis-substituted compound (R)-3-57 in 29% 





Scheme 3-33 Synthesis of analog (R)-3-58 
 
In collaboration with group members who also carried out research on the SAR of JP4-
039, nitroxide (S)-992-38 became a lead compound. When our group first tested the ferroptosis 
activity of JP4-039 in 2016, the bis-nitroxide derivative of JP4-039 was 3.5x more active. It was 
proposed that the improvement in activity was due to its increased ability to scavenge reactive 
oxygen species.156 Accordingly, as a modification in Zone V, we synthesized both the carbamate 
and urea linked bis-nitroxide of nitroxide (S)-992-38 to test the ROS scavenging of a dual nitroxide 
analog (Scheme 3-34). Similar to the chemistry used to synthesize nitroxide (S)-3-49, 4-hydroxy-
tempo or 4-AT was reacted with N,N’-disuccinimidyl carbonate to form the respective carbonate 
or carbamate, 3-48 or 3-59. The Boc-protecting group of nitroxide (S)-992-38 was cleaved with 
TFA and the resulting free amine was coupled to the carbonate/carbamate with K3PO4 to provide 




Scheme 3-34 Synthesis of analogs (S)-3-60 and (S)-3-61 
3.2.4 Activity of JP4-039 Analogs in an Erastin-Induced Ferroptosis Assay 
We considered the SAR (Table 3-9) based on the five designated zones for modifications 
(Figure 3-15). We first considered Zone I and II modifications. JP4-039 has a leucine residue in 
Zone I and (S)-stereochemistry in Zone II. (R)-3-44 has 4-fluorophenyl in Zone I and (R)-
stereochemistry in Zone II. (R)-3-44 was >10x more active than JP4-039 (Figure 3-25). (R)-3-44 
is more than twice as lipophilic as JP4-039; further modifications of (R)-3-44 could help indicate 
whether this activity increase was sequence-dependent or lipophilicity-dependent. We cannot 
make any conclusions about preferred stereochemistry from this result. Ultimately, residues other 




Figure 3-25 Activity and logP comparison of JP4-039 and (R)-3-44 
 
Next, we looked as specific modifications to Zone III in (R)-3-44 as well as the impact of 
stereochemistry in Zone II (Figure 3-26). When 4-flurophenyl is in Zone I, substitution  to the 
amide was not significantly beneficial for activity. (R)-3-47, the direct comparison to (R)-3-44, 
had an EC80 of 355 nM and a greatly increased logP of 7.88. The enantiomer of this compound, 
(S)-3-47, also had a similar EC80 of 371 nM. If activity was lipophilicity-dependent, we would 
expect that these -substituted analogs would have improved activity. Our previous work points 
to the role -amide substitutions have in determining the secondary structure of the compound and 
how it interacts with the mitochondrial membrane.79, 93 We do not know the exact mechanism of 
action of these analogs but the EC80 activities indicate that both substituted analogs (R)- and (S)-
3-47 and unsubstituted (R)-3-44 may have similar mitochondrial locating efficiency. 
 
 
Figure 3-26 Activity and logP comparison of (R)-3-44, (R)-3-47 and (S)-3-47 
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To further test the effect of lipophilicity, we looked at an additional modification in Zone 
III in this series of 4-fluorophenyl analogs. Incorporation of a heteroatom in the -substituents of 
(R)-3-53 reduced the logP from 7.88 to 5.78 but lead to a complete loss of activity (Figure 3-27). 
If the activity trend in this series of analogs was correlated to logP, we would expect (R)-3-53 to 
have intermediate activity between (R)-3-44, which has a lower logP, and (R)-3-47, which has a 
higher logP. The pyridine heterocycles may affect secondary structure or interactions with the 
mitochondrial membrane.  
 
 
Figure 3-27 Activity and logP comparison of (R)-3-47 and (R)-3-53 
 
Finally, for this series of Zone I, 4-fluorophenyl analogs we looked at the location of the 
nitroxide by moving it from Zone IV to Zone V (Figure 3-28). (S)-3-49 with a methyl ester in Zone 
IV and TEMPO radical scavenging moiety in Zone V had an EC80 of 225 nM and similar logP of 
7.68. This analog was 1.6x more active than its direct comparison (S)-3-47. This is the first time 
we have moved the lone-nitroxide around the molecule and the SAR indicates that it is better 
positioned on the allylic amine. Further modifications of nitroxide species and linkers should be 




Figure 3-28 Activity and logP comparison of (S)-3-47 and (S)-3-49 
 
With the success of the 4-flurophenyl side chain in Zone I, we looked at the incorporation 
of a furan in Zone I because it would lower the overall logP thus improving the drug-like properties 
(Figure 3-29). Incorporation of a furan in Zone I of (R)- and (S)-3-56 reduced the logP from 7.88 
to 6.03 but did not improve the activity; almost equivalent activity was maintained. This supported 
our hypothesis that the activity is not correlated to lipophilicity only. Analog (S)-3-56 was 1.7x 
more active than (R)-3-56. With the 4-flurophenyl residue in Zone I, we did not see a significant 
difference in activity. Substitutions in Zone I affect the activity of enantiomers differently. 
In the furan series, we also compared analog (R)-3-58 with a 3-fluorobenzyl side chain to 
(R)-3-56 with a 4-fluorobenzyl side chain. There was not a statistically significant difference in 





Figure 3-29 Activity and logP comparison of (R)-3-56 and (R)-3-58 
 
Finally, we looked at modifications in Zone V through introduction of a second nitroxide 
moiety (Figure 3-30). Our previous results indicated that the introduction of a second nitroxide 
increased activity by enhancing the innate radical-scavenging ability of the compound. This result 
was confirmed as introduction of a carbamate linked nitroxide in (S)-3-60 resulted in a 2.2x 
increase in activity (Figure 3-30). Bis-nitroxide (S)-3-60 was one of the most potent compounds 




Figure 3-30 Activity and logP comparison of (S)-992-38 and (S)-3-60 and (S)-3-61 
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aN = 4 
blogP determined by Chemdraw calculations. 
cEnantiopurity determined by SFC from methyl ester intermediate 
dRange of EC80 based on Prism generated curve 
eFerroptosis assay in RSL3 induced macrophage model indicated that (R)-3-47 in 2.5x more active than (R)-3-44  
 
In summary, the SAR revealed that different groups with various degrees of lipophilicity 
could be incorporated in Zone I to improve activity. For Zone II it appears that the residue in Zone 
I affects whether the enantiomers will have similar activity to one another or if one will be more 
active. In Zone III, -substitutions maintained or increased activity while also raising the overall 
logP. Activity was sequence-dependent. Activity did not correlate to lipophilicity alone but an 
increase in logP was beneficial for activity. For Zone IV and Zone V it was determined for the first 
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time that activity can be improved by installing the nitroxide on the allylic amine in Zone V. The 
presence of a nitroxide in Zone IV and Zone V, however, is optimal from purely an activity 
standpoint. 
3.3 Conclusions 
We have developed a new synthetic route to analogs of the nitroxide JP4-039 (Scheme 3-
35). The key step of the sequence, a vinylogous Mannich reaction, allows the formation of the JP4-
039 backbone and chiral amine in a single step; protecting group interchange is not necessary. 
Isomerization and amide coupling lead to JP4-039 analogs in five steps and only four purifications 
while deconjugative alkylation and amide coupling from the corresponding methyl ester allowed 
the synthesis of analogs with substitutions at the α-position of the carbonyl group. Several analogs 
that are more protective in preventing erastin-induced ferroptosis cell death were synthesized. 
Various functionalities could be incorporated in Zone I and substitutions α to the amide in Zone 
III were effective. Activity was sequence-dependent but did show some lipophilicity-dependence 
as, generally, the most active compounds had a higher logP. The two most potent compounds, (S)-
3-49 (EC80 = 225 nM) and (S)-3-60 (EC80 = 163 nM) incorporated a Tempo-nitroxide in Zone V 




Scheme 3-35 Synthetic scheme proceeding through a vinylogogus Mannich reaction and deconjugative 
alkylation towards JP4-039 analogs 
3.4 Experimental Procedures 
General. All glassware was flame-dried or oven-dried and cooled under dry N2 or Ar prior to use.  
All moisture sensitive reactions were performed under dry N2 or Ar. Reactions carried out below 
0 °C employed an acetone/dry ice bath or a cryocool and an isopropanol or acetone bath. Reagents 
obtained from commercial sources were used as received unless otherwise specified. THF, Et2O, 
and 1,4-dioxane were distilled from sodium/benzophenone ketyl; DIPEA and TEA were distilled 
from CaH2 and stored over KOH; and CH2Cl2 and toluene were purified by passage through an 
activated alumina filtration system. Concentrating under reduced pressure refers to the use of a 
123 
rotary evaporator connected to a membrane vacuum pump to remove solvent.  
Melting points were determined using a Laboratory Devices Mel-Temp II in open capillary 
tubes and are uncorrected. Infrared spectra were determined as neat solids or oils (unless otherwise 
specified) on a Perkin Elmer Spectrum 100. Low-resolution mass spectra were obtained on a 
Agilent Technologies 1260 Infinity II LCMS. High-resolution mass spectra were obtained on a 
Thermo Scientific Exactive Orbitrap LCMS or Agilent QTOF LCMS 6545A. Purity of compounds 
tested in biological assays was assessed using an Agilent Technologies 1260 Infinity II LC at 220 
nm UV absorption  (Waters XBridge BEH C18 2.1 x 50 mm, 2.5 µm). Microwave reactions were 
performed using a Biotage Initiator in glass microwave vials (cap sealed) with continuous 
magnetic stirring and an external surface temperature sensor. 
1H and 13C NMR spectra were recorded on a Bruker Avance III 300MHz, 400 MHz, 500 
MHz, and a cryoprobe equipped 600 MHz instruments. CDCl3 was filtered though basic Al2O3 
immediately prior to sample preparation.  Chemical shifts (δ) were reported in parts per million 
with the residual solvent peak used as an internal standard δ 1H / 13C (Solvent); 7.26 / 77.16 
(CDCl3); 2.50 / 39.52 (DMSO-d6); 3.31 / 49.00 (MeOD) and are tabulated as follows: chemical 
shift, multiplicity (s = singlet, brd = broad, d = doublet, t = triplet, q = quartet, m = multiplet), 
number of protons, and coupling constant(s). 13C NMR spectra were obtained at 75 MHz, 100 
MHz, 125, and 150 MHz using a proton-decoupled pulse sequence and are tabulated by observed 
peak. All 1D NMR spectra were processed using Bruker Topspin NMR. Thin-layer 
chromatography was performed using pre-coated silica gel 60 F254 plates (EMD, 250 μm 
thickness) and visualization was accomplished with a 254 nm UV light and by staining with a 
phosphomolybdic acid solution (5 g of phosphomolybdic acid in 100 mL of 95% EtOH), a p-
anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 
100 mL of 95% EtOH), a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 
0.1% NaOH solution), or Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 
in 100 mL of a 3.5 N H2SO4 solution). Flash chromatography on SiO2 (Silicycle, Silia-P Flash 
Silica Gel or SiliaFlash® P60, 40-63 μm) was used to purify crude reaction mixtures. 
Enantiomeric and diastereomeric ratios were determined either by analytical HPLC on 
Rainin Dynamax HPLC (Dual Pump, Model SD-200) with Dynamax UV-1 absorbance detector 
using Chiralpak AD-H column, or analytical SFC performed on Mettler Toledo instrument using 
Chiralpak-IC semiprep or Cellulose-2 column. 
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HT-1080 ferroptosis assay at CRO pharmaron. A 50,000 cell/mL solution (200 µL) of
HT-1080 cells was added to a 96-well plate and incubated at 37 °C, 5% CO2, 95% humidity for 
24 h. The compounds were dissolved in DMSO and a serial dilution was performed to 
achieve the desired testing concentration. This compound dilution (1 µL) was added to culture 
medium (1 mL) containing erastin (10 µM) to make the working solution. This working 
solution replaced the culture medium in each cell and the plate was incubated at 37 °C, 5% CO2, 
95% humidity for 24 h. After 24 h, medium (100 µL) was removed from each well and CellTiter-
Glo® (50 µL) reagent was added to each well. The plate was incubated for 30 min at rt to 
stabilize the luminescence signal. The plate was sealed, centrifuged for 1 min at 1,000 rpm to 
remove bubbles, and shaken for 1 min on an orbital shaker. Replicates of N=4 was used for all 
sample wells and ferrostatin-1 was used as a control in all assays. The luminescence was read 
in Enspire. The % remaining activity was determined by Equation 3-1:  
%𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑆 − 𝑀
𝑉 − 𝑀
 𝑥 100% Equation 3-1 
where S = readout of the test sample, V = readout of the vehicle sample, and M = readout of well 
with only Erastin treatment. Accordingly, the greater the luminescence signal the more protective 
the compound was. EC80’s were determined by plotting the data in GraphPad Prism and fitting the 
curves to a nonlinear regression model, either : [Agonist] vs. response -- variable slope (4-
parameters) or [Agonist] vs. normalized response -- variable slope depending on the data type. The 





 𝑥 𝐸𝐶50 
Equation 3-2 
where H is the Prism determined Hill slope. 
General procedure A. For the preparation of Boc-sulfones. The reaction was carried out 
according to a literature procedure and the product was prepared as described.235 A mixture of 
aldehyde (16.3 mmol, 1.0 equiv), t-butyl carbamate (16.3 mmol, 1.0 equiv), and sodium benzene 
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sulfinate (16.3 mmol, 1.0 equiv) was treated sequentially, and under vigorous stirring, with THF 
(6.5 mL), H2O (14.9 mL), and formic acid (3.9 mL, 98.1 mmol, 6.0 equiv). The reaction mixture 
was stirred at room temperature for 72 h under a N2 atmosphere. The white precipitate was filtered, 
washed with H2O (50 mL), suspended in a mixture of hexanes (25 mL) and CH2Cl2 (2.5 mL), and 
stirred for 2 h at room temperature. The residue was filtered and washed with hexanes. The 
colorless sulfone was dried under high vacuum and used without further purification. 
 
 tert-Butyl (phenyl(phenylsulfonyl)methyl)carbamate (3-15).236 According 
to General Procedure A, benzaldehyde (2.00 mL, 19.5 mmol, 1 equiv), t-butyl carbamate (2.28 g, 
19.5 mmol, 1 equiv), sodium benzene sulfinate (3.27 g, 19.5 mmol, 1 equiv), and formic acid (4.65 
mL, 117 mmol, 6 equiv) afforded 3-15 (5.70 g, 16.4 mmol, 84%) as a white solid: 1H NMR (400 
MHz, CDCl3) δ 7.91 (d, J = 7.6 Hz, 2H), 7.66-7.62 (m, 1H), 7.56-7.43 (m, 2H), 7.42 (brd s, 5H), 
5.92 (d, J = 10.8 Hz, 1H), 5.75 (d, J = 10.8 Hz, 1H), 1.26 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
192.5, 136.4, 134.5, 132.0, 130.1, 129.9, 129.84, 129.78, 129.5, 129.1, 129.0, 128.9, 128.8, 128.7, 
126.4, 124.9, 28.2. 
 
 tert-Butyl (3-methyl-1-(phenylsulfonyl)butyl)carbamate (3-16).235 
According to General Procedure A, isovaleraldehyde (2.03 mL, 18.4 mmol, 1 equiv), t-butyl 
carbamate (2.15 g, 18.4 mmol, 1 equiv), sodium benzene sulfinate (3.07 g, 18.4 mmol, 1 equiv), 
and formic acid (5.12 mL, 110 mmol, 6 equiv) afforded 3-16 (5.45 g, 16.6 mmol, 91%) as a white 
solid: Mp 119.8-121.9 °C; IR (ATR, neat) 3301, 2967, 1692, 1523, 1447, 1306, 1245, 1104, 1085, 
1047, 1025, 873, 845, 750, 688 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.91 (app d, J = 7.6 Hz, 2H), 
7.64-7.61 (m, 1H), 7.55-7.52 (m, 2H), 4.92 (d, J = 5.2 Hz, 1H), 2.05-2.00 (m, 1H), 1.80-1.70 (m, 
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2H), 1.20 (s, 9H), 1.00 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 153.6, 137.0, 133.8, 129.3, 129.2, 129.0, 80.8, 69.6, 34.5, 28.0, 24.8, 23.2, 21.1; HRMS (HESI) 
m/z calcd for C16H26NO4SNa [M+H]
+ 350.1393, found 350.1393. 
 
 tert-Butyl (furan-3-yl(phenylsulfonyl)methyl)carbamate (3-37).237 
According to General Procedure A, 3-furaldehyde (2.88 mL, 33.0 mmol, 1 equiv), t-butyl 
carbamate (3.86 g, 33.0 mmol, 1 equiv), sodium benzene sulfinate (5.58 g, 33.0 mmol, 1 equiv), 
and formic acid (7.86 mL, 198 mmol, 6 equiv) afforded 3-37 (6.32 g, 18.7 mmol, 57%) as a white 
solid: Mp 164.0-167.5 °C; IR (ATR, neat) 3248, 1686, 1529, 1448, 1369, 1317, 1250, 1132, 1083, 
1016, 872, 859, 680 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 7.5 Hz, 2H), 7.68-7.48 (m, 
4H), 7.47 (s, 1H), 5.93 (d, J = 10.5 Hz, 1H), 5.57 (d, J = 10.5 Hz, 1H), 1.25 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 184.5, 153.4, 151.4, 145.0, 143.8, 142.6, 134.0, 131.8, 129.5, 129.1, 129.0, 124.9, 
115.4, 109.7, 107.0, 28.2. 
 
 tert-Butyl ((4-fluorophenyl)(phenylsulfonyl)methyl)carbamate (3-
40).236 According to General Procedure A, 4-fluorobenzaldehyde (3.60 mL, 32.7 mmol, 1 equiv), 
t-butyl carbamate (3.83 g, 32.7 mmol, 1 equiv), sodium benzene sulfinate (5.53 g, 32.7 mmol, 1 
equiv), and formic acid (7.79 mL, 196 mmol, 6 equiv) afforded 3-40 (4.87 g, 13.3 mmol, 82% 
yield) as a  white solid: 1H NMR (300 MHz, CDCl3) δ 7.93–7.90 (app d, J = 7.2 Hz, 2H), 7.68–
7.64 (m, 1H), 7.58–7.53 (m, 2H), 7.46–7.41 (m, 2H), 7.12 (t, J = 8.4 Hz, 2H), 5.90 (br d, J = 10.5 
Hz, 1H), 5.68 (br d, J = 10.5 Hz, 1H), 1.25 (s, 9H). 19F NMR (470 MHz, CDCl3) δ -110.8. 
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General procedure B. For the preparation of Boc-imines. The reaction was carried out 
according to a literature procedure and the product was prepared as described.202 A mixture of 
sulfone (0.903 mmol, 1.0 equiv) and cesium carbonate (2.71 mmol, 3.0 equiv) was dried under 
high vacuum for 1 h in a 50 mL round bottom flask. Anhydrous CH2Cl2 (0.2 M, 5.0 mL) 
was added and the suspension was stirred for 45 min at 40 °C under an N2 atmosphere. The 
reaction mixture was diluted with cold hexanes (3.0 mL, 0 °C) and filtered through a plug of 
Hyflo® Super-Cel®. The plug was washed with hexanes (10.0 mL), and the filtrate was 
concentrated under reduced pressure (bath temperature maintained at 20 °C) and dried under 
high vacuum to afford the desired Boc-imine that was used in the following step without further 
purification. 
 tert-Butyl benzylcarbamate (3-17).236 According to General Procedure B, 3-
15 (0.825 g, 2.26 mmol, 1 equiv) and Cs2CO3 (2.23 g, 6.77 mmol, 3 equiv) afforded 3-17 (quant.) 
as a colorless oil: 1H NMR showed quantitative conversion and minor impurities. Diagnostic NMR 
peaks: 1H NMR (300 MHz, CDCl3) δ 8.87 (s, 1H), 7.91 (d, J = 6.9 Hz, 2H), 7.59-7.53 (m, 1H), 
7.49-7.44 (m, 2H), 1.59 (s, 9H). 
 tert-Butyl (3-methylbutylidene)carbamate (3-18).235 According to General 
Procedure B, 3-16 (0.535 g, 1.63 mmol, 1 equiv) and Cs2CO3 (1.61 g, 4.90 mmol, 3 equiv) afforded 
3-18 (quant) as a colorless oil: 1H NMR showed quantitative conversion and minor impurities.
Diagnostic NMR peak: 1H NMR (CDCl3, 400 MHz) δ 8.24 (s, 1 H). 
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 tert-Butyl (furan-3-ylmethyl)carbamate (3-38).237 According to General 
Procedure B, 3-37 (0.750 g, 2.22 mmol, 1 equiv) and Cs2CO3 (2.17 g, 6.67 mmol, 3 equiv) afforded 
3-38 (0.360 g, 1.84 mmol, 83%) as a white solid: 1H NMR (300 MHz, DMSO-d6) δ 8.82 (s, 1H), 
8.48 (s, 1H), 7.56 (d, J = 2.1 Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 1.48 (s, 9H). 
 
 tert-Butyl (E)-(4-fluorobenzylidene)carbamate (3-41).236 According to 
General Procedure B, 3-40 (1.00 g, 2.74 mmol, 1 equiv) and Cs2CO3 (2.67 g, 8.21 mmol, 3 equiv) 
afforded 3-41 (0.590 g, 2.64 mmol, 97%) as a white solid: 1H NMR (300 MHz, CDCl3) δ 8.85 (s, 
1H), 7.96-7.91 (m, 2H), 7.16 (t, J = 8.4 Hz, 2H), 1.58 (s, 9H). 
 
1-(3,5-Diphenyl-1H-pyrazol-1-yl)but-3-en-1-one (3-19).161 To a 
mixture of but-3-enoic acid (1.00 mL, 11.4 mmol, 1 equiv) and 3,5-diphenylpyrazole (2.56 g, 11.4 
mmol, 1 equiv) in dry CH2Cl2 (23 mL , 0.5 M) was added EDC·HCl (3.49 g, 18.2 mmol, 1.6 equiv) 
at 0 °C. After stirring for 60 min, the reaction was quenched with saturated brine (10 mL). The 
organic layer was separated and the aqueous phase was extracted with CH2Cl2 (50 mL x 2). The 
combined organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure. The crude product was purified by chromatography on SiO2 (9:1, hexanes:EtOAc) to 
afford 3-19 (4.38 g, 15.2 mmol, 67%) as a white solid: Mp 70.5-72.4 C; IR (ATR) 3059, 1736, 
1557, 1487, 1459, 1439, 1399, 1340, 1247, 1195, 1026, 986, 945, 921, 907, 800, 760, 698 cm-1; 
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1H NMR (CDCl3, 500 MHz) δ 7.90 (dd, J = 14.0, 3.0 Hz, 2H), 7.46-7.40 (m, 8H), 6.72 (s, 1H), 
6.15-6.01 (m, 1H), 5.32-5.22 (m, 2H), 4.05 (d, J = 11.5 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 
171.1, 153.5, 147.5, 131.8, 131.0, 130.2, 129.2, 129.0, 128.8, 127.9, 126.3, 119.3, 109.8, 40.5; 
HRMS (LCMS ESI+) m/z calcd for C19H17N2O [M+H]
+ 289.1335, found 289.1332. 
 
 tert-Butyl (S,E)-(8-(3,5-diphenyl-1H-pyrazol-1-yl)-2-
methyl-8-oxooct-6-en-4-yl)carbamate ((S)-3-20).161 A dried 25 mL round bottom flask equipped 
with a magnetic stir bar was charged with [Cu(CH3CN)4]PF6 (0.010 g, 0.028 mmol, 0.02 equiv) 
and (S)-DTBM-SEGPHOS (0.033 g, 0.028 mmol, 0.02 equiv) under an Ar atmosphere. Distilled 
anhydrous THF (12.5 mL) was added via syringe. The mixture was stirred for 15 min to give a 
colorless catalyst solution that was kept sealed under Ar at room temperature until the imine was 
prepared (3 h). To a freshly prepared 3-18 (1.11 g by mass - residual hexanes and CH2Cl2, 4 equiv) 
was added the catalyst solution containing the copper(I) complex via syringe (12.5 mL), and, 
immediately, the combined solution was added to 3-19 (0.400 g, 1.39 mmol, 1 equiv) in a dried 
25-mL round bottom flask equipped with a magnetic stir bar under Ar atmosphere at room 
temperature. Upon addition of imine and catalyst, the reaction turned a faint yellow color. 
The reaction mixture was cooled to -50 C and Et3N (0.02 M in THF, 0.70 mL, 0.028 mmol, 0.02 
equiv) was added. Immediately upon addition of Et3N, the reaction turned a golden yellow color. 
The resulting reaction mixture was stirred at -50 C for 17.5 h, filtered through a plug of basic 
alumina, and concentrated under reduce pressure. The crude product was purified by 
chromatography on SiO2 (8:1, hexanes:EtOAc) to afford (S)-3-20 (0.644 g, 1.36 mmol, 98%) as a 
colorless crystalline solid: Mp 134.3-137.2 C; IR (ATR, neat) 3348, 2955, 1701, 1640, 1524, 
1438, 1350, 1275, 1242, 1166, 971, 945, 886, 760, 668 cm-1; [α]𝐷
25 -16.0 (c 0.50, CH2Cl2); 
1H 
NMR (CD3OD, 400 MHz) δ 7.98 (d, J = 6.8 Hz, 2H), 7.50-7.40 (m, 9H), 7.19-7.12 (m, 1H), 6.94 
(s, 1H), 6.63 (d, J = 9.2 Hz, 1H), 3.83-3.73 (m, 1H), 2.58-2.52 (m, 1H), 2.45-2.38 (m, 1H), 1.74-
1.67 (m, 1H), 1.49-1.44 (m, 1H), 1.34 (s, 9H), 1.30-1.22 (m, 1H), 0.95-0.89 (m, 6 H); 13C NMR 
(100 MHz, CD3OD) δ 164.0, 148.4, 147.6, 131.8, 131.3, 128.9, 128.6, 128.4, 128.3, 127.5, 126.0, 
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123.0, 109.6, 78.5, 43.8, 39.2, 27.3, 24.7, 22.2, 20.9; HRMS (LCMS ESI+) m/z calcd for 
C29H36N3O3 [M+H]
+ 474.2751, found 474.2751. The enantiomeric ratio was determined as 81:19 
by chiral HPLC (Chiralcel ADH; 98:2 hexane:EtOH, 254 nm; 1.0 mL/min; Rt 23.7 min). 
 
 
 Methyl (S,E)-5-((tert-butoxycarbonyl)amino)-7-methyloct-2-enoate 
((S)-3-21). To a flame-dried round bottom flask containing MeOH (1 mL, 0.2 M) was added (S)-
3-20 (0.107 g, 0.226 mmol, 1 equiv). The mixture was stirred at 60 C for 18 h, the solvent was 
removed under reduced pressure, and the residue was purified by chromatography on SiO2 (9:1, 
hexanes:EtOAc) to afford (S)-3-21 (0.053 g, 0.18 mmol, 88%) as a white solid: 1H NMR (CD3OD, 
300 MHz) δ 6.99-6.88 (m, 1H), 6.51 (d, J = 9.0 Hz, 1H), 5.87 (d, J = 15.6 Hz, 1H), 3.70 (s, 3H), 
2.43-2.34 (m, 1H), 2.28-2.18 (m, 1H), 1.69-1.60 (m, 1H), 1.45 (s, 9H), 1.26-1.22 (m, 2H), 0.93-
0.89 (m, 6H); 13C NMR (100 MHz, CD3OD) δ 167.0, 156.7, 146.2, 122.4, 78.4, 50.5, 43.7, 38.6, 
27.3, 24.6, 22.2, 20.8; HRMS (LCMS ESI+) m/z calcd for C15H28NO4 [M+H]





methyloct-2-enoate ((S)-3-22). To a flame-dried round bottom flask containing 2,2,2-
trifluoroethanol (10 mL, 0.1 M) was added (S)-3-20 (0.546 g, 1.15 mmol). The mixture was stirred 
at 75 C for 7 h, the solvent was removed under reduced pressure, and the residue was purified by 
chromatography on SiO2 (9:1, hexanes:EtOAc) to afford (S)-3-22 (0.344 g, 0.973 mmol, 84%) as 
a colorless solid: Mp 69.5-71.3 C; IR (ATR, neat) 3342, 296, 2931, 1736, 1678, 1654, 1526, 1440, 
1365, 1338, 1280, 1207, 1170, 1059, 981, 844, 751 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.09-6.99 
(m, 1H), 5.92 (d, J = 15.6 Hz, 1H) 4.50 (q, J = 8.8 Hz, 2H), 4.28 (d, J = 8.4 Hz, 1H),  3.81 (t, J = 
6.0 Hz, 1H), 2.45 (q, J = 6.0 Hz, 1H), 2.31 (q, J = 6.4 Hz, 1H), 1.70-1.65 (m, 1H), 1.45 (s, 9H), 
1.34-1.24 (m, 2H), 0.91 (d, J = 6.8 Hz, 6H); 13C NMR (CDCl3, 400 MHz) δ 162.4, 159.1, 155.2, 
148.2, 139.0, 134.2, 122.0, 60.3, 50.2, 28.3, 27.0, 24.9, 23.0; HRMS (LCMS ESI+) m/z calcd for 
C11H19F3NO2 (MW – C5H8O2 (Boc group)) [M+H]
+ 254.1362, found 254.1361. 
 
 Methyl (S,E)-5-((tert-butoxycarbonyl)amino)-7-methyloct-3-enoate 
((S)-3-23).79 A solution of (S)-3-21 (50 mg, 0.17 mmol, 1 equiv) and 1,2-dimethylimidazole (24 
mg, 0.24 mmol, 1.4 equiv) in methanol (1.5 mL, 0.1 M) was irradiated in a quartz cuvette in a 
Rayonet reactor with 15 low-pressure mercury lamps. The reaction was monitored by NMR to 
determine the ratio of conjugated to unconjugated product. After 23 h under irradiation, TLC 
analysis (5:1, hexanes:EtOAc, developed 2x) indicated that starting material was entirely 
consumed. The crude reaction mixture (5:1, trans:cis) was purified by chromatography on SiO2 
(9:1, hexanes:EtOAc) to afford (S)-3-23 (0.018 g, 0.063 mmol, 36%) as a white solid: Mp 55.0-
56.4 C; IR (ATR, neat) 3322, 2954, 1735, 1685, 1534, 1436, 1390, 1364, 1250, 1176, 1051, 972, 
873, 752, 686 cm-1; 1H NMR (CD3OD, 400 MHz) δ 6.63 (d, J = 6.8 Hz, 1H), 5.65 (ddt, J = 15.6, 
7.2, 0.9 Hz, 1H) 5.48 (dd, J = 15.6, 6.4 Hz, 1H), 4.06 (brd s, 1H), 3.66 (s, 3H), 3.07 (d, J = 6.8 Hz, 
2H), 1.68-1.61 (m, 1H), 1.44 (s, 9H), 1.37-1.29 (m, 2H), 0.91 (d, J = 6.8 Hz, 6H); 13C NMR 
132 
(CD3OD, 400 MHz) δ 172.5, 156.5, 135.3, 121.5, 50.9, 50.1, 43.9, 36.8, 27.4, 24.5, 21.7, 21.1; 
HRMS (LCMS ESI+) m/z calcd for C15H28NO4 [M+H]
+ 286.2013, found 286.2009. 
 
2,2,2-Trifluoroethyl (S,E)-5-((tert-butoxycarbonyl)amino)-7-
methyloct-3-enoate ((S)-3-24). A solution containing (S)-3-22, (0.160 g, 0.453 mmol, 1 equiv) 
and 1,2-dimethylimidazole (0.062 g, 0.63 mmol, 1.4 equiv) in methanol (1.5 mL, 0.3 M) was 
irradiated in a quartz cuvette in a Rayonet reactor with 15 low-pressure mercury lamps. The 
reaction was monitored by NMR to determine the ratio of conjugated to unconjugated product. 
After 24 h under irradiation, TLC (5:1, hexanes:EtOAc, developed 2x) indicated that starting 
material was entirely consumed. The crude reaction mixture (5:1, trans:cis) was purified by 
chromatography on SiO2 (9:1, hexanes:EtOAc) to afford (S)-3-24 (0.054 g, 0.15 mmol, 34%) as a 
colorless solid: 1H NMR (MeOD, 400 MHz) δ 6.64 (d, J = 7.6 Hz, 1H), 5.70-5.63 (m, 1H), 5.53 
(dd, J = 15.2, 6.0 Hz, 1H), 4.59 (q, J = 8.4 Hz, 2H), 4.06 (brd s, 1H), 3.18 (d, J = 6.4 Hz, 2H), 
1.69-1.58 (m, 1H), 1.43 (s, 9H), 1.33-1.24 (m, 2H), 0.91 (d, J = 6.8 Hz, 6H). 
 
(S,E)-N-(2,2,6,6-Tetramethyl-1-oxo-piperidin-4-yl)-5-(tert-
butoxycarbonylamino)-7-methyloct-2-enamide (4-25). To a dried microwave vial equipped 
with a magnetic stir bar was added (S)-3-20, (0.200 g, 0.422 mmol, 1 equiv) and 4-AT (0.304 g, 
1.69 mmol, 4 equiv.). Anhydrous THF (6 mL, 0.07 M) was added and the mixture was heated in 
the microwave at 90 C for 1 h. The reaction was concentrated under reduced pressured and 
purified by chromatography on SiO2 with gradient elution (2:1 to 1:1, hexanes:EtOAc) to afford 
(S)-3-25 (0.070 g, 0.16 mmol, 39%) as an orange solid: Mp 175.5-178.3 C; IR (ATR, neat) 3088, 
1671, 1606, 1509, 1457, 1224, 1107, 1039, 900, 822, 765, 705 cm-1; HRMS (LCMS ESI+) m/z 
calcd for C23H43N3O4 [M+H]
+ 425.3248, found 425.3247. 
133 
For 1H NMR characterization, 16 mg of the nitroxide was reduced to the corresponding 
hydroxylamine: A solution of (S)-3-25 (16 mg, 0.038 mmol, 1 equiv) in MeOH (1.5 mL, 0.1 M) 
was treated with ascorbic acid (33 mg, 0.19 mmol, 5 equiv) and stirred for 1 h until it turned from 
orange to colorless. The solution was diluted with ether, washed with sat. NaHCO3 and water, and 
the organic layer was dried (MgSO4), concentrated, and dissolved in CD3OD for analysis: 
1H NMR 
(CD3OD, 500 MHz) δ 6.65-6.59 (m, 1H), 6.38 (d, J = 9.0 Hz, 1H), 5.80 (d, J = 15.5 Hz, 1H), 4.45 
(s, 1H), 4.08-4.03 (m, 1H), 3.58 (brd s, 1H), 2.26-2.22 (m, 1H), 2.15-2.12 (m, 1H), 1.67-1.63 (m, 
2H), 1.61-1.57 (m, 1H), 1.44 (s, 9H) 1.34-1.32 (m, 4H), 1.19 (s, 6H), 1.09 (s, 6H), 0.82-0.80 (d, J 
= 6.5 Hz, 6H). 
 
 tert-Butyl (S,E)-(8-((1-hydroxy-2,2,6,6-tetramethylpiperidin-
4-yl)amino)-2-methyl-8-oxooct-5-en-4-yl)carbamate (JP4-039 hydroxyl amine).79 A solution 
of (S)-3-25, (58 mg, 0.14 mmol, 1 equiv) and 1,2-dimethylimidazole (19 mg, 0.19 mmol, 1.4 
equiv) in methanol (1.0 mL, 0.1 M) in a quartz cuvette was irradiated with 15 low-pressure 
mercury lamps for 24 h. After 24 h under irradiation, TLC anlaysis (1:2, hexanes:EtOAc, 
developed 2x) indicated that starting material was consumed. The mixture was concentrated under 
reduced pressure and purified by chromatography on SiO2 with gradient elution (3:1 to 1:1, 
hexanes:EtOAc) to afford JP4-039 hydroxyl amine (19.4 mg, 0.046 mmol, 34%) as a white solid: 
Mp 69.3-72.0 C; IR (ATR, neat) 3311, 2931, 1644, 1523, 1365, 1244, 1176, 972 cm-1; 1H NMR 
(CD3OD, 400 MHz) δ 6.65 (brd s, 1H), 5.65 (ddt, J = 14.8, 7.2, 0.9 Hz, 1H) 5.50 (dd, J = 14.8, 6.8 
Hz, 1H), 4.13-4.04 (m, 2H), 2.88 (d, J =  6.8 Hz, 2H),  1.74-1.70 (m, 2 H), 1.66-1.61 (m, 1H), 1.44 
(s, 9H), 1.36-1.29 (m, 4H), 1.17 (s, 6H), 1.15 (s, 6H), 0.91 (d, J =  6.0 Hz, 6H); HRMS (LCMS 
ESI+) m/z calcd for C23H44N3O4 [M+H]






butoxycarbonylamino)-7-methyloct-3-enamide (JP4-039).79 To a solution of JP4-039 
hydroxyl amine (18 mg, 0.042 mmol, 1 equiv) in t-butyl methyl ether (1.0 mL, 0.04 M) was added 
a 10% aqueous solution of potassium ferricyanide (0.37 mL, 0.21 mmol, 5 equiv). The solution 
was stirred vigorously at rt. The conversion was monitored by TLC analysis (1:1, hexanes:EtOAc). 
After 2.5 h, the mixture was extracted with EtOAc (3 mL) and the combined organic layers were 
filtered through a plug of sand and SiO2 to afford JP4-039 (17.9 mg, 0.042 mmol, quant) as an 
orange solid: Rf=0.6 (1:1, hexanes:EtOAc), HRMS (LCMS ESI+) m/z calcd for C23H43N3O4 
[M+H]+ 425.3248, found 425.3245. 
General procedure C. For the preparation of acyl oxazolidinones. To a solution of but-3-enoic 
acid (7.90 mmol, 1.4 equiv) in dry THF (30 mL, 0.3 M) at 0 °C under N2 atmosphere was added 
N-methylmorpholine (7.90 mmol, 1.4 equiv) and pivaloyl chloride (7.90 mmol, 1.4 equiv). The 
colorless mixture was stirred at -78 °C for 1 h. 
In a separate flask, n-BuLi (2.5 M solution in hexane, 2.60 mL, 6.49 mmol, 1.15 equiv) was added 
to a solution of oxazolidinone (5.64 mmol, 1 equiv) in dry THF (30 mL, 0.2 M) under an N2 
atmosphere at -78 °C. After 30 min at -78 °C, the clear solution of the lithium anion of the 
oxazolidinone was transferred dropwise to the flask containing the mixed anhydride and stirred at 
-78 °C for 1 h and then warmed to rt and stirred for 16 h. The reaction mixture was diluted with 
saturated aqueous NH4Cl (20 mL) and the aqueous layer was extracted with EtOAc (3 x 20 mL). 
The combined organic layers were dried (MgSO4) and the solvent was evaporated. The residue 
was purified by chromatography on SiO2 with gradient elution (6:1 to 3:1, hexanes:EtOAc) to 
afford the desired acyl oxazolidinone. 
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 (R)-3-(But-3-enoyl)-4-isopropyloxazolidin-2-one ((R)-3-26). According to 
General Procedure C but using Et3N instead of NMM, but-3-enoic acid (0.494 mL, 5.58 mmol, 1 
equiv), (R)-4-isopropyl-2-oxazolidinone (0.798 g, 6.13 mmol, 1.1 equiv), Et3N (0.871 mL, 6.13 
mmol, 1.1 equiv), n-BuLi (2.5 M in hexanes, 2.45 mL, 6.13 mmol, 1.1 equiv), and pivaloyl 
chloride (0.735 mL, 5.85 mmol, 1.05 equiv) afforded (R)-3-26 (0.520 g, 2.64 mmol, 47%) as a 
light yellow liquid: IR (ATR, neat) 2965, 2878, 1771, 1698, 1387,1366, 1300, 1197, 1144, 
1095,1057, 1021, 974, 923, 773, 716 cm-1; [α]𝐷
25 -99.2 (c 0.9, CHCl3);  
1H NMR (500 MHz, CDCl3) 
δ 6.03-5.95 (m, 1H), 5.24-5.20 (m, 2H), 4.45-4.42 (m, 1H), 4.30-4.21 (m, 2H), 3.72  (dq, J = 7.0, 
1.5 Hz, 2H), 2.42-2.35 (m, 1H), 0.91 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 171.2, 154.0, 129.9, 119.1, 63.4, 58.4, 40.2, 28.3, 18.0, 14.7; HRMS (LCMS ESI+) 
m/z calcd for C10H16NO3 [M+H] 198.1125, found 198.1124. 
 
(S)-3-(But-3-enoyl)-4-isopropyloxazolidin-2-one ((S)-3-26). According to 
General Procedure C but using Et3N instead of NMM, but-3-enoic acid (0.988 mL, 11.2 mmol, 1 
equiv), (S)-4-isopropyl-2-oxazolidinone (1.62 g, 12.3 mmol, 1.1 equiv), Et3N (1.74 mL, 12.3 
mmol, 1.1 equiv), n-BuLi (2.5 M in hexanes, 4.91 mL, 12.3 mmol, 1.1 equiv), and pivaloyl 
chloride (1.47 mL, 11.7 mmol, 1.05 equiv) afforded (S)-3-26 (1.31 g, 6.64 mmol, 60%) as a light 
yellow liquid: [α]𝐷




According to General Procedure C but using Et3N instead of NMM, but-3-enoic acid (0.247 mL, 
2.79 mmol, 1 equiv), (R)-(-)-4-(1H-indol-3-ylmethyl)-2-oxazolidinone (0.677 g, 3.07 mmol, 1.1 
equiv), Et3N (0.435 mL, 3.07 mmol, 1.1 equiv), n-BuLi (2.5 M in hexanes, 1.23 mL, 3.07 mmol, 
1.1 equiv), and pivaloyl chloride (0.367 mL, 2.93 mmol, 1.05 equiv) afforded (R)-3-27 (0.587 g, 
2.06 mmol, 74%) as a colorless semi-solid: IR (ATR, neat) 3394, 2981, 2917, 1768, 1692, 1424, 
1386, 1363, 1339, 1199, 1095, 1044, 991, 925, 726, 710 cm-1; [α]𝐷
25 -80.0 (c 0.1, CHCl3); 
1H NMR 
(500 MHz, CDCl3) δ 8.11 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.25-7.18 (m, 
1H), 7.16-7.15 (m, 1H), 7.07 (s, 1H), 6.09-6.03 (m, 1H), 5.29-5.25 (m, 2H), 4.80-4.77 (m, 1H), 
4.24-4.19 (m, 2H), 3.76 (dq, J = 7.0, 1.5 Hz, 2H), 3.49-3.46 (m, 1H), 2.95-2.90 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 171.4, 153.6, 136.3, 130.5, 129.21, 129.19, 127.4, 123.3, 122.0, 120.7, 120.6, 
119.5, 118.3, 118.1, 112.0, 110.7, 109.7, 68.2, 67.0, 65.8, 55.0, 53.8, 41.3, 40.3, 39.2, 29.1, 28.1, 
27.0; HRMS (LCMS ESI+) m/z calcd for C16H17N2O3 [M+H] 285.1234, found 285.1230. 
 
(R)-4-Benzyl-3-(but-3-enoyl)oxazolidin-2-one ((R)-3-28).216 According to 
General Procedure C, but-3-enoic acid (0.700 mL, 7.90 mmol, 1.4 equiv), (R)-4-benzyl-2-
oxazolidinone (1.00 g, 5.64 mmol, 1 equiv), NMM (0.877 mL, 7.90 mmol, 1.4 equiv), n-BuLi (2.5 
M in hexanes, 2.60 mL, 6.49 mmol, 1.15 equiv), and pivaloyl chloride (0.992 mL, 7.90 mmol, 1.4 
equiv) afforded (R)-3-28 (0.938 g, 3.82 mmol, 68%) as a colorless oil: IR (ATR, neat) 3084, 3029, 
2981, 2919, 1771, 1697, 1354, 1208, 1197, 1099, 994, 922, 750, 700 cm-1; [α]𝐷
25 –61.0 (c 0.2, 
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CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.36-7.29 (m, 3H), 7.22-7.19 (m, 2H), 6.07-5.98 (m, 1H), 
5.28-5.22 (m, 2H), 4.70-4.65 (m, 1H), 4.22-4.17 (m, 2H), 3.74 (dq, J = 7.0, 1.5 Hz, 2H), 3.34-3.28 
(m, 1H), 2.81-2.74 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 171.3, 153.5, 135.3, 129.8, 129.5, 129.1, 
127.5, 119.4, 66.4, 55.3, 40.3, 38.0; HRMS (LCMS ESI+) m/z calcd for C14H16NO3 [M+H]
+ 
246.1125, found 246.1124. 
 
(S)-4-Benzyl-3-(but-3-enoyl)oxazolidin-2-one ((S)-3-28).216 According to 
General Procedure C, but-3-enoic acid (0.693 mL, 7.82 mmol, 1.4 equiv), (S)-4-benzyl-2-
oxazolidinone (1.00 g, 5.59 mmol, 1 equiv), NMM (0.869 mL, 7.82 mmol, 1.4 equiv), n-BuLi (2.5 
M in hexanes, 2.57 mL, 6.42 mmol, 1.15 equiv), and pivaloyl chloride (0.982 mL, 7.82 mmol, 1.4 
equiv) afforded (S)-3-28 (0.827 g, 3.37 mmol, 61%) as a colorless oil: [α]𝐷
25 +63.2 (c 0.2, CHCl3).  
 
(R)-4-Benzyl-3-(but-3-enoyl)-5,5-diphenyloxazolidin-2-one ((R)-3-29). 
According to General Procedure C but using Et3N instead of NMM, but-3-enoic acid (0.148 mL, 
1.67 mmol, 1 equiv), (R)-(+)-5,5-diphenyl-4-benzyl-2-oxazolidinone (0.612 g, 1.84 mmol, 1.1 
equiv), Et3N (0.261 mL, 1.84 mmol, 1.1 equiv), n-BuLi (2.5 M in hexanes, 0.736 mL, 1.84 mmol, 
1.1 equiv), and pivaloyl chloride (0.220 mL, 1.76 mmol, 1.05 equiv) afforded (R)-3-29 (0.183 g, 
0.460 mmol, 28%) as a colorless liquid: IR (ATR, neat) 2955, 2873, 1783, 1702, 1450, 1356, 1216, 
1167, 996, 918, 758, 702 cm-1; [α]𝐷
25 +206.7 (c 0.1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.44-
7.42 (m, 3H), 7.36-7.30 (m, 4H), 7.23-719 (m, 4H), 7.09-7.08 (m, 4H), 5.85-5.60 (m, 1H), 5.62-
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5.59 (m, 1H), 5.13-5.07 (m, 2H), 3.57 (dq, J = 7.0, 1.5 Hz, 2H), 2.88-2.95 (m, 1H), 2.77-2.73 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ 170.4, 152.0, 141.3, 137.4, 136.1, 129.5, 129.0, 128.83, 128.77, 
128.2, 128.1, 126.44, 126.40, 125.9, 119.0, 88.6, 62.0, 39.9, 36.5; HRMS (LCMS ESI+) m/z calcd 
for C26H24NO3 [M+H] 398.1751, found 398.1747. 
 
 (R)-1-(4-benzyl-2-thioxothiazolidin-3-yl)but-3-en-1-one ((R)-3-30). To a 
suspension of (R)-4-benzyl-1,3-thiazolidine-2-thione (0.100 g, 0.468 mmol), DMAP (0.006 g, 0.05 
mmol, 0.1 equiv), and but-3-enoic acid (0.058 mL, 0.65 mmol, 1.4 equiv) in CH2Cl2 (2 mL, 0.2 
M) at 0 °C was added DCC (0.147 g, 0.655 mmol, 1.4 equiv) in one portion and the mixture was 
stirred at rt for 20 h. The dicyclohexylurea formed was filtered and the precipitate washed with 
CH2Cl2. The filtrate was washed with sat. NaHCO3, dried (MgSO4), concentrated under reduced 
pressure, and the residue was purified by chromatography on SiO2 (6:1, hexanes:EtOAc) to afford 
(R)-3-30 (0.086 g, 0.31 mmol, 66%) as a yellow viscous oil: IR (ATR, neat) 3079, 32026, 2923, 
1691, 1495, 1338, 1291, 1258, 1156, 1140, 1039, 991, 920, 888, 740, 700 cm-1; [α]𝐷
25 -211.4 (c 
0.1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ7.36-7.33 (m, 2H), 7.30-7.27 (m, 3H), 6.03-5.97 (m, 
1H), 5.39-5.36 (m, 1H), 5.25-5.18 (m, 2H), 4.16 (dq, J = 6.5, 1.5 Hz, 1H), 3.98 (dq, J = 4.0, 1.5 
Hz, 1H), 3.41-3.37 (m, 1H), 3.22 (dd, J = 13.5, 4.0 Hz, 1H), 3.04 (dd, J = 13.0, 10.5 Hz, 1H), 2.89 
(app d, J = 11.5 Hz, 1H); HRMS (LCMS ESI+) m/z calcd for C14H16NOS2 [M+H] 278.0668, found 
278.0676. 
 
3-(But-3-enoyl)oxazolidin-2-one (3-31).238 According to General Procedure C, 
but-3-enoic acid (2.09 mL, 23.6 mmol, 1.4 equiv), 2-oxazolidinone (1.50 g, 16.9 mmol, 1 equiv), 
NMM (2.62 mL, 23.6 mmol, 1.4 equiv), n-BuLi (2.5 M in hexanes, 7.60 mL, 19.4 mmol, 1.15 
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equiv), and pivaloyl chloride (2.97 mL, 23.6 mmol, 1.4 equiv) afforded 3-31 (1.16 g, 7.48 mmol, 
44%) as a colorless oil: IR (ATR, neat) 2989, 2920, 1768, 1694, 1637, 1479, 1386, 1362, 1219, 
1196, 1102, 1038, 1020, 970, 921, 758, 709 cm-1; 1H NMR (CDCl3, 300 MHz) δ 6.06-5.86 (m, 
1H), 5.25 (dd, J = 3.3, 1.8 Hz, 1H), 5.20 (d, J = 1.2 Hz, 1H), 4.43 (t, J = 7.8 Hz, 2H), 4.03 (t, J = 
7.8 Hz, 2H), 3.72 (d, J = 6.9 Hz, 2H); 13C NMR (CDCl3, 75 MHz) δ 171.4, 153.6, 129.8, 119.3, 
62.2, 42.6, 39.9; HRMS (LCMS ESI+) m/z calcd for C7H10NO3 [M+H]
+ 156.0655, found 
156.0656. 
General procedure D. For the vinylogous Mannich reaction. A dried 50-mL round bottom flask 
equipped with a magnetic stirring bar was charged with [Cu(CH3CN)4]PF6 (0.306 mmol, 0.25 
equiv) and (S)- or (R)-DTBM-SEGPHOS (0.306 mmol, 0.25 equiv) under an N2 atmosphere. 
Anhydrous THF (13 mL, 0.1 M) was added and the colorless catalyst solution was stirred for ca. 
15 min at rt, then at -20 °C for 15 min until the imine was prepared. The oxazolidinone (1.22 
mmol, 1.0 equiv) was added to the catalyst solution followed by the freshly prepared N-Boc 
imine (2.45 mmol, 2.0 equiv). After 5 min, DABCO (1.0 M in THF, 0.611 mmol, 0.5 equiv) was 
added. The resulting reaction mixture was stirred at –20 °C for 5-18 h, filtered through a plug of 
basic alumina (EtOAc), washed with 1M NH4OH (3 x 15 mL), NaHCO3 (1 x 15 mL), brine (2 x 
15 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. The residue 
was purified by chromatography on SiO2 with gradient elution (9:1 to 2:1, hexanes:EtOAc) to 
afford the desired β,α-unsaturated vinylogous Mannich product. 
 tert-Butyl ((S,E)-8-((R)-4-isopropyl-2-oxooxazolidin-3-yl)-2-
methyl-8-oxooct-6-en-4-yl)carbamate (3-32). According to General Procedure D but using Et3N 
instead of DABCO, (R)-3-26 (0.150 g, 0.760 mmol, 1 equiv), 3-18 (0.563 g, 3.04 mmol, 4 equiv), 
[Cu(CH3CN)4]PF6 (0.029 g, 0.076 mmol, 0.1 equiv), (S)-DTBM-SEGPHOS (0.091 g, 0.076 
mmol, 0.1 equiv), and Et3N (0.76 mL, 0.078 mmol, 1 equiv) afforded 3-32 (0.186 g, 0.486 mmol, 
60%) as a colorless viscous oil: IR (ATR, neat) 3354, 2960, 1776, 1686, 1634, 1520, 1364, 1239, 
140 
1204, 1184, 1014, 772, 753, 715 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.28 (d, J = 15.6 Hz, 1H), 
7.11-7.06 (m, 1H), 4.48-4.47 (m, 1H), 4.30 (brd s, 1H), 4.28-4.25 (m, 1H), 4.20 (dd, J = 8.4, 2.4 
Hz, 1H), 3.81 (brd s, 1H), 2.50-2.47 (m, 1H), 2.44-2.39 (m, 2H), 1.72-1.65 (m, 1H), 1.44 (s, 9H), 
1.32-1.27 (m, 2H), 1.25-0.90 (m, 12H); 13C NMR (150 MHz, CDCl3) δ 164.6, 155.3, 153.9, 146.7, 
123.0, 79.6, 63.4, 58.6, 28.6, 28.3, 28.2, 24.9, 22.9, 22.1, 17.9, 14.8; HRMS (LCMS ESI+) m/z 
calcd for C20H35N2O5 [M+H] 383.2540, found 383.2540. The diastereomeric ratio was determined 







8-oxooct-6-en-4-yl)carbamate ((S,R)-3-33). According to General Procedure D but using Et3N 
instead of DABCO, (R)-3-28 (0.100 g, 0.408 mmol, 1 equiv), 3-18 (0.302 g, 1.63 mmol, 4 equiv), 
[Cu(CH3CN)4]PF6 (0.023 g, 0.061 mmol, 0.15 equiv), (S)-DTBM-SEGPHOS (0.073 g, 0.061 
mmol, 0.15 equiv), and Et3N (0.61 mL, 0.061 mmol, 0.15 equiv) afforded (S,R)-3-33 (0.175 g, 
0.203 mmol, 50%) as a colorless solid: Mp 77.5-79.2 °C; IR (ATR, neat) 3358, 2961, 1775, 1685, 
1634, 1499, 1353, 1258, 1284, 1103, 1006, 761, 700 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.35-
7.27 (m, 4H), 7.23-7.21 (m, 2H), 7.16 (dt, J = 15.0, 7.5 Hz, 1H), 4.75-4.70 (m, 1H), 4.35 (d, J = 
8.0 Hz, 1H), 4.23-4.16 (m, 2H), 3.86 (d, J = 5.0 Hz, 1H), 3.34 (dd, J = 13.5, 3.5 Hz, 1H), 2.82-
2.76 (m, 1H), 2.55-2.51 (m, 1H), 2.43-2.40 (m, 1H), 1.69-1.65 (m, 1H), 1.43 (s, 9H), 1.35-1.24 
(m, 2H), 0.92 (d, J = 6.5 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 164.6, 155.3, 153.4, 147.9, 
146.7, 135.4, 130.1, 129.64, 129.58, 128.8, 128.4, 128.3, 128.0, 126.7, 123.4, 66.2, 64.9, 56.0, 
54.8, 38.9, 37.9, 28.92, 28.89, 27.9; HRMS (LCMS ESI+) m/z calcd for C24H35N2O5 [M+H] 
431.2540, found 431.2537. The diastereomeric ratio was determined to be 70:30 by chiral SFC 




phenylpent-3-en-1-yl)carbamate ((R,R)-3-34). According to General Procedure D, (R)-3-28 
(0.050 g, 0.204 mmol, 1 equiv), 3-17 (0.084 g, 0.408 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 
0.051 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.061 g, 0.051 mmol, 0.25 equiv), and DABCO 
(2 M solution in THF, 0.051 mL, 0.101 mmol, 0.5 equiv) afforded (R,R)-3-34 (0.053 g, 0.118 
mmol, 58%) as a colorless solid: Mp 59.6-62.7 °C; IR (ATR, neat) 3358, 2974, 2927, 1774, 1685, 
1635, 1496, 1355, 1243, 1209, 1164, 1000, 752, 681 cm-1; [α]𝐷
25 –33.5 (c 1.3, CHCl3); 
1H NMR 
(500 MHz, CDCl3) δ 7.37-7.27 (m, 9H), 7.21-7.19 (m, 2H), 7.07 (dt, J = 15.2, 7.6 Hz, 1H), 4.89 
(brd s, 2H), 4.72-4.67 (m, 1H), 4.22-4.15 (m, 2H), 3.30 (dd, J = 13.6, 3.2 Hz, 1H), 2.79-2.75 (m, 
3H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 164.4, 155.0, 153.4, 146.3, 135.3, 129.4, 129.0, 
128.8, 127.6, 127.4, 126.3, 123.1, 79.8, 77.2, 66.2, 55.3, 39.9, 37.9, 31.7, 28.3; HRMS (LCMS 
ESI+) m/z calcd for C26H31N2O5 [M+H] 451.2227, found 451.2224. The diastereomeric ratio was 
determined to be 86:14 by chiral SFC (Cellulose-2, (250 x 4.6 mm); 11% MeOH; 220 nm; 1.25 





phenylpent-3-en-1-yl)carbamate ((S,S)-3-34). According to General Procedure D, (S)-3-28 
(0.050 g, 0.204 mmol, 1 equiv), 3-17 (0.084 g, 0.408 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 
0.051 mmol, 0.25 equiv), (R)-DTBM-SEGPHOS (0.061 g, 0.051 mmol, 0.25 equiv), and DABCO 
(2 M solution in THF, 0.051 mL, 0.101 mmol, 0.5 equiv) afforded (S,S)-3-34 (0.046 g, 0.103 
mmol, 50%) as a colorless solid: [α]𝐷
25 +30.7 (c 0.5, CHCl3). The diastereomeric ratio was 
determined to be 86:14 by chiral SFC (Chiralpak-IC (250 x 10 mm); 13% MeOH; 254 nm; 5.0 




phenylpent-3-en-1-yl)carbamate ((R,S)-3-34). According to General Procedure D, (S)-3-28 
(0.050 g, 0.204 mmol, 1 equiv), 3-17 (0.084 g, 0.408 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 
144 
0.051 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.061 g, 0.051 mmol, 0.25 equiv), and DABCO 
(2 M solution in THF, 0.051 mL, 0.101 mmol, 0.5 equiv) afforded (R,S)-3-34 (0.024 g, 0.053 
mmol, 26%) as a colorless solid: Mp 60.2-64.1 °C; IR (ATR, neat) 3374, 2981, 2924, 1785, 1719, 
1676, 1516, 1348, 1243, 1216, 1169, 1023, 1011, 816, 755, 702 cm-1; [α]𝐷
25 +32.4 (c 0.4, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.41-7.27 (m, 9H), 7.20-7.17 (m, 2H), 7.06 (dt, J = 15.3, 7.8 Hz, 
1H), 4.88 (brd s, 2H), 4.72-4.67 (m, 1H), 4.19-4.16 (m, 2H), 3.30 (dd, J = 13.5, 3.3 Hz, 1H), 2.81-
2.74 (m, 3H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 164.4, 155.0, 153.3, 146.2, 138.4, 129.4, 
128.9, 128.6, 127.6, 127.3, 126.2, 123.1, 79.2, 77.2, 66.2, 55.3, 39.9, 37.9, 31.7, 28.3; HRMS 
(LCMS ESI+) m/z calcd for C26H31N2O5 [M+H] 451.2219, found 451.2224. The diastereomeric 
ratio was determined to be 91:9 by chiral SFC (Chiralpak-IC (250 x 10 mm); 13% MeOH; 254 




phenylpent-3-en-1-yl)carbamate ((S,R)-3-34). According to General Procedure D, (R)-3-28 
(0.050 g, 0.204 mmol, 1 equiv), 3-17 (0.084 g, 0.408 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 
0.051 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.061 g, 0.051 mmol, 0.25 equiv), and DABCO 
(2 M solution in THF, 0.051 mL, 0.101 mmol, 0.5 equiv) afforded (S,R)-3-34 (0.030 g, 0.067 
145 
mmol, 33%) as a colorless solid: [α]𝐷
25 -35.5 (c 0.8, CHCl3). The diastereomeric ratio was 
determined to be 92:8 by chiral SFC (Cellulose-2 (250 x 4.6 mm); 11% MeOH; 220 nm; 1.25 




en-1-yl)carbamate ((R)-3-34). According to General Procedure D, 3-31 (0.031 g, 0.200 mmol, 1 
equiv), 3-17 (0.082 g, 0.400 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 0.050 mmol, 0.25 equiv), 
(S)-DTBM-SEGPHOS (0.060 g, 0.050 mmol, 0.25 equiv), and DABCO (2 M solution in THF, 
0.050 mL, 0.100 mmol, 0.5 equiv) afforded (R)-3-34 (0.048 g, 0.134 mmol, 67%) as a colorless 
solid: Mp 142.3-145.4 °C; IR (ATR, neat) 3371, 2978, 2921, 1789, 1774, 1680, 1636, 1517, 1327, 
1334, 1246, 1223, 1203, 1171, 1121, 1046, 1015, 971, 747, 683 cm-1; [α]𝐷
25 +14.7 (c 0.3, CHCl3);
 
1H NMR (300 MHz, CDCl3) δ 7.36-7.32 (m, 6H), 7.02 (dt, J = 15.0, 7.8 Hz, 1H), 4.85 (brd s, 2H), 
4.41 (t, J = 7.8 Hz, 2H), 4.04 (t, J = 7.8 Hz, 2H), 2.77 (brd s, 2H), 1.41 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 164.7, 155.1, 153.5, 146.3, 128.9, 127.7, 126.4, 122.8, 62.2, 42.8, 28.5; HRMS (LCMS 
ESI+) m/z calcd for C19H25N2O5 [M+H] 360.1685, found 360.1687. The enantiomeric ratio was 
determined to be 96:4 by chiral SFC (Chiralpak-IC (250 x 10 mm); 13% MeOH; 254 nm; 5.0 





en-1-yl)carbamate ((S)-3-34). According to General Procedure D, 3-31 (0.031 g, 0.200 mmol, 1 
equiv), 3-17 (0.082 g, 0.400 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.019 g, 0.050 mmol, 0.25 equiv), 
(R)-DTBM-SEGPHOS (0.060 g, 0.050 mmol, 0.25 equiv), and DABCO (2 M solution in THF, 
0.050 mL, 0.100 mmol, 0.5 equiv) afforded (S)-3-34 (0.036 g, 0.100 mmol, 50%) as a colorless 
solid: [α]𝐷
25 -20.4 (c 0.7, CHCl3). The enantiomeric ratio was determined to be 96:4 by chiral SFC 





3-en-1-yl)carbamate (3-35). According to General Procedure D using P2-t-Bu instead of 
DABCO, (R)-3-28 (0.050 g, 0.204 mmol, 1 equiv), 3-17 (0.084 g, 0.408 mmol, 2 equiv), 
[Cu(CH3CN)4]PF6 (0.019 g, 0.051 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.061 g, 0.051 
mmol, 0.25 equiv), and DABCO (2 M solution in THF, 0.051 mL, 0.101 mmol, 0.5 equiv) afforded 
3-35 (0.0918 g, 0.108 mmol, 53%) as a colorless solid: Mp 55.7-58.2 °C; IR (ATR, neat) 3369, 
2977, 1773, 1691, 1495, 1364, 1288, 1165, 1102, 1048, 1020, 995, 926, 757, 702 cm-1; [α]𝐷
25 -64.0 
(c 0.1, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.31-7.22 (m, 8H), 7.16-7.13 (m, 2H), 6.11-5.98 
(m, 1H), 5.32-5.22 (m, 3H), 4.95 (t, J = 8.4 Hz, 2H), 4.32 (t, J = 8.4 Hz, 1H), 4.00 (dd, J = 9.0, 1.8 
Hz, 1H), 3.87 (brd s, 1H), 3.17 (dd, J = 13.5, 3.0 Hz, 1H), 2.72-2.65 (m, 1H), 1.39 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 171.6, 155.3, 135.3, 129.6, 129.0, 128.6, 127.7, 127.4, 127.0, 121.5, 




tert-Butyl (R)-(3-hydroxy-1-phenylpropyl)carbamate ((R)-3-36).161, 224 
Ozone was bubbled through a solution of (R)-3-34 (0.028 g, 0.078 mmol, 1 equiv) or (R,R)-3-34 
(100 mg, 0.222 mmol, 1 equiv) in MeOH (0.06 M) at -78 °C until the appearance of a light 
persistent blue color (20 min). The reaction solution was then allowed to warm to 0 °C and the 
mixture was subsequently treated with NaBH4 (10 equiv) at 0 °C. The reaction mixture was 
allowed to warm to rt and stirred for an additional 2 h, quenched with H2O (5 mL) and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered, and the 
solvent was removed under reduced pressure. The crude product was purified by chromatography 
on SiO2 (3:1, hexanes:EtOAc) to afford (R)-3-36 (0.020 g, 0.047 mmol, 61%) or (46.8 mg, 0.186 
mmol, 84%) as a colorless oil: [α]𝐷
25 +48.3 (c 0.3, CHCl3);
 1H NMR (600 MHz, MeOD) δ 7.36-
7.28 (m, 5H), 4.99 (s, 1H), 4.90 (s, 1H), 3.70 (dd, J = 7.8, 3.0 Hz, 2H), 2.40 (brd s, 1H), 2.08-2.07 
(m, 1H), 1.84-1.80 (m, 1H), 1.44 (s, 9H). The enantiomeric ratio was determined to be 95:5 (from 
(R)-3-33 and 85:15 from (R,R)-3-33 by chiral SFC (Chiralpak-IC (250 x 10 mm); 5% MeOH; 210 





yl)-5-oxopent-3-en-1-yl)carbamate ((R,R)-3-39). According to General Procedure D, (R)-3-28 
(0.250 g, 1.02 mmol, 1 equiv), 3-38 (0.398 g, 2.04 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.098 g, 
0.254 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.307 g, 0.255 mmol, 0.25 equiv), and DABCO 
(1 M solution in THF, 0.501 mL, 0.501 mmol, 0.5 equiv) afforded (R,R)-3-39 (0.276 g, 0.627 
mmol, 62%) as a white solid: Mp 41.5-44.3 °C; IR (ATR, neat) 3358, 2978, 2929, 1773, 1683, 
1635, 1499, 1389, 1361, 1212, 1172, 1020, 1000, 874, 761, 701 cm-1; [α]𝐷
25 -21.7 (c 0.2, CHCl3); 
150 
1H NMR (600 MHz, CDCl3) δ 7.39 (d, J = 1.2 Hz, 1H), 7.38-7.28 (m, 5H), 7.20 (d, J = 7.2 Hz, 
2H), 7.10 (dt, J =15.0, 7.2 Hz, 1H), 6.35 (d, J = 1.2 Hz, 1H), 4.88 (brd s, 1H), 4.73-4.69 (m, 2H), 
4.23-4.16 (m, 2H), 3.32 (dd, J = 13.2, 3.0 Hz, 1H), 2.81-2.75 (m, 3H), 1.45 (s, 9H); 13C NMR (150 
MHz, CDCl3) δ 164.4, 155.0, 153.4, 146.2, 143.6, 139.2, 135.3, 129.4, 129.0, 127.3, 126.0, 123.2, 
108.9, 79.8, 66.2, 55.3, 46.1, 38.7, 37.8, 28.3; HRMS (LCMS ESI+) m/z calcd for C24H28N2O6 
[M+Na] 463.1840, found 463.1831. The enantiomeric ratio was determined to be 57:43 by chiral 




yl)-5-oxopent-3-en-1-yl)carbamate ((S,R)-3-39). According to General Procedure D, (R)-3-28 
(0.088 g, 0.359 mmol, 1 equiv), 3-38 (0.147 g, 0.718 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.034 g, 
0.090 mmol, 0.25 equiv), (R)-DTBM-SEGPHOS (0.107 g, 0.090 mmol, 0.25 equiv), and DABCO 
(1 M solution in THF, 0.179 mL, 0.179 mmol, 0.5 equiv) afforded (S,R)-3-39 (0.063 g, 0.143 
mmol, 40%) as a white solid: Mp 50.7-53.3 °C; IR (ATR, neat) 3978, 2977, 2929, 1784, 1682, 
1638, 1513, 1352, 1247, 1214, 1190, 1022, 874, 797, 748, 700 cm-1; [α]𝐷
25 –39.7 (c 0.3, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.40 (d, J = 1.2 Hz, 1H), 7.37-7.27 (m, 5H), 7.21 (d, J = 6.6 Hz, 
2H), 7.10 (dt, J = 15.2, 7.2 Hz, 1H), 6.37 (d, J = 1.2 Hz, 1H), 4.87 (brd s, 1H), 4.75-4.70 (m, 2H), 
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4.25-4.14 (m, 2H), 3.33 (dd, J = 13.5, 3.3 Hz, 1H), 2.84-2.76 (m, 3H), 1.46 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 164.4, 155.0, 153.3, 146.1, 143.6, 139.2, 135.3, 129.4, 128.9, 127.3, 126.0, 123.2, 
108.9, 77.8, 66.2, 55.3, 46.1, 38.5, 37.8, 28.3; HRMS (LCMS ESI+) m/z calcd for C24H28N2O6 
[M+Na] 463.1840, found 463.1836. The diastereomeric ratio was determined to be 16:84 by chiral 




yl)-5-oxopent-3-en-1-yl)carbamate ((R,S)-3-39). According to General Procedure D, (S)-3-28 
(0.300 g, 1.22 mmol, 1 equiv), 3-38 (0.48 g, 2.45 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.118 g, 
0.306 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.368 g, 0.306 mmol, 0.25 equiv), and DABCO 
(1 M solution in THF, 0.612 mL, 0.612 mmol, 0.5 equiv) afforded (R,S)-3-39 (0.181 g, 0.411 
mmol, 34%) as a white solid: [α]𝐷
25 +46.5 (c 0.2, CHCl3). The diasteromeric ratio was determined 
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to be 83:17 by chiral SFC (Cellulose-2 (OZ-H) (250 x 4.6 mm); 12% MeOH; 220 nm; 1.5 mL/min; 




yl)pent-3-en-1-yl)carbamate ((R)-3-39). According to General Procedure D, 3-31 (0.214 g, 1.38 
mmol, 1 equiv), 3-38 (0.538 g, 2.76 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.132 g, 0.345 mmol, 
0.25 equiv), (S)-DTBM-SEGPHOS (0.415 g, 0.345 mmol, 0.25 equiv), and DABCO (1 M solution 
in THF, 0.690 mL, 0.690 mmol, 0.5 equiv) afforded (R)-3-39 (0.358 g, 1.02 mmol, 74%) as a 
white solid: Mp 145.8-147.1 °C; IR (ATR, neat) 3370, 2983, 2782, 1792 1774, 1664, 1640, 1520, 
187, 1363, 1327 1249, 1223, 1207, 1172, 1120, 1046, 1018, 972, 873, 753, 708 cm-1; [α]𝐷
25 –22.3 
(c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 1.5 Hz, 1H), 7.34-7.28 (m, 2H), 7.06 
(dt, J = 15.0, 7.5 Hz, 1H), 6.34 (d, J = 1.2 Hz, 1H), 4.84 (brd s, 1H), 4.71 (s, 1H), 4.42 (t, J = 7.8 
Hz, 2H), 4.05 (t, J = 7.8 Hz, 1H), 2.75 (t, J = 6.9 Hz, 2H), 1.44 (s, 9H); 13C NMR (75 MHz, CDCl3) 
δ 164.6, 153.4, 145.9, 143.6, 139.8, 139.2, 126.0, 122.8, 108.9, 79.9, 62.0, 45.9, 42.6, 38.6, 28.3; 
HRMS (LCMS ESI+) m/z calcd for C17H22N2O6 [M+Na] 373.1370, found 373.1375. The 
enantiomeric ratio was determined to be 18:82 by chiral SFC (ChiralPak-IC (250 x 10 mm); 10% 
MeOH; 220 nm; 5.0 mL/min; Rt 26.4 min). 
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Alternative purification 1.5 mmol scale: According to General Procedure D, 3-31 (0.220 g, 1.42 
mmol, 1 equiv), 3-38 (0.554 g, 2.84 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.136 g, 0.355 mmol, 
0.25 equiv), (S)-DTBM-SEGPHOS (0.427 g, 0.355 mmol, 0.25 equiv), and DABCO (1 M solution 
in THF, 0.709 mL, 0.709 mmol, 0.5 equiv) were stirred at -20 °C, filtered through a plug of basic 
alumina (EtOAc) and washed with NH4OH (3 x 15 mL), NaHCO3 (1 x 10 mL), and brine (2 x 15 
mL). The combined organic layers were dried (MgSO4), filtered, and concentrated under reduced 
pressure. The resulting solid was washed with additional hexanes (2 x 5 mL) and dried, to afford 




yl)pent-3-en-1-yl)carbamate ((S)-3-39). According to General Procedure D, 3-31 (0.091 g, 0.586 
mmol, 1 equiv), 3-38 (0.229 g, 1.17 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.056 g, 0.147 mmol, 
0.25 equiv), (R)-DTBM-SEGPHOS (0.176 g, 0.147 mmol, 0.25 equiv), and DABCO (1 M solution 
in THF, 0.293 mL, 0.293 mmol, 0.5 equiv) afforded (S)-3-39 (0.128 g, 0.365 mmol, 62%) as a 
white solid: [α]𝐷
25 +11.3 (c 0.2, CHCl3). The enantiomeric ratio was determined to be 79:21 by 





fluorophenyl)-5-oxopent-3-en-1-yl)carbamate ((R,R)-3-42). According to General Procedure 
D, (R)-3-28 (0.300 g, 1.22 mmol, 1 equiv), 3-41 (0.502 g, 2.45 mmol, 2 equiv), [Cu(CH3CN)4]PF6 
(0.116 g, 0.306 mmol, 0.25 equiv), (S)-DTBM-SEGPHOS (0.364 g, 0.306 mmol, 0.25 equiv), and 
DABCO (1 M solution in THF, 0.612 mL, 0.612 mmol, 0.5 equiv) afforded (R,R)-3-42 (0.199 g, 
0.425 mmol, 34%) as a white solid: Mp 53.5-55.8 °C; IR (neat) 3356, 2978, 2929, 1774, 1683, 
1509, 1356, 1220, 1190, 836, 701 cm-1; [α]𝐷
25 –32.3 (c 0.5, CHCl3); 
1H NMR (500 MHz, CDCl3) 
δ 7.34-7.25 (m, 6H), 7.20-7.16 (m, 2H), 7.04-7.01 (m, 3H), 4.85 (brd s, 2H), 4.71-4.67 (m, 1H), 
4.22-4.15 (m, 2H), 3.30 (dd, J = 13.5, 3.0 Hz, 1H), 2.79-2.73 (m, 3H), 1.41 (s, 9H); 13C NMR (150 
MHz, CDCl3) δ 164.3, 162.9, 161.3, 154.9, 153.4, 145.8, 135.2, 129.43, 129.40, 129.0, 127.91, 
127.86, 127.4, 123.3, 115.7, 115.6, 79.9, 66.2, 55.3, 53.2, 39.7, 37.8, 28.3; 19F NMR (470 MHz, 
CDCl3) δ -114.9; HRMS (LCMS ESI+) m/z calcd for C26H30FN2O5 [M+H] 469.2133, found 
469.2135. The diastereomeric ratio was determined to be 85:15 by chiral SFC (Cellulose-2 (OZ-





fluorophenyl)-5-oxopent-3-en-1-yl)carbamate ((S,R)-3-42). According to General Procedure D, 
(R)-3-28 (0.130 g, 0.530 mmol, 1 equiv), 3-41 (0.237 g, 1.06 mmol, 2 equiv), [Cu(CH3CN)4]PF6 
(0.051 g, 0.132 mmol, 0.25 equiv), (R)-DTBM-SEGPHOS (0.158 g, 0.132 mmol, 0.25 equiv), and 
DABCO (1 M solution in THF, 0.265 mL, 0.265 mmol, 0.5 equiv) afforded (S,R)-3-42 (0.041 g, 
0.088 mmol, 17%) as a white solid: Mp 61.1-64.2 °C; IR (neat) 3380, 2981, 1800, 1772, 1674, 
1636, 1604, 1507, 1356, 1239, 1211, 1172, 1134, 1013, 972, 832, 760, 712, 699 cm-1; [α]𝐷
25 –26.3 
(c 0.2, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.33-7.18 (m, 6H), 7.21-7.18 (m, 2H), 7.07-6.97 
(m, 3H), 4.84 (brd s, 2H), 4.73-4.68 (m, 1H), 4.21-4.17 (m, 2H), 3.30 (dd, J = 13.5, 3.0 Hz, 1H), 
2.82-2.74 (m, 3H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 164.3, 163.7, 160.5, 154.9, 153.3, 
145.7, 135.2, 129.4, 129.0, 127.93, 127.86, 127.82, 127.4, 123.3, 115.8, 115.5, 77.2, 66.2, 55.3, 
52.3, 39.7, 37.8, 28.3; δ 19F NMR (282 MHz, CDCl3) δ -114.9; HRMS (LCMS ESI+) m/z calcd 
for C26H30FN2O5 [M+H] 469.2133, found 469.2139. The diastereomeric ratio was determined to 






3-yl)pent-3-en-1-yl)carbamate ((S)-3-42). According to General Procedure D, 3-31 (0.206 g, 
1.33 mmol, 1 equiv), 3-41 (0.593 g, 2.66 mmol, 2 equiv), [Cu(CH3CN)4]PF6 (0.127 g, 0.332 mmol, 
0.25 equiv), (R)-DTBM-SEGPHOS (0.395 g, 0.332 mmol, 0.25 equiv), and DABCO (1 M solution 
in THF, 0.664 mL, 0.664 mmol, 0.5 equiv) afforded (S)-3-42 (0.197 g, 0.521 mmol, 39%) as a 
white solid: Mp 144.5-147.6 °C; IR (neat) 3371, 2981, 2921, 1791, 1774, 1680, 1637, 1607, 1501, 
1475, 1363, 1327, 1223, 1203, 1172, 1220, 1046, 1015, 970, 824, 753, 708 cm-1; [α]𝐷
25 –19.2 (c 
0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.29-7.23 (m, 3H), 7.05-6.96 (m, 3H), 4.83 (brd s, 
2H), 4.42 (t, J = 7.5 Hz, 2H), 4.05 (t, J = 7.5 Hz, 2H), 2.74 (brd s, 2H), 1.41 (s, 9H); 13C NMR 
(150 MHz, CDCl3) δ 164.5, 163.1, 161.1, 154.9, 153.4, 145.6, 127.9, 127.8, 122.9, 115.7, 115.5, 
79.9, 62.0, 53.2, 42.6, 39.6, 28.3; 19F NMR (470 MHz, CDCl3) δ -115.0; HRMS (LCMS ESI+) 
m/z calcd for C19H24FN2O5 [M+H] 379.1669, found 379.1671. The enantiomeric ratio was 
determined to be 94:6 by chiral SFC (ChiralPak-IC (250 x 10 mm); 13% MeOH; 220 nM; 5 





fluorophenyl)pent-3-enoate ((R)-3-43). A solution of n-BuLi (0.29 mL, 0.728 mmol, 3.1 equiv) 
was added dropwise to a solution of DIPEA (0.10 mL, 0.704 mmol, 3.0 equiv) in anhydrous THF 
(3.0 mL) at –78 °C. The reaction mixture was kept at -78 °C for 15 min, then cooled to 0 °C for 
15 min, and re-cooled to –78 °C. DMPU (0.09 mL, 0.704 mmol, 3.0 equiv) was added and the 
reaction was stirred for 15 min. A solution of oxazolidinone (R,R)-3-42 (0.110 g, 0.235 mmol, 1.0 
equiv) in anhydrous THF (0.7 mL) was added over a period of 2 min. After the addition was 
complete, the mixture was stirred for 15 min at –78 °C, 15 min at –40 °C, and 60 min at –20 °C. 
The solution was re-cooled to –78 °C, treated with and MeOH (0.5 mL), stirred for 45 min at –78 
°C. The reaction was quenched with saturated aqueous NH4Cl (5 mL) and H2O (5 mL). The 
aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic layer was dried 
(MgSO4), filtered, and concentrated. Purification by chromatography on SiO2 (20:1, 
hexanes:EtOAc) afforded (R)-3-43 (0.0498 g, 0.154 mmol, 66% yield) as a pale yellow oil: IR 
(ATR, neat) 3354, 2978, 1694, 1508, 1222, 1188, 1014, 838 cm-1; [α]𝐷
25 +16.3 (c 0.2, CHCl3); 
1H 
NMR (400 MHz, CDCl3) δ 7.26-7.23 (m, 2H), 7.02 (t, J = 8.4 Hz, 2H), 5.74-5.71 (m, 2H), 5.26 
(brd s, 1H), 4.88-4.83 (m, 1H), 3.69 (s, 3H), 3.11 (d, J = 5.2 Hz, 2H), 1.43 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 171.8, 162.9, 161.3, 154.8, 137.0, 133.7, 128.6, 123.6, 115.5, 115.4, 51.9, 37.3, 
158 
28.3; 19F NMR (376 MHz, CDCl3) δ -115.1; HRMS (LCMS ESI+) m/z calcd for C17H23FNO4 [M
+H] 324.1606, found 324.1618. 
General procedure E. For the preparation of β,α-unsaturated methyl esters. A solution of 
Yb(OTf)3 (0.0437 mmol, 0.05 equiv) in MeOH (10 mL, 0.08 M) was stirred at rt for 30 min. The 
β,α-unsaturated vinylogous Mannich product (0.875 mmol, 1 equiv) was added and the mixture 
was stirred at 60 °C for 2 h. The solvent was removed under reduced pressure and the crude 
product was purified by chromatography on SiO2 (3:1, hexanes:EtOAc) to afford the 
desired β,α-unsaturated methyl ester. 
Methyl (R,E)-5-((tert-butoxycarbonyl)amino)-5-(4-
fluorophenyl)pent-2-enoate ((R)-3-45). According to General Procedure E, Yb(OTf)3 (27.9 mg, 
0.044 mmol, 0.05 equiv) and (R,R)-3-42 (0.410 g, 0.875 mmol, 1 equiv) afforded (R)-3-45 (0.273 
g, 0.844 mmol, 96%) as a white solid: Mp 59.9-61.2 °C; IR (ATR, neat) 3380, 2983, 2957, 1717, 
1680, 1509, 1435, 1366, 1266, 1223, 1164, 1042, 1018, 980, 838, 780, 760 cm-1; [α]𝐷
25 +16.8 (c
0.2, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.25-7.22 (m, 2H), 7.03 (t, J = 8.4 Hz, 2H), 6.81 (dt, 
J = 15.6, 7.8 Hz, 1H), 5.86 (d, J = 15.6 Hz, 1H), 4.80 (brd s, 2H), 3.71 (s, 3H), 2.67 (brd s, 2H), 
1.41 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 166.4, 162.9, 161.3, 154.9, 143.8, 127.9, 124.0, 115.7, 
115.5, 51.6, 28.3; 19F NMR (564 MHz, CDCl3) δ -114.88; HRMS (LCMS ESI+) m/z calcd for 
C17H22FNO4Na [M+Na] 346.1431, found 346.1419. The enantiomeric ratio was determined to be 





fluorophenyl)pent-2-enoate ((S)-3-45). According to General Procedure E, Yb(OTf)3 (20.3 mg, 
0.031 mmol, 0.05 equiv) and (S)-3-42 (0.238 g, 0.629 mmol, 1 equiv) afforded (S)-3-45 (0.199 g, 
0.615 mmol, 98%) as a white solid: [α]𝐷
25 -19.3 (c 0.1, CHCl3). The enantiomeric ratio was 
determined to be 94:6 by chiral SFC (ChiralPak-IC (250 x 10 mm); 5% MeOH; 220 nm; 5.0 




enoate ((R)-3-54). According to General Procedure E, Yb(OTf)3 (35.8 mg, 0.056 mmol, 0.05 
equiv) and (R,R)-3-39 (0.490 g, 1.11 mmol, 1 equiv) afforded (R)-3-54 (0.307 g, 1.04 mmol, 93%) 
as a colorless viscous oil: IR (ATR, neat) 3350, 2978, 1702, 1502, 1436, 1366, 1271, 149, 1184, 
1022, 874, 783 cm-1; [α]𝐷
25 +14.1 (c 0.1, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.38 (d, J = 1.2 
Hz, 1H), 7.34 (s, 1H), 6.88 (dt, J = 15.6, 7.2 Hz, 1H), 6.33 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 15.6, 
1H), 4.82 (brd s, 1H), 4.67 (brd s, 1H), 3.71 (s, 3H), 2.70-2.66 (m, 2H), 1.44 (s, 9H); 13C NMR 
(150 MHz, CDCl3) δ 166.5, 155.0, 144.1, 143.6, 139.2, 126.0, 123.9, 108.9, 79.9, 51.5, 46.0, 38.2, 
28.3; HRMS (LCMS ESI+) m/z calcd for C15H21NO5Na [M+Na] 318.1212, found 318.1317. The 
enantiomers were separated by SFC and the resulting enantiomeric ratio was determined to be 3:97 




enoate ((S)-3-54). According to General Procedure E, Yb(OTf)3 (10.5 mg, 0.016 mmol, 0.05 
equiv) and (S)-3-39 (0.114 g, 0.323 mmol, 1 equiv) afforded (S)-3-54 (0.095 g, 0.322 mmol, 99%) 
161 
as a colorless viscous oil: [α]𝐷
25 -8.8 (c 0.1, CHCl3). The enantiomers were separated by SFC and 
the resulting enantiomeric ratio was determined to be >99:1 by chiral SFC (ChiralPak-IC (250 x 
10 mm); 6% MeOH; 220 nm; 5.0 mL/min; Rt 10.6 min). 
 
 
 (5-Fluoropyridin-2-yl)methanol (3-50).239 To a solution of 5-fluoro-2-
formylpyridine (0.79 mL, 7.67 mmol, 1 equiv) in MeOH (35 mL, 0.2 M) was added sodium 
borohydride (0.871 g, 23.0 mmol, 3 equiv). The mixture was stirred at rt for 21 h, quenched with 
water (15 mL), and the organic layer was extracted with EtOAc (3 x 15 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure to afford 3-50 (0.970 g, 7.62 mmol, quant) as a 
colorless liquid: IR (ATR, neat) 3279, 2865, 2859, 1586, 1485, 1389, 1238, 1060, 1022, 832, 715 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 7.46-7.42 (m, 1H), 7.31-7.29 (m, 1H), 4.76 (s, 
2H), 2.71 (brd s, 1H); 13C NMR (100 MHz, CDCl3) δ 155.0, 136.8, 136.5, 124.0, 123.7, 121.4, 
63.9; 19F NMR (470 MHz, CDCl3) δ -129.1. 
 
2-(Bromomethyl)-5-fluoropyridine (3-51).239 To a solution of 3-50 (1.00 mL, 
7.87 mmol, 1 equiv) in anhydrous CH2Cl2 (40 mL, 0.2 M) was added dropwise a solution of 
tribromophosphane (0.757 mL, 7.87 mmol, 1 equiv) in anhydrous CH2Cl2 (5 mL) at 0 °C. The 
162 
mixture was stirred for 22 h at rt and diluted with NH4Cl. The aqueous layer was extracted with 
CH2Cl2 (2 x 15 mL), washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure to afford 3-51 (0.996 g, 5.24 mmol, 67%) as a red liquid: 1H NMR (300 MHz, CDCl3) δ 
8.44 (s, 1H), 7.50-7.38 (m, 2H), 4.56 (s, 2H); 19F NMR (282 MHz, CDCl3) δ -127.1. 
General procedure F. For the preparation of bis-alkylated γ,β-unsaturated methyl esters. To a 
flame-dried round bottom flask containing dry THF (2.0 mL) at - 78 °C was added DIPEA 
(0.184 mL, 1.30 mmol, 3.0 equiv) followed by n-BuLi (2.5 M hexanes, 0.520 mL, 1.30 mmol, 
3.0 equiv). After 20 min at -78 °C, the solution was warmed to 0 °C for 10 min and then cooled 
back down to -78 °C. To this solution was added DMPU (0.166 mL, 1.34 mmol, 3.1 equiv). 
After 10 min, theβ,α-unsaturated methyl ester (0.165 g, 0.306 mmol, 1 equiv) in THF (2.0 mL) 
was added dropwise over 15 min. After 20 min, the alkyl bromide (0.172 mL, 1.34 mmol, 
3.1 equiv) was added dropwise and the solution was allowed to warm slowly 
to rt over 21 h. After 21 h, the solution was treated with satd. NH4Cl (3 mL) and 
extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified 
by chromatography on SiO2 (5:1, hexanes:EtOAc) to afford the desired bis-alkylated γ,β-
unsaturated methyl ester.  
Methyl (R,E)-5-((tert-butoxycarbonyl)amino)-2,2-bis(4-
fluorobenzyl)-5-(4-fluorophenyl)pent-3-enoate ((R)-3-46). According to General Procedure F, 
(R)-3-45 (0.140 g, 0.433 mmol, 1 equiv), 4-fluorobenzyl bromide (0.172 mL, 1.34 mmol, 3.1 
equiv), n-BuLi (2.5 M hexanes, 0.520 mL, 1.30 mmol, 3.0 equiv), DIPEA (0.184 mL, 1.30 mmol, 
3.0 equiv), and DMPU (0.166 mL, 1.34 mmol, 3.1 equiv) afforded (R)-3-46 (0.165 g, 0.306 mmol, 
71%) as a colorless sticky semi-solid: IR (ATR, neat) 3345, 2979, 1709, 1510, 1451, 1366, 1220, 
163 
1157, 1101, 1016, 836 cm-1; [α]𝐷
25 -9.2 (c 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.07-7.04 
(m, 2H), 7.01-6.96 (m, 6H), 6.92-6.87 (m, 4H), 5.78 (dd, J = 16.0, 1.0 Hz, 1H), 5.57 (dd, J = 16.0, 
6.0 Hz, 1H), 5.25 (brd s, 1H), 4.71 (brd s, 1H), 3.65 (s, 3H), 3.19 (dd, J = 14.0, 5.0 Hz, 2H), 2.96-
2.91 (m, 2H), 1.45 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 174.2, 162.8, 162.5, 161.2, 160.9, 154.8, 
132.4, 132.30, 132.28, 131.8, 131.7, 131.61, 131.56, 128.4, 115.4, 115.3, 114.88, 114.86, 114.74, 
114.72, 60.4, 54.0, 51.8, 43.8, 43.3, 28.3; 19F NMR (470 MHz, CDCl3) δ -116.20, -114.94; HRMS 
(LCMS ESI+) m/z calcd for C31H32F3NO4Na [M+Na] 562.2176, found 562.2184. 
 
 Methyl (S,E)-5-((tert-butoxycarbonyl)amino)-2,2-bis(4-
fluorobenzyl)-5-(4-fluorophenyl)pent-3-enoate ((S)-3-46). According to General Procedure F,  
(S)-3-45 (0.176 g, 0.544 mmol, 1 equiv), 4-fluorobenzyl bromide (0.217 mL, 1.69 mmol, 3.1 
equiv), n-BuLi (2.5 M hexanes, 0.653 mL, 1.63 mmol, 3.0 equiv), DIPEA (0.232 mL, 1.63 mmol, 
3.0 equiv), and DMPU (0.206 mL, 1.69 mmol, 3.1 equiv) afforded (S)-3-46 (0.276 g, 0.512 mmol, 
94%) as a colorless sticky semi-solid: [α]𝐷
25 +18.9 (c 0.2, CHCl3). 
 
 Methyl (R,E)-5-((tert-butoxycarbonyl)amino)-5-(4-fluorophenyl)-
2,2-bis((5-fluoropyridin-2-yl)methyl)pent-3-enoate ((R)-3-52). According to General 
Procedure F, (R)-3-45 (0.160 g, 0.495 mmol, 1 equiv), 3-51 (0.292 g, 1.53 mmol, 3.1 equiv), n-
BuLi (2.5 M hexanes, 0.594 mL, 1.48 mmol, 3.0 equiv), DIPEA (0.211 mL, 1.48 mmol, 3.0 equiv), 
and DMPU (0.189 mL, 1.53 mmol, 3.1 equiv) afforded (R)-3-52 (0.096 g, 0.160 mmol, 32%, 90% 
pure) as a colorless sticky semi-solid: IR (ATR, neat) 3351, 2979, 1708, 1602, 1585, 1508, 1482, 
164 
1391, 1367, 1209, 1168, 1158, 1045, 1019, 974, 834 cm-1; [α]𝐷
25 +7.7 (c 0.2, CHCl3); 
1H NMR 
(300 MHz, CDCl3) δ 8.33-8.31 (m, 2H), 7.16-7.03 (m, 3H), 7.01-6.89 (m, 5H), 5.87 (dd, J = 16.2, 
1.2 Hz, 1H), 5.46 (dd, J = 16.2, 6.0 Hz, 1H), 5.15 (brd s, 1H), 4.82 (brd s, 1H), 3.69 (s, 3H), 3.40-
3.22 (m, 4H), 1.42 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 174.7, 171.2, 162.8, 161.2, 159.1, 
157.42, 157.40, 154.8, 153.7, 153.5, 136.9, 136.7, 130.7, 128.5, 125.6, 125.5, 122.8, 122.7, 115.3, 
115.2, 79.7, 60.4, 52.1, 52.0, 42.8, 28.3; 19F NMR (282 MHz, CDCl3) δ -115.18, -130.48; HRMS 
(LCMS ESI+) m/z calcd for C29H30F3N3O4Na [M+Na] 564.2081, found 564.2090. 
 
 Methyl (R,E)-5-((tert-butoxycarbonyl)amino)-2,2-bis(4-
fluorobenzyl)-5-(furan-3-yl)pent-3-enoate ((R)-3-55). According to General Procedure F, (R)-
3-54 (0.145 g, 0.491 mmol, 1 equiv), 4-fluorobenzyl bromide (0.196 mL, 1.52 mmol, 3.1 equiv), 
n-BuLi (2.5 M hexanes, 0.589 mL, 1.47 mmol, 3.0 equiv), DIPEA (0.209 mL, 1.47 mmol, 3.0 
equiv), and DMPU (0.188 mL, 1.52 mmol, 3.1 equiv) afforded (R)-3-55 (0.198 g, 0.387 mmol, 
79%) as a colorless solid: Mp 91.3-94.6 °C; IR (neat) 3344, 2983, 1720, 1687, 1604 1512, 1450, 
1366, 1313, 1216, 1160, 1105, 1018, 982, 873, 812, 734 cm-1; [α]𝐷
25 -9.2 (c 0.1, CHCl3); 
1H NMR 
(600 MHz, CDCl3) δ 7.36 (d, J = 1.2 Hz, 1H), 7.08 (s, 1H), 7.05-7.01 (m, 4H), 6.93 (m, 4H), 6.19 
(d, J = 1.2 Hz, 1H), 5.85 (dd, J = 16.2, 1.2 Hz, 1H), 5.59 (dd, J = 16.2, 6.6 Hz, 1H), 5.22 (brd s, 
1H), 4.66 (brd s, 1H), 3.63 (s, 3H), 3.18 (d, J = 13.8 Hz, 2H), 2.96 (t, J = 13.8 Hz, 2H), 1.47 (s, 
9H); 13C NMR (150 MHz, CDCl3) δ 174.2, 162.5, 160.9, 154.9, 143.4, 139.4, 132.43, 132.41, 
132.38, 132.36, 131.69, 131.66, 131.6, 131.2, 125.9, 114.88, 114.86, 114.74, 114.72, 109.3, 79.8, 
53.9, 51.8, 48.7, 43.5, 28.4; 19F NMR (564 MHz, CDCl3) δ -116.28; HRMS (LCMS ESI+) m/z 




fluorobenzyl)-5-(furan-3-yl)pent-3-enoate ((S)-3-55). According to General Procedure F, (S)-3-
54 (0.085 g, 0.288 mmol, 1 equiv), 4-fluorobenzyl bromide (0.115 mL, 0.892 mmol, 3.1 equiv), 
n-BuLi (2.5 M hexanes, 0.345 mL, 0.863 mmol, 3.0 equiv), DIPEA (0.123 mL, 0.863 mmol, 3.0
equiv), and DMPU (0.110 mL, 0.892 mmol, 3.1 equiv) afforded (S)-3-55 (0.122 g, 0.238 mmol, 
83%) as a white solid: [α]𝐷
25 +11.7 (c 0.1, CHCl3).
Methyl (R,E)-5-((tert-butoxycarbonyl)amino)-2,2-bis(3-
fluorobenzyl)-5-(furan-3-yl)pent-3-enoate ((R)-3-57). According to General Procedure F, 
(R)-3-54 (0.081 g, 0.274 mmol, 1 equiv), 3-fluorobenzyl bromide (0.106 mL, 0.850 mmol, 3.1 
equiv), n-BuLi (2.5 M hexanes, 0.329 mL, 0.823 mmol, 3.0 equiv), DIPEA (0.117 mL, 0.823 
mmol, 3.0 equiv), and DMPU (0.105 mL, 0.850 mmol, 3.1 equiv) afforded (R)-3-57 (0.041 g, 
0.080 mmol, 29%) as a colorless oil that was used directly in next step without further 
purification. Diagnostic peaks: 1H NMR (300 MHz, CDCl3) δ 3.22 (d, J = 13.8 Hz, 2H), 3.00 (d, 
J = 13.8, 2H); 19F NMR (282 MHz, CDCl3) δ -113.41; HRMS (LCMS ESI+) m/z calcd for 
C29H31F2NO5 [M+Na] 534.2063, found 534.2063. 
General procedure G. For the preparation of JP4-039 analogs. To a solution of γ,β-unsaturated 
methyl ester (0.140 g, 0.246 mmol, 1.0 equiv) in MeOH (2.5 mL) and THF (1.0 mL) was added 
KOH (2.0 M in H2O, 0.62 mL, 1.23 mmol, 5.0 equiv) and the mixture was heated at reflux for 20 
h, and acidified with 1 M KHSO4 (ca. 2 mL) at 0 °C. The aqueous layer was extracted with CH2Cl2 
166 
(3 × 10 mL) and the combined organic layers were dried (MgSO4), filtered, concentrated under 
reduced pressure, and dried under high vacuum to afford the carboxylic acid as colorless oil.  
To a solution of crude carboxylic acid in anhydrous CH2Cl2 (3.5 mL, 0.07 M) was added 
sequentially 4-AT (0.062 g, 0.345 mmol, 1.4 equiv), DMAP (0.036 g, 0.296 mmol, 1.2 equiv), 
HOBT•H2O (0.041 g, 0.296 mmol, 1.2 equiv), and EDC•HCl (0.057 g, 0.296 mmol, 1.2 equiv). 
The resulting orange solution was stirred at rt for 14.5 h under a N2 atmosphere. The reaction 
mixture was diluted with CH2Cl2 (10 mL) and the organic layer was washed with an aqueous 
solution of saturated NH4Cl (2 × 15 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude product was purified by 
chromatography on SiO2 with gradient elution (6:1 to 1:1, hexanes:EtOAc) to afford the desired 
JP4-039 analog. 
General procedure H. For the preparation of JP4-039 hydroxyl amine analogs for 1H NMR 
analysis. A sample of the nitroxide (0.0069 g, 0.0149 mmol, 1.0 equiv) was dissolved in MeOH 
(degassed, 1 mL, 0.1 M) and L-ascorbic acid (0.013 g, 0.0744 mmol, 5.0 equiv) was added. 
Complete discoloration of the solution occurred within a few seconds. The reaction mixture was 
stirred for 1 h at rt. The solvent was removed under reduced pressure and the residue was 
partitioned between CH2Cl2 (3 mL) and H2O (1 mL) and the aqueous phase was extracted with 
CH2Cl2 (2 × 3 mL). The combined organic layers were dried (MgSO4), filtered, concentrated under 




44). According to General Procedures G and H, (R)-3-43 (0.045 g, 0.14 mmol, 1 equiv), KOH (1.0 
M in H2O, 0.70 mL, 0.70 mmol, 5.0 equiv), 4-AT (0.035 g, 0.20 mmol, 1.4 equiv), DMAP (0.020 
g, 0.17 mmol, 1.2 equiv), HOBT•H2O (0.023 g, 0.17 mmol, 1.2 equiv), and EDC•HCl (0.032 g, 
167 
0.17 mmol, 1.2 equiv) afforded (R)-3-44 (35.4 mg, 0.0765 mmol, 55%) as a peach colored solid: 
Mp 68.5-70.2 °C; IR (neat) 3294, 2941, 2932, 1647, 1508, 1365, 1222, 1184, 1014, 974, 838 cm-
1; [α]𝐷
25 +33.4 (c 0.2, CHCl3); 
1H NMR (600 MHz, MeOD) δ 7.31 (dd, J = 8.4, 5.4 Hz, 2H), 7.05 
(t, J = 8.4 Hz, 2H), 5.74 (dd, J = 15.6, 6.0 Hz, 1H), 5.70-5.65 (ddt, J = 15.0, 6.0, 1.0 Hz, 1H), 5.17 
(brd s, 1H), 4.10-4.06 (m, 1H), 2.94 (d, J = 6.6 Hz, 2H), 1.74-1.72 (m, 2H), 1.44 (s, 9H), 1.40-1.29 
(m, 2H), 1.18-1.16 (m, 12H); 13C NMR (150 MHz, MeOD) δ 173.1, 164.2, 162.6, 139.1, 135.1, 
129.9, 129.8, 116.2, 116.0, 80.5, 60.2, 54.8, 45.8, 42.2, 40.5, 32.6, 28.8, 20.3; 19F NMR (564 MHz, 





1-piperidinyloxy ((R)-3-47). According to General Procedures G and H, (R)-3-46 (0.140 g, 0.246 
mmol, 1 equiv), KOH (2.0 M in H2O, 0.62 mL, 1.2 mmol, 5.0 equiv), 4-AT (0.062 g, 0.35 mmol, 
1.4 equiv), DMAP (0.036 g, 0.30 mmol, 1.2 equiv), HOBT•H2O (0.041 g, 0.30 mmol, 1.2 equiv), 
and EDC•HCl (0.057 g, 0.30 mmol, 1.2 equiv) afforded (R)-3-47 (62.0 mg, 0.0913 mmol, 37%), 
as a peach colored solid: Mp 112.4-115.5 °C; IR (ATR, neat) 3324, 2976, 2936, 1700, 1646, 1605, 
1518, 1365, 1221, 1157, 837, 780 cm-1; [α]𝐷
25 +19.6 (c 0.2, CHCl3); 
1H NMR (500 MHz, MeOD) 
δ 7.24- 7.21 (m, 2H), 7.13-7.11 (m, 2H), 7.09-7.04 (m, 4H), 6.90-6.86 (m, 4H), 6.65 (d, J = 7.5 
Hz, 1H), 5.76 (dd, J = 16.5, 6.0 Hz, 1H) 5.67 (d, J = 16.5 Hz, 1H), 5.11 (d, J = 6.0 Hz, 1H), 4.03-
3.98 (m, 1H), 3.22-3.16 (m, 2H), 2.89 (app t, J = 15.0 Hz, 2H), 1.43 (s, 9H), 1.43-1.25 (m, 4H), 
1.16-1.11 (m, 12H); 13C NMR (150 MHz, MeOD) δ 175.1, 164.3, 163.9, 162.7, 162.3, 157.6, 
138.5, 135.1, 134.7, 134.6, 133.4, 133.3, 132.4, 130.1, 116.3, 116.2, 115.57, 115.55, 115.43, 
115.41, 80.4, 60.2, 57.9, 55.1, 45.5, 44.5, 44.4, 43.7, 42.7, 32.6, 28.9, 20.3; 19F NMR (470 MHz, 
MeOD) δ -117.27, -118.82 (2F); HRMS (LCMS ESI+) m/z calcd for C39H48F3N3O4 [M+H] 




1-piperidinyloxy ((S)-3-47). According to General Procedures G and H, (S)-3-46 (0.080 g, 0.15 
mmol, 1 equiv), KOH (2.0 M in H2O, 0.37 mL, 0.74 mmol, 5.0 equiv), 4-AT (0.037 g, 0.21 mmol, 
1.4 equiv), DMAP (0.022 g, 0.18 mmol, 1.2 equiv), HOBT•H2O (0.024 g, 0.18 mmol, 1.2 equiv), 
and EDC•HCl (0.034 g, 0.18 mmol, 1.2 equiv) afforded (S)-3-47 (62.2 mg, 0.0916 mmol, 62%) 
as a peach colored solid: [α]𝐷




tetramethyl-1-piperidinyloxy ((R)-3-53). According to General Procedures G and H, (R)-3-52 
(0.084 g, 0.14 mmol, 1 equiv), KOH (2.0 M in H2O, 0.35 mL, 0.70 mmol, 5.0 equiv), 4-AT (0.035 
g, 0.29 mmol, 1.4 equiv), DMAP (0.020 g, 0.17 mmol, 1.2 equiv), HOBT•H2O (0.023 g, 0.17 
mmol, 1.2 equiv), and EDC•HCl (0.032 g, 0.17 mmol, 1.2 equiv) afforded (R)-3-53 (61.9 mg, 
0.0909 mmol, 65%) as a peach colored solid: Mp 79.5-81.7 °C; IR (ATR, neat) 3314, 2978, 2937, 
1701, 1650, 1508, 1492, 1390, 1365, 1224, 1158, 1021, 835 cm-1; [α]𝐷
25 +41.7 (c 0.2, CHCl3); 
1H 
NMR (600 MHz, MeOD) δ 8.30 (dd, J = 5.3, 2.9 Hz, 2H), 7.57 (brd s, 1H), 7.44 (m, 2H), 7.36-
7.32 (m, 2H), 7.15 (s, 1H), 7.10 (dd, J = 8.7, 5.3 Hz, 2H), 6.99 (t, J =  8.7 Hz, 2H), 5.65 (brd s, 
2H), 5.03 (brd s, 1H), 4.09-4.05 (m, 1H), 3.28-3.26 (m, 4H), 1.64-1.62 (m, 2H), 1.42 (s, 9H), 1.38-
1.34 (m, 2H), 1.17-1.15 (m, 12H); 13C NMR (150 MHz, MeOD) δ 175.1, 164.2, 162.6, 160.9, 
169 
159.2, 157.5, 155.5, 138.6, 137.4, 137.3, 137.22, 137.16, 133.9, 133.2, 129.9, 127.85, 127.82, 
127.78, 124.5, 124.44, 124.38, 124.3, 116.1, 116.0, 80.3, 60.0, 57.4, 54.3, 45.80, 45.75, 44.4, 44.0, 
42.8, 32.7, 28.8, 20.3; 19F NMR (564 MHz, MeOD) δ -117.51, -132.28 (2F); HRMS (LCMS ESI+) 




piperidinyloxy ((S)-3-56). According to General Procedures G and H, (S)-3-55 (0.115 g, 0.225 
mmol, 1 equiv), KOH (2.0 M in H2O, 0.56 mL, 1.1 mmol, 5.0 equiv), 4-AT (0.057 g, 0.32 mmol, 
1.4 equiv), DMAP (0.033 g, 0.27 mmol, 1.2 equiv), HOBT•H2O (0.037 g, 0.27 mmol, 1.2 equiv), 
and EDC•HCl (0.052 g, 0.27 mmol, 1.2 equiv) afforded (S)-3-56 (81.0 mg, 0.124 mmol, 55%) as 
a peach colored solid: Mp 65.9-68.7 °C; IR (ATR, neat) 3329, 2977, 2934, 1698, 1649, 1511, 
1365, 1221, 1159, 1018, 874, 846, 825, 780 cm-1; [α]𝐷
25 +6.1 (c 0.2, CHCl3); 
1H NMR (600 MHz, 
MeOD) 7.47 (s, 1H), 7.30 (s, 1H), 7.14 (ddd, J = 19.8, 6.0, 2.4 Hz, 4H), 7.06 (brd s, 1H), 6.90 (t, 
J = 8.4 Hz, 4H),  6.64 (d, J = 7.2 Hz, 1H), 6.34 (s, 1H), 5.76 (dd, J = 15.6, 6.0 Hz, 1H), 5.69 (d, J 
= 15.6 Hz, 1H), 5.06 (brd s, 1H), 4.02-4.00 (m, 1H), 3.24-3.16 (m, 2H), 2.93-2.87 (m, 2H), 1.54-
1.48 (m, 1H), 1.43 (s, 9H), 1.30-1.23 (m, 3H), 1.16-1.10 (m, 12H); 13C NMR (150 MHz, MeOD) 
δ 175.2, 175.1, 163.93, 163.90, 162.32, 162.29, 157.6, 144.7, 140.7, 134.70, 134.68, 134.6, 133.40, 
133.35, 132.1, 126.9, 115.6, 115.4, 110.5, 80.4, 60.0, 55.0, 50.7, 45.60, 45.58, 44.5, 43.6, 42.9, 
42.8, 32.7, 28.9, 20.2; δ 19F NMR (564 MHz, MeOD) δ -118.80, -118.89; HRMS (LCMS ESI+) 





piperidinyloxy ((R)-3-56). According to General Procedures G and H, (R)-3-55 (0.068 g, 0.13 
mmol, 1 equiv), KOH (2.0 M in H2O, 0.33 mL, 0.66 mmol, 5.0 equiv), 4-AT (0.034 g, 0.19 mmol, 
1.4 equiv), DMAP (0.019 g, 0.16 mmol, 1.2 equiv), HOBT•H2O (0.022 g, 0.16 mmol, 1.2 equiv), 
and EDC•HCl (0.031 g, 0.16 mmol, 1.2 equiv) afforded (R)-3-56 (62.2 mg, 0.0956 mmol, 72%) 
as a peach colored solid: [α]𝐷




piperidinyloxy ((R)-3-58). According to General Procedures G and H, (R)-3-55 (0.035 g, 0.068 
mmol, 1 equiv), KOH (2.0 M in H2O, 0.17 mL, 0.34 mmol, 5.0 equiv), 4-AT (0.017 g, 0.096 mmol, 
1.4 equiv), DMAP (0.010 g, 0.082 mmol, 1.2 equiv), HOBT•H2O (0.011 g, 0.082 mmol, 1.2 
equiv), and EDC•HCl (0.016 g, 0.082 mmol, 1.2 equiv) afforded (R)-3-58 (18.0 mg, 0.026 mmol, 
38%) as a peach colored solid: Mp 52.7-54.6 °C; IR (ATR, neat) 3327, 2975, 2927, 1697, 1648, 
1587, 1517, 1488, 1449, 1366, 1245, 1168, 1020, 874, 782, 693 cm-1; [α]𝐷
25 -6.6 (c 0.4, CHCl3); 
1H NMR (600 MHz, MeOD) δ 7.45 (s, 1H), 7.27 (s, 1H), 7.23-7.19 (m, 2H), 6.98 (d, J = 7.2 Hz, 
1H), 6.94-6.88 (m, 6H), 6.79 (d, J = 7.8 Hz, 1H), 6.32 (s, 1H), 5.81 (dd, J = 16.2, 6.0 Hz, 1H), 
5.71 (d, J = 16.2 Hz, 1H), 5.05 (brd s, 1H), 4.12-4.06 (m, 1H), 3.23 (app d, J = 13.2 Hz, 2H), 3.03-
2.90 (m, 2H), 1.57-1.54 (m, 1H), 1.42 (s, 9H), 1.38-1.29 (m, 3H), 1.19-1.11 (m, 12H); 13C NMR 
171 
(125 MHz, MeOD) δ 175.0, 164.9, 162.9, 157.6, 144.7, 141.6, 141.50, 141.46, 141.4, 140.7, 140.5, 
134.6, 131.8, 130.6, 130.5, 130.3, 127.7, 118.4, 118.3, 118.19, 118.15, 114.34, 114.32, 114.17, 
114.15, 110.5, 80.4, 60.7, 54.8, 50.7, 45.44, 45.40, 45.3, 44.3, 42.7, 32.4, 28.9, 20.3; 19F NMR 
(564 MHz, MeOD) δ -115.76, -115.86; HRMS (LCMS ESI+) m/z calcd for C37H47F2N3O5 [M+H] 
652.3557, found 652.3534. 
General procedure I. For the preparation of allylic amine nitroxides. To a solution of 4-
hydroxy-Tempo (0.015 g, 0.086 mmol, 1.2 equiv) or 4-AT (0.011 g, 0.062 mmol, 1 equiv) in 
DMF (300 µL) was added disuccinimidyl carbonate (0.026 g, 0.103 mmol, 1.4 equiv) and 
pyridine (0.001 mL, 0.017 mmol, 0.25 equiv). The mixture was heated at 40 °C for 14 h to give 
the Tempo-mixed carbonate, 3-48 or 3-59. Separately, trifluoroacetic acid (0.129 mL, 1.72 
mmol, 20 equiv) was added to a solution of Boc-protected (S)-3-46 (0.170 g, 0.315 mmol, 1 
equiv) or 983-35 (0.055 g, 0.086 mmol, 1 equiv) in CH2Cl2 (1.2 mL) at 0 °C. The reaction was 
stirred 3 h until the starting carbamate was consumed, and the solvent and excess acid were 
evaporated. The material was dissolved in EtOAc and washed 3x with 10% aqueous Na2CO3. 
The combined aqueous layers were extracted with EtOAc (2 x 5 mL), and the combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. The Tempo-
mixed carbonate or carbamate solution, 3-48 or 3-59, was cooled to rt and transferred to a 
solution of the above amine and K3PO4 (0.019 g, 0.086 mmol, 1.1 equiv) in DMF (0.7 mL) and 
water (80 µL). The mixture was stirred 17 h, then diluted with water (10 mL) and EtOAc (10 
mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers 
were washed with 5% aqueous LiCl, dried (MgSO4), and concentrated under reduced pressure. 
The residue was purified by chromatography on SiO2 with gradient elution (4:1 to 1:1, 




According to General Procedures I and H, (S)-3-46 (0.170 g, 0.315 mmol, 1 equiv), 4-hydroxy-
Tempo (0.067 g, 0.38 mmol, 1.2 equiv), disuccinimidyl carbonate (0.113 g, 0.441 mmol, 1.4 
equiv), pyridine (0.006 mL, 0.08 mmol, 0.25 equiv), TFA (0.47 mL, 6.3 mmol, 20 equiv), and 
K3PO4 (0.076 g, 0.35 mmol, 1.1 equiv), afforded (S)-3-49 (96.3 mg, 0.151 mmol, 48%) as a peach 
colored solid: Mp 46.5-48.3 °C; IR (ATR, neat) 3313, 2933, 1719, 1603, 1508, 1449, 1342, 1219, 
1177, 1158, 1100, 1047, 976, 836, 774, 739 cm-1; [α]𝐷
25 -6.9 (c 0.2, CHCl3); 
1H NMR (400 MHz, 
MeOD) δ 7.17-7.15 (m, 2H), 7.08-7.06 (m, 6H), 6.91-6.85 (m, 4H), 5.81 (d, J = 18.0 Hz, 1H) 5.74 
(dd, J = 18.0, 6.0 Hz, 1H), 5.22 (d, J = 5.4 Hz, 1H), 4.94 (brd s, 1H), 3.63 (s, 3H), 3.22 (dd, J = 
13.8, 3.6 Hz, 2H), 3.03 (d, J = 13.8 Hz, 1H), 2.95 (d, J = 13.8 Hz, 1H), 1.48-1.46 (m, 4H), 1.32-
1.14 (m, 12H); 13C NMR (150 MHz, MeOD) δ 175.8, 164.2, 163.9, 162.6, 162.3, 134.33, 134.31, 
134.2, 133.2, 133.1, 133.0, 131.1, 130.2, 129.92, 129.88, 125.9, 125.8, 124.01, 123.99, 116.1, 
116.0, 115.61, 115.57, 115.47, 115.42, 60.2, 57.8, 55.6, 52.2, 45.3, 44.7, 28.6; 19F NMR (564 
MHz, MeOD) δ -64.09, -64.12, -64.14; HRMS (LCMS ESI+) m/z calcd for C36H41F3N2O5 [M+H] 





((S)-3-60). According to General Procedures I and H, 983-35 (0.055 g, 0.086 mmol, 1 equiv), 4-
hydroxy-Tempo (0.015 g, 0.086 mmol, 1 equiv), disuccinimidyl carbonate (0.026 g, 0.10 mmol, 
1.2 equiv), pyridine (0.001 mL, 0.02 mmol, 0.2 equiv), TFA (0.13 mL, 1.7 mmol, 20 equiv), and 
K3PO4 (0.019 g, 0.086 mmol, 1 equiv), afforded (S)-3-60 (17.1 mg, 0.0231 mmol, 27%) as a peach 
colored solid: Mp 75.6-78.0 °C; IR (ATR, neat) 3328, 2932, 2867, 1703, 1651, 1604, 1512, 1463, 
1364, 1314, 1221, 118, 1159, 1018, 992, 848, 825, 780 cm-1; [α]𝐷
25 +4.8 (c 0.3, CHCl3); 
1H NMR 
(400 MHz, MeOD) δ 7.16 (brd s, 4H), 6.94-6.91 (m, 4H), 6.42 (brd s, 1H), 5.59 (d, J = 14.4 Hz, 
1H), 5.50 (dt, J = 14.4, 5.6 Hz, 1H), 4.86 (brd s, 1H), 4.01 (s, 2H), 3.26-3.14 (m, 2H), 2.93 (dd, J 
= 14.0, 4.8 Hz, 1H), 2.84 (d, J = 14.4 Hz, 1H), 1.84-1.81 (m, 2H), 1.54-1.48 (m, 2H), 1.29 (brd s, 
8H), 1.18-1.16 (m, 16H), 1.12-1.10 (m, 6H), 0.93-0.90 (m, 9H); 19F NMR (376 MHz, MeOD) δ -





enamide ((S)-3-61). According to General Procedure I, 983-35 (0.040 g, 0.062 mmol, 1 equiv), 4-
AT (0.011 g, 0.062 mmol, 1 equiv), disuccinimidyl carbonate (0.019 g, 0.075 mmol, 1.2 equiv), 
pyridine (0.001 mL, 0.01 mmol, 0.2 equiv), TFA (0.094 mL, 1.3 mmol, 20 equiv), and K3PO4 
(0.014 g, 0.062 mmol, 1 equiv), afforded (S)-3-61 (15.6 mg, 0.021 mmol, 34%) as a peach colored 
solid: Mp 102.1-105.5 °C; IR (ATR, neat) 3375, 2932, 2870, 1653, 1536, 1505, 1464, 1364, 1303, 
1221, 1178, 1158, 1017, 988, 843, 825, 778 cm-1; [α]𝐷
25 +8.8 (c 0.4, CHCl3); HRMS (LCMS ESI+) 





4.0 Appendix A 
1H NMR, 13C NMR, and 19F spectra for compounds 1-6B, 1-10, 2-5, and representative 





































Figure 4-5 13C NMR spectra of vinylogous Mannich product (R,R)-3-39 
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Figure 4-6 1H NMR spectra of vinylogous Mannich product (R)-3-39 
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Figure 4-7 13C NMR spectra of vinylogous Mannich product (R)-3-39 
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Figure 4-8 1H NMR spectra of ester (R)-3-54 
184 
 
Figure 4-9 13C NMR spectra of ester (R)-3-54 
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Figure 4-11 13C NMR spectra of bis-alkylated ester (R)-3-55 
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Figure 4-12 19F NMR spectra of bis-alkylated ester (R)-3-55 
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Figure 4-13 1H NMR spectra of nitroxide analog (R)-3-44 
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Figure 4-14 13C NMR spectra of nitroxide analog (R)-3-44 
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Figure 4-15 19F NMR spectra of nitroxide analog (R)-3-44 
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Figure 4-16 1H NMR spectra of nitroxide analog (R)-3-47 
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Figure 4-17 13C NMR spectra of nitroxide analog (R)-3-47 
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Figure 4-19 1H NMR spectra of nitroxide analog (R)-3-53 
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Figure 4-20 13C NMR spectra of nitroxide analog (R)-3-53 
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Figure 4-21 19F NMR spectra of nitroxide analog (R)-3-53 
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Figure 4-22 1H NMR spectra of nitroxide analog (S)-3-56 
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Figure 4-23 13C NMR spectra of nitroxide analog (S)-3-56 
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Figure 4-24 19F NMR spectra of nitroxide analog (S)-3-56 
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Figure 4-25 1H NMR spectra of nitroxide analog (R)-3-58 
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Figure 4-26 13C NMR spectra of nitroxide analog (R)-3-58 
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Figure 4-27 19F NMR spectra of nitroxide analog (R)-3-58 
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Figure 4-28 1H NMR spectra of nitroxide analog (S)-3-60 
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Figure 4-29 19F NMR spectra of nitroxide analog (S)-3-60
205 
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